Photoreceptor precursor cell (PRP) compositions and uses thereof

Abstract

The present invention relates to compositions comprising photoreceptor precursor cells (PRPs), as well as methods of generating the composition of PRPs and methods of using the composition of PRPs for regenerative cell therapy.

Description

Attorney Docket No.: 132042-5009- WOPHOTORECEPTOR PRECURSOR CELL (PRP) COMPOSITIONS AND USES THEREOFCROSS-REFERENCE TO RELATED APPLICATIONS

[0001] The present application claims the benefit of and priority to U. S. Patent Application No. U. S. 63 / 726,133, filed on November 27, 2024, and U. S. 63 / 808,222, filed on May 19, 2025; entitled “PHOTORECEPTOR PRECURSOR CELL (PRP) COMPOSITIONS AND USES THEREOF,” both of which are incorporated herein by reference in their entirety.FIELD

[0002] The present disclosure relates generally to the field of cellular-based therapy. More particularly, it concerns photoreceptor precursor (PRP) cells and methods of use thereof.BACKGROUND

[0003] Primary photoreceptor diseases are a subgroup of inherited retinal diseases that include retinitis pigmentosa and cone-rod dystrophies. These diseases affect the structure and function of the photoreceptor cells in the retina, leading to irreversible vision loss in both children and adults. Current treatments for primary photoreceptor disease are mostly supportive and primarily limited to the use of specialized low-vision aids such as eyeglasses, magnifiers, adaptation devices, and services for the blind. Thus, there remains a significant unmet medical need for patients with loss of photoreceptor cells.SUMMARY

[0004] The present disclosure addresses the above need by providing compositions of photoreceptor precursor cells, methods for generating photoreceptor precursor cells, and methods of use of photoreceptor precursor cells, including methods for treating an inherited retinal disease in a subject in need thereof by administering a therapeutically effective amount of photoreceptor precursor cells.

[0005] In an aspect, described herein is a composition of cells comprising photoreceptor precursor cells (PRPs), wherein the composition comprises: NR2E3+ cells and between at least about 20% to about 60% PPP4R4+ cells; wherein the PRPs comprise less than or equal to about 0.5 copies of VIM per copy of SDHA.Attorney Docket No.: 132042-5009- WO

[0006] In an aspect, provided herein is a composition of cells comprising photoreceptor precursor cells (PRPs), wherein the composition comprises NR2E3+ cells and between at least about 20% to about 60% PPP4R4+ cells.

[0007] In some embodiments, at least about 20% to about 60% of the PRPs are PPP4R4+, wherein the cells are substantially NR2E3+, and wherein the cells comprise less than or equal to about 0.5 copies of VIM per copy of SDHA.

[0008] In some embodiments, the cells comprise at least about 90% AIPL1+ cells; at least about 90% RCVRN+ cells; less than or equal to about 7% PAX6+ cells; less than or equal to about 7% CHX10+ cells; less than or equal to about 0.5% TYRP1+ cells; and less than or equal to about 0.5% Ki67+ cells.

[0009] In some embodiments, a percentage NR2E3+, PPP4R4+, AIPL1+, RCVRN+, PAX6+, CHX10+, TYRP1+, and / or Ki67+ cells is determined by flow cytometry.

[0010] In some embodiments, copies of VIM per copy of SDHA is determined by droplet digital polymerase chain reaction (ddPCR).

[0011] In some embodiments, the cells have a percentage viability of at least about 50%.

[0012] In some embodiments, the percentage viability is determined by automated cell counting using acridine orange and propidium iodide.

[0013] In some embodiments, the cells are of human origin.

[0014] In some embodiments, the cells are derived from pluripotent stem cells (PSCs) or PSC-derived cells, optionally induced PSCs (iPSCs).

[0015] In some embodiments, the cells express HLA Class II during physiological inflammatory cytokine stimulation, and wherein approximately 50% of the HLA Class II is HLA-DR.

[0016] In an aspect, provided herein is a composition of cells consisting of photoreceptor precursor cells (PRPs) and, optionally, a pharmaceutically acceptable excipient thereof, wherein the cells consist of: NR2E3+ cells and between at least about 20% to about 60% PPP4R4+ cells; and wherein the PRPs comprise less than or equal to about 0.5 copies of VIM per copy of SDHA.

[0017] In some embodiments, the cells consist of at least about 90% AIPL1 + cells; at least about 90% RCVRN+ cells; less than or equal to about 7% PAX6+ cells; less than or equal to about 7%Attorney Docket No.: 132042-5009- WOCHX10+ cells; less than or equal to about 0.5% TYRP1 + cells; and less than or equal to about 0.5% Ki67+ cells.

[0018] In some embodiments, a percentage NR2E3+, PPP4R4+, AIPL1+, RCVRN+, PAX6+, CHX10+, TYRP1+, and / or Ki67+ cells is determined by flow cytometry.

[0019] In some embodiments, copies of VIM per copy of SDHA is determined by droplet digital polymerase chain reaction (ddPCR).

[0020] In some embodiments the cells have a percentage viability of at least about 40%.

[0021] In some embodiments, the percentage viability is determined by automated cell counting using acridine orange and propidium iodide.

[0022] In some embodiments, the cells are of human origin.

[0023] In some embodiments, the cells are derived from pluripotent stem cells (PSCs) or PSC-derived cells, optionally induced PSCs (iPSCs).

[0024] In some embodiments, the cells express HLA Class II during physiological inflammatory cytokine stimulation, and wherein approximately 50% of the HLA Class II is HLA-DR.

[0025] In an aspect, provided herein is a composition of cells comprising PRPs, wherein the composition comprises cell aggregates, wherein the cell aggregates have a median diameter of about 30 pm to about 60 pm.

[0026] In some embodiments, the median diameter of the cell aggregates is determined by a particle size analyzer.

[0027] In some embodiments, each cell is NR2E3+ or PPP4R4+.

[0028] In some embodiments, the cells comprise between at least about 20% to about 60% PPP4R4+ cells and wherein the cells comprise less than or equal to about 0.5 copies of VIM per copy of SDHA.

[0029] In some embodiments, a percentage of NR2E3+ and / or PPP4R4+ cells is determined by flow cytometry.

[0030] In some embodiments, copies of VIM per copy of SDHA is determined by ddPCR.

[0031] In some embodiments, the cells express HLA Class II during physiological inflammatory cytokine stimulation, and wherein approximately 50% of the HLA Class II is HLA-DR.Attorney Docket No.: 132042-5009- WO

[0032] In some embodiments, the cells are in a single cell form, an aggregate form, or a suspended form.

[0033] In some embodiments, the cells are in a single cell form or an aggregate form.

[0034] In some embodiments, the cells are in a suspended form.

[0035] In some embodiments, described herein is the composition comprising cells and a pharmaceutically acceptable carrier.

[0036] In some embodiments, the cells are suitable for grafting to a subretinal space of a subject’s eye.

[0037] In an aspect, provided herein is a method of identifying a cell population for treatment of an eye disease or disorder, the method comprising: assaying for PPP4R4+ cells in a cell population, wherein the cell population comprises between at least about 20% to about 60% PPP4R4+ cells, and wherein and the cells comprise less than or equal to 0.5 copies of VIM per copy of SDHA.

[0038] In some embodiments, the method further comprises assaying for AIPL1+ and / or RCVRN+ cells in the cell population, wherein the cells are substantially NR2E3, at least about 90% of the cells in the cell population are AIPL1+; at least about 90% of the cells in the cell population are RCVRN+; no more than about 7% of the cells are PAX6+; no more than about 7% of the cells are CHX10+; no more than about 0.5% of the cells are TYRP1+; or no more than about 0.5% of the cells are Ki67+.

[0039] In some embodiments, a percentage of NR2E3+, PPP4R4+, AIPL1+, RCVRN+, PAX6+, CHX10+, TYRP1+, and / or Ki67+ cells is determined by flow cytometry.

[0040] In some embodiments, copies of VIM per copy of SDHA is determined by ddPCR.

[0041] In some embodiments, the cell population has a percentage viability of at least about 40%.

[0042] In some embodiments, the percentage viability is determined by an automated cell counting using acridine orange and propidium iodide.

[0043] In some embodiments, the cell population is of human origin.

[0044] In some embodiments, the cell population is derived from PSCs or PSC-derived cells, optionally iPSCs.Attorney Docket No.: 132042-5009- WO

[0045] In some embodiments, the cell population is in a single cell form, an aggregate form, or a suspended form.

[0046] In some embodiments, the cell population is in a single cell form or an aggregate form.

[0047] In some embodiments, the cell population is in a suspended form.

[0048] In some embodiments, the cell population is suitable for grafting to a subretinal space of a subject’s eye.

[0049] In some embodiments, the eye (e.g., ocular) disease or disorder is a retinal disorder.

[0050] In some embodiments, the retinal disorder is characterized by a loss of photoreceptors and / or a loss of photoreceptor cell function.

[0051] In some embodiments, the eye disease is a primary photoreceptor disease, including retinitis pigmentosa, cone-rod disease, rod-cone disease, cone dystrophy, and / or cone-rod dystrophy.

[0052] In some embodiments, the eye disease of disorder is an inherited retinal disease.

[0053] In some embodiments, the eye disease or disorder is Usher Syndrome.

[0054] In an aspect, provided herein is a method of identifying a suitable cell population for treatment of an eye disease, the method comprising a) obtaining a population of cells comprising PRPs; b) measuring a percentage of PPP4R4+ cells in a cell population; and c) measuring a copy number of VIM per copy SDHA wherein the cell population is identified as a suitable cell population for treatment of an eye disease when the percentage of PPP4R4+ cells in the cell population is between about 20% and about 60%, and the copy number of VIM per copy of SDHA is less than or equal to about 0.5 copies.

[0055] In some embodiments, the method further comprises: d) measuring a percentage of AIPL1+ RCVRN+, PAX6+, CHX10+, TYRP1+; and / or Ki67+ cells in the cell population, wherein the cell population is identified as a suitable cell population for treatment of an eye disease when the percentage of AIPL1+ cells is least about 90%, the percentage of RCVRN+ cells is least about 90%, the percentage of PAX6+ cells is no more than about 7%, the percentage of CHX10+ cells is no more than about 7%, the percentage of TYRP1+ cells is no more than about 0.5%, and the percentage of Ki67+ cells is no more than about 0.5%.Attorney Docket No.: 132042-5009- WO

[0056] In some embodiments, a percentage of PPP4R4+, AIPL1+, RCVRN+, PAX6+, CHX10+, TYRP1+, or Ki67+ cells is determined by flow cytometry.

[0057] In some embodiments, copies of VIM per copy of SDHA is determined by ddPCR.

[0058] In some embodiments, the cell population is of human origin.

[0059] In some embodiments, the cell population is derived from PSCs or PSC-derived cells, optionally iPSCs.

[0060] In some embodiments, the cell population is in a single cell form, an aggregate form, or a suspended form.

[0061] In some embodiments, the cell population is in a suspended form.

[0062] In some embodiments, the cell population is suitable for grafting to a subretinal space of a subject’s eye.

[0063] In an aspect, provided herein is a composition comprising human PRPs for treatment of an eye disease or disorder, wherein the composition is in suspension form, and at least a portion of the composition is aggregated.

[0064] In some embodiments, the composition comprises 1.70X106total cells, 3.15x106total cells, 4.45x106total cells, or 5.90x106total cells in a 50 pL volume so that an administered dose comprises about 1X106, about 2x106, about 3x106, or about 4x106total viable cells, respectively.

[0065] In some embodiments, the composition comprises 2.04x106total cells, 3.78x106total cells, 5.35x106total cells, or 7.10x106total cells in a 50 pL volume so that an administered dose comprises about 1X106, about 2x106, about 3x106, or about 4x106total viable cells, respectively.

[0066] In some embodiments, a dose for administration comprises a) about 2.72x107total cells / mL to about 4.08x107total cells / mL are present in the composition; b) about 5.04x107total cells / mL to about 7.56X107total cells / mL are present in the composition; c) about 7.12xio7total cells / mL to about 1.07x108total cells / mL are present in the composition; ord) about 9.44x107total cells / mL to about 1.42X108total cells / mL are present in the composition.

[0067] In some embodiments, the dose for administration further comprises balanced salt solution buffer supplemented with 0.2% human serum albumin (HSA).

[0068] In some embodiments, cells / mL is determined by automated cell counting using acridine orange and / or propidium iodide.Attorney Docket No.: 132042-5009- WO

[0069] In an aspect, provided herein is a drug product comprising human PRPs comprising between at least about 20% to about 60% PPP4R4+ cells, wherein the drug product comprising the human PRPs are NR2E3+; and wherein the drug product comprising the human PRPs comprise less than or equal to about 0.5 copies of VIM per copy of SDHA.

[0070] In some embodiments, the drug product further comprises human PRPs comprising at least about 90% AIPL1+ cells; at least about 90% RCVRN+ cells; less than or equal to about 7% PAX6+ cells; less than or equal to about 7% CHX10+ cells; less than or equal to about 0.5% TYRP1+ cells; and / or less than or equal to about 0.5% Ki67+ cells.

[0071] In some embodiments, a percentage of NR2E3+, PPP4R4+, AIPL1+, RCVRN+, PAX6+, CHX10+, TYRP1+, and / or Ki67+ cells is determined by flow cytometry.

[0072] In some embodiments, copies of VIM per copy of SDHA is determined by ddPCR.

[0073] In some embodiments, the drug product comprising the human PRPs have a percentage viability of at least about 50%.

[0074] In some embodiments, the percentage viability is determined by automated cell counting using acridine orange and propidium iodide.

[0075] In some embodiments, the drug product comprising the human PRPs comprise cell aggregates wherein a median diameter of a cell aggregate is about 30 pm to about 60 pm.

[0076] In some embodiments, the median diameter of a cell aggregate is determined by a particle size analyzer.

[0077] In some embodiments, the drug product is resuspended in media.

[0078] In some embodiments, the drug product is resuspended in CryoSTOR® CS10 solution.

[0079] In some embodiments, the drug product is reformulated after thaw.

[0080] In some embodiments, the drug product comprises about 25x106cells.

[0081] In some embodiments, the human PRPs express HLA Class II during physiological inflammatory cytokine stimulation, and wherein approximately 50% of the HLA Class II is HLA-DR.

[0082] In an aspect, provided herein is a composition comprising human PRPs for treatment of an eye disease or disorder, comprising a therapeutically effective amount of the composition, wherein the composition is in an aggregated form.Attorney Docket No.: 132042-5009- WO

[0083] In some embodiments, the composition comprises 1.70x106total cells, 3.15x106total cells, 4.45x106total cells, or 5.90x106total cells in a 50 pL volume so that an administered dose comprises about 1X106, about 2x106, about 3x106, or about 4x106total viable cells, respectively.

[0084] In some embodiments, the composition comprises 2.04x106total cells, 3.78x106total cells, 5.35x106total cells, or 7.10x106total cells in a 50 pL volume so that an administered dose comprises about 1X106, about 2x106, about 3x106, or about 4x106total viable cells, respectively.

[0085] In some embodiments, a dose for administration comprises a) about 2.72x107total cells / mL to about 4.08x107total cells / mL are present in the composition; b) about 5.04x107total cells / mL to about 7.56x107total cells / mL are present in the composition;^ about 7.12X107total cells / mL to about 1.07x108total cells / mL are present in the composition; ord) about 9.44x107total cells / mLto about 1.42X108total cells / mL are present in the composition.

[0086] In some embodiments, the dose for administration is administered within 28 hours after reformulation from a drug product.

[0087] In some embodiments, cells / mL is determined by automated cell counting using acridine orange and / or propidium iodide.

[0088] In some embodiments, a drug product comprising the human PRPs comprises between at least about 20% to about 60% PPP4R4+ cells, wherein the PRPs are NR2E3+; and wherein the PRPs comprise less than or equal to about 0.5 copies of VIM per copy of SDHA.

[0089] In some embodiments, the composition comprises at least about 90% AIPL1+ cells; at least about 90% RCVRN+ cells; less than or equal to about 7% PAX6+ cells; less than or equal to about 7% CHX10+ cells; less than or equal to about 0.5% TYRP1+ cells; and / or less than or equal to about 0.5% Ki67+ cells.

[0090] In some embodiments, a percentage of NR2E3+, PPP4R4+, AIPL1+, RCVRN+, PAX6+, CHX10+, TYRP1+, and / or Ki67+ cells is determined by flow cytometry.

[0091] In some embodiments, copies of VIM per copy of SDHA is determined by ddPCR.

[0092] In some embodiments, the composition has a percentage viability of at least about 50%.

[0093] In some embodiments, the percentage viability is determined by automated cell counting using acridine orange and propidium iodide.Attorney Docket No.: 132042-5009- WO

[0094] In some embodiments, the composition further comprises cell aggregates wherein a median diameter of a cell aggregate is about 30 pm to about 60 pm.

[0095] In some embodiments, the median diameter of a cell aggregate is determined by a particle size analyzer.

[0096] In some embodiments, the composition expresses HLA Class II during physiological inflammatory cytokine stimulation, and wherein approximately 50% of the HLA Class II is HLA-DR.

[0097] In an aspect, provided herein is a composition comprising human PRPs and a pharmaceutically acceptable carrier. In some embodiments, the pharmaceutically acceptable carrier is balanced salt solution buffer supplemented with about 0.2% human serum albumin (HSA).

[0098] In some embodiments, the human PRPs are stable at about 1-8 °C for about 4-31 hours.

[0099] In some embodiments, the human PRPs are stable at about 1-8 °C for about 4-7 hours.

[0100] In some embodiments, the human PRPs are stable at about 1-8 °C for about 24-27 hours.

[0101] In some embodiments, the human PRPs are stable at about 1-8 °C for about 28-31 hours.

[0102] In some embodiments, stability is assessed by one or more of percentage viability, viable cell concentration, and / or percentage aggregate biomass.

[0103] In some embodiments, the balanced salt solution buffer comprises about 0.3 mg / mL of magnesium chloride, about 0.48 mg / mL of calcium chloride, about 0.75 mg / mL of potassium chloride, about 1.7 mg / mL of sodium citrate, about 3.9 mg / mL of sodium acetate, and / or about 6.4 mg / mL of sodium chloride.

[0104] In an aspect, provided herein is a method for assessing whether a dose for administration comprising PRPs is compatible with a system for administration comprising a) exposing the PRPs to about 1-8 °C; b) agitating the PRPs; c) aspirating the PRPs into a cannula and syringe; d) optionally holding the PRPs in the syringe in a vertical orientation; e) injecting the PRPs from the cannula and syringe into a tube and / or cell culture plate; and f) measuring percentage aggregate biomass, percentage cell viability, and / or viable cell concentration of the PRPs in the tube and / or cell culture plate, wherein the dose for administration comprising PRPs is compatible with a system for administration if there is no substantial change in percentage aggregate biomass,Attorney Docket No.: 132042-5009- WOpercentage cell viability, and / or viable cell concentration of the dose for administration comprising PRPs compared to a composition comprising control PRPs.

[0105] In some embodiments, provided herein is a kit comprising any of the above-described compositions or drug products.BRIEF DESCRIPTION OF THE OF THE DRAWINGS

[0106] The foregoing summary, as well as the following detailed description, will be better understood when read in conjunction with the appended figures. For the purpose of illustration, shown in the figures are embodiments. It should be understood, however, that the summary, detailed description, and figures are not limited to the precise arrangements, examples, and instrumentalities shown.

[0107] Figure 1: depicts a particle size and percentage aggregate analysis acquired using a Multisizer 4e on a cell product comprising cell aggregates. The percentage volume of the solution is measured for each particle diameter (pm). Aggregates are characterized as having a diameter between 16.97 pm and 168.0 pm. The median diameter was 49.55 pm with 96.0% of cells present in aggregates.

[0108] Figure 2: shows a representative image of aggregated cells acquired using a DMi1 inverted microscope at 20X magnification. Aggregated cells are shown as large clumps. Scale bar represents 100 pm.

[0109] Figure 3: shows VIM gene expression level as measured by droplet digital polymerase chain reaction (ddPCR) with a reportable value, copies VIM / copy SDHA where target (VIM) expression (copies / pL) divided by reference gene (SDHA) expression (copies / pL). Non-clinical data generated using three non-representative drug product batches which have high VIM expression are shown in open circles. These data demonstrate negative outcomes with high VIM expression.

[0110] Figure 4: shows a representative image of a cell product comprising cell aggregates acquired using the IncuCyte® Live-Cell Analysis System Spheroid Module software.

[0111] Figure 5A-H: depicts a panel of graphs showing representative flow cytometric analyses of cell product comprising cell aggregates for 5A) AIPL1+ cells, 5B) RCVRN+ cells, 5C) PAX6+ cells, 5D) CHX10+ cells, 5E) TYRP1+ cells, 5F) Ki67+ cells, 5G) NR2E3+ cells, and 5H) PPP4R4+ cells.Attorney Docket No.: 132042-5009- WO

[0112] Figure 6A-E: depicts a panel of graphs showing representative flow cytometric analyses of cell product comprising cell aggregates measuring HLA Class II expression (y-axis) and HLA Class I expression (x-axis) for 6A) untreated cells, 6B) cells treated with 100 pg / mL IFN-y and 20 pg / mLTNFa, 6C) cells treated with 1 ng / mL IFN-y and 200 pg / mLTNFa, 6D) cells treated with 10 ng / mL IFN-y and 2 ng / mLTNFa, and 6E) cells treated with 100 ng / mL IFN-y and 20 ng / mLTNFa.

[0113] Figure 7A-D: depicts a panel of graphs showing representative flow cytometric analyses of cell product comprising cell aggregates measuring HLA Class I expression (y-axis) and HLA Class II expression (x-axis) for 7A) untreated cells, 7B) cells treated with 100 ng / mL IFN-y, 7C) cells treated with 100 ng / mL TNFa, and 7D) cells treated with 100 ng / mL IFN-y and 20 ng / mL TNFa.

[0114] Figure 8A-E: depicts a panel of graphs showing representative flow cytometric analyses of cell product comprising cell aggregates measuring side scatter (y-axis) and either pan-HLA Class II expression (x-axis, top) or and H LA-DR expression (x-axis, bottom) for 8A) untreated cells, 8B) cells treated with 100 pg / mL IFN-y and 20 pg / mLTNFa, 8C) cells treated with 1 ng / mL IFN-y and 200 pg / mL TNFa, 8D) cells treated with 10 ng / mL IFN-y and 2 ng / mL TNFa, and 8E) cells treated with 100 ng / mL IFN-y and 20 ng / mLTNFa.DETAILED DESCRIPTION

[0115] Provided herein are compositions of cells comprising photoreceptor precursor cells and methods of making or using the same. Such compositions may be useful in treating inherited (e.g., genetic) retinal diseases (e.g., a primary photoreceptor disease such as retinitis pigmentosa, Usher Syndrome, cone-rod disease, rod-cone disease, cone dystrophy, or cone-rod dystrophy, etc.). Such compositions may comprise an amount (e.g., a therapeutically effective amount) of photoreceptor precursor cells for administration to an eye of a subject in need thereof, such as a human. Advantageously, the compositions comprise substantially pure photoreceptor precursor cells that express PPP4R4 and / or NR2E3 (which indicates rod and / or cone photoreceptor development) and low expression of VIM. Such compositions are suitable for treating inherited retinal diseases such as a primary photoreceptor disease without the drawbacks associated with compositions of less purity.Definitions

[0116] Definitions of certain terms to be used herein are provided. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood.Attorney Docket No.: 132042-5009- WO

[0117] As used herein, the terms "cell", "cell line", and "cell culture" may be used interchangeably and all such designations include the progeny thereof.

[0118] The terms “cell dissociation’’ or “dissociation” refer to providing a cell composition containing cell aggregates or aggregated cells and separating the aggregated cells into singularized cells and / or reduced-size cell aggregates. Cell dissociation may be mechanical, physical, enzymatic, chemical, or any combination thereof. In an example, cell dissociation may be induced via incubation with TrypLE™ (Thermo Fisher Scientific, Waltham, MA; Catalog No.: A1217701). Cell dissociation may further involve agitation, vortexing, trituration, or mixing in order to break cell aggregates apart.

[0119] The terms “cells in aggregates,” “aggregated cells,” “aggregates,” “clumps,” or “cell aggregates” refer to cells associated with one another by means of intercellular adhesion or other mechanisms of association. In some embodiments, a cell suspension may comprise aggregated cells.

[0120] The term "cell population" or “cell composition” is used herein to refer to a group of cells. The cell population can be derived from a common progenitor or may comprise more than one cell type. An "enriched" cell population refers to a cell population derived from a starting cell population (e.g., an unfractionated, heterogeneous cell population) that contains a greater percentage of a specific cell type than the percentage of that cell type in the starting population. The cell populations may be enriched for one or more cell types and depleted of one or more cell types.

[0121] The term “clinical significance” or “a clinically significant improvement,” used interchangeably herein, may be used to quantify treatment effectiveness, set clinical practice guidelines, and / or interpret trial results. The term relates to the practical importance of a treatment effect. For example, a clinically significant improvement may measure whether a treatment has a real genuine, palpable, noticeable effect on daily life of a patient or subject. A measure of clinical significance may differ based on the measurement, test, readout, protocol, trial, and / or patient outcome being assessed. Clinical significance may be measured by any methods know in the art for the corresponding measurements, tests, readouts, protocols, trials, and / or patient outcomes. Clinical significance may be an objective or subjective measure.

[0122] The phrase “composition of cells comprising photoreceptor precursor cells” refers to a cell population wherein the composition comprises at least about 90%, at least about 91%, atAttorney Docket No.: 132042-5009- WOleast about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% PRP cells.

[0123] The term "defined" or "fully defined," when used in relation to a medium, an extracellular matrix, or a culture condition, refers to a medium, an extracellular matrix, or a culture condition in which the chemical composition and amounts of approximately all the components are known. For example, a defined medium does not contain undefined factors such as in fetal bovine serum, human plasma, or human serum. Generally, a defined medium comprises a basal media (e.g., Dulbecco's Modified Eagle's Medium (DMEM), F12, or Roswell Park Memorial Institute Medium (RPM1) 1640, containing amino acids, vitamins, inorganic salts, buffers, antioxidants, and energy sources) which is supplemented with recombinant albumin, chemically defined lipids, and / or recombinant insulin. An example of a fully defined medium is ESSENTIAL 8™ medium (Thermo Fisher Scientific, Waltham, MA; Cat. No. A1517001).

[0124] The term "differentiation" or “maturation” refers to the process by which an unspecialized cell becomes a more specialized type with changes in structural and / or functional properties. The mature cell typically has altered cellular structure and tissue-specific proteins.

[0125] As used herein, "essentially" or "essentially free," in terms of a specified component, is used herein to mean that none of the specified component has been purposefully formulated into a composition and / or is present only as a contaminant or in trace amounts. The total amount of the specified component resulting from any unintended contamination of a composition is therefore well below 0.05%, preferably below 0.01%. Most preferred is a composition in which no amount of the specified component can be detected with standard analytical methods.

[0126] The terms "individual," "host," "subject," “participant,” and "patient" are used interchangeably herein, and refer to a mammal, including, but not limited to, human and nonhuman primates, including simians and humans; mammalian sport animals (e.g., horses); mammalian farm animals (e.g., sheep, goats, etc.); mammalian pets (dogs, cats, etc.); and rodents (e.g., mice, rats, etc.). Preferably, the mammal is a human.

[0127] The term "induced pluripotent stem cells” or “iPSCs" are cells generated by reprogramming a somatic cell by expressing or inducing expression of a combination of factors (herein referred to as reprogramming factors). iPSCs can be generated using fetal, postnatal, newborn, juvenile, or adult somatic cells. In certain embodiments, factors that can be used to reprogram somatic cells to pluripotent stem cells include, for example, Oct4 (sometimes referred to as Oct 3 / 4), Sox2, c-Myc, and Klf4, Nanog, and Lin28. In some embodiments, somatic cells areAttorney Docket No.: 132042-5009- WOreprogrammed by expressing at least two reprogramming factors, at least three reprogramming factors, or at least four reprogramming factors to reprogram a somatic cell to a pluripotent stem cell.

[0128] The terms “inherited retinal disease” or “I RD” refer to a clinically and genetically diverse group of disorders characterized by outer retina degeneration and / or dysfunction. IRDs may involve impaired or complete loss of function of photoreceptor cells, leading to irreversible blindness. Some IRDs may be non-syndromic and affect only the eyes, whereas others may be considered syndromic, affecting the eyes as well as other organs.

[0129] An "isolated" cell has been substantially separated or purified from others cells in an organism or culture. Isolated cells can be, for example, at least about 99%, at least about 98% pure, at least about 95% pure, or at least about 90% pure.

[0130] The term "neural retinal progenitors" or" NRPs" refers to cells which are restricted in their differentiation potential to neural retina cell types.

[0131] The term “outer nuclear layer” or “ONL” refers to the light-detecting portion of the eye in a vertebrate. The ONL may include rod cell nuclei, cone cell nuclei, both rod and cone cell nuclei, or neither rod nor cone cell nuclei.

[0132] The term “outer retinal layer” refers to a layer of the retina that includes the ONL, as well as other layers such as the outer plexiform layer (OPL), the Henle fiber layer, the myoid and ellipsoid zone (MEZ), and the photoreceptor outer segments (OS).

[0133] The terms "photoreceptor precursor cells," “photoreceptor progenitor cells,” " PRP cells,” or “PRPs” refer to cells differentiated from embryonic stem cells or induced pluripotent stem cells which can differentiate into photoreceptor cells that expresses the cell marker rhodopsin or any of the three cone opsins, and optionally express the rod or cone cyclic guanosine monophosphate (cGMP). PRP cells and / or compositions comprising PRPS do not express or have substantially no expression of CRALBP, BEST1, IGFBP5, COL8A1, ELN, UPK3B, TPM2, PTGDS, SERPINE3, TIMP3, MITF, and / or PMEL17. Additionally, PRP cells have low or substantially no expression of PAX6, CHX10, TYRP1, Ki67, and / or ONECUT1. The photoreceptors may be rod and / or cone photoreceptors. The plasma membrane of a photoreceptor cell contains two compartments: outer segments and inner segments. The term “outer segments” refers to a specialized compartment of rod and / or cone photoreceptor cells where phototransduction (e.g., capture of light and its conversion into electrical signals) takes place. The term “inner segments” refers to theAttorney Docket No.: 132042-5009- WOcompartment of the rod and / or cone cells where metabolism and membrane potential regulation occurs.

[0134] The " Photoreceptor Precursor Induction Medium” or “FDSC" refers to a growth medium which comprises a TGF[3 inhibitor, a WNT inhibitor, and / or a y-secretase inhibitor. The FDSC may comprise basic FGF and ascorbic acid.

[0135] The term "pluripotent" refers to the property of a cell to differentiate into all other cell types in an organism, with the exception of extraembryonic, or placental, cells. Pluripotent stem cells are capable of differentiating to cell types of all three germ layers (e.g., ectodermal, mesodermal, and endodermal cell types) even after prolonged culture. A pluripotent stem cell may be an embryonic stem cell derived from the inner cell mass of a blastocyst. In other embodiments, the pluripotent stem cell may be an induced pluripotent stem cell derived by reprogramming somatic cells.

[0136] “Pre-confluent" refers to a cell culture in which the proportion of the culture surface which is covered by cells is about 60% to about 80%. Usually, pre-confluent refers to a culture in which about 70% of the culture surface is covered by cells.

[0137] The terms “primary photoreceptor disease” or “PPD” refer to a subclass of inherited retinal diseases that include degenerative and non-degenerative diseases. Examples of degenerative PPDs may include retinitis pigmentosa, Usher Syndrome, cone-rod disease, rodcone disease, cone dystrophy, and cone-rod dystrophy. Examples of non-degenerative PRDs may include achromatopsia. PPDs may be non-syndromic or syndromic and may be familial or sporadic.

[0138] The term "purified" does not require absolute purity; rather, it is intended as a relative term. Thus, a purified population of cells is greater than about 90% 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% pure, or, preferably, essentially free of other cell types.

[0139] The " Retinal Differentiation Medium," “RD medium,” or “RD” is defined herein as a medium that comprises a WNT inhibitor, a TGFp inhibitor, and a MEK inhibitor and differentiates anterior neuroectoderm cells. The RD medium may (e.g., RD1) or may not (e.g., RD2) comprise a BMP inhibitor and may comprise IGF-1 and ascorbic acid.

[0140] " Retinal Induction Medium (RIM)" refers herein to a growth media that comprises a WNT pathway inhibitor and a BMP pathway inhibitor and can result in the differentiation of PSCs toAttorney Docket No.: 132042-5009- WOretinal lineage cells. The RIM may also comprise a TGFp pathway inhibitor and may comprise IGF- 1 and ascorbic acid.

[0141] The " Retinal Maturation Medium,” or “RM medium,” or “RM" is defined as a growth medium for the culture of retinal cells comprising nicotinamide and ascorbic acid. The RM is preferably free of Activin A. The RM may (e.g., RM1) or may not (e.g., RM2) comprise a y-secretase inhibitor, such as DAPT, or a TGFp inhibitor, such as SB431542 and may comprise IGF- 1 and ascorbic acid.

[0142] The term "retinal pigment epithelium" or “RPE” refers to a layer of pigmented cells between the choroid, a layer filled with blood vessels, and the neural retina.

[0143] The term "retinal progenitor cells", also called "retinal precursor cells" or " RPCs", encompass cells which are competent for generating all cell types of the retina, including neural retina cells, such as rods, cones, photoreceptor precursor cells, as well as cells which can differentiate and / or mature into retinal pigment epithelium (RPE) cells.

[0144] As used herein, the term “stable” refer to cells which are able to withstand one or more conditions (e.g., elevated temperature, etc.) fora period of time. For example, stable cells have a less than 95%, 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 15%, 10%, 5%, or 1% decrease in viability over a period of time (e.g., about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours, about 12 hours, about 13 hours, about 14 hours, about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 23 hours, about 24 hours, about 25 hours, about 26 hours, about 27 hours, about 28 hours, about 29 hours, about 30 hours, about 31 hours, about 32 hours, about 33 hours, about 34 hours, about 35 hours, about 36 hours, about 37 hours, about 38 hours, about 39 hours, about 40 hours, about 41 hours, about 42 hours, about 43 hours, about 44 hours, about 45 hours, about 46 hours, about 47 hours, about 48 hours, about 49 hours, about 50 hours or more) at about 1 °C to about 8 °C (e.g., about 1 °C, about 2 °C, about 3 °C, about 4 °C, about 5 °C, about 6 °C, about 7 °C, or about 8 °C).

[0145] The term "stem cell" refers herein to a cell that under suitable conditions is capable of differentiating into a diverse range of specialized cell types, while under other suitable conditions is capable of self-renewing and remaining in an essentially undifferentiated pluripotent state. The term "stem cell" also encompasses a pluripotent cell, multipotent cell, precursor cell and progenitor cell. Exemplary human stem cells can be obtained from hematopoietic orAttorney Docket No.: 132042-5009- WOmesenchymal stem cells obtained from bone marrow tissue, embryonic stem cells obtained from embryonic tissue, or embryonic germ cells obtained from genital tissue of a fetus. Exemplary pluripotent stem cells can also be produced from somatic cells by reprogramming them to a pluripotent state by the expression of certain transcription factors associated with pluripotency; these cells are called "induced pluripotent stem cells" or "iPSCs".

[0146] A "therapeutically effective amount" used herein refers to the amount of a compound or cells (e.g., PRPs) that, when administered to a subject for treatment of a disease or condition, is sufficient to affect such treatment. As used herein, the term “effective amount” means that dose of a composition comprising PRP cells that will elicit the biological or medical response of a tissue, system, animal, or human that is being sought, for instance, by a researcher or clinician. Furthermore, the term “therapeutically effective dose” means any dose that, as compared to a corresponding subject who has not received such dose, results in improved treatment, healing, or amelioration of a disease, disorder, or side effect, or a decrease in the rate of advancement of a disease or disorder. The term also includes within its scope doses effective to enhance normal physiological function. Therapeutically effective amounts and treatment regimens are generally determined empirically and may be dependent on factors, such as the age, weight, and health status of the subject and disease or disorder to be treated. Such factors are within the purview of the attending physician.

[0147] The terms "treatment" and "therapy" and the like, as used herein, are meant to include therapeutic as well as prophylactic, or suppressive measures for a disease or disorder leading to any clinically desirable or beneficial effect, including but not limited to alleviation or relief of one or more symptoms, regression, slowing or cessation of progression of the disease or disorder. Thus, for example, the term treatment includes the administration of an agent prior to or following the onset of a symptom of a disease or disorder thereby removing one or more signs of the disease or disorder. As another example, the term includes the administration of an agent after clinical manifestation of the disease to combat the symptoms of the disease. Further, administration of an agent after onset and after clinical symptoms have developed where administration affects clinical parameters of the disease or disorder, whether or not the treatment leads to amelioration of the disease, comprises "treatment" or "therapy" as used herein. Moreover, as long as the compositions of the disclosure either alone or in combination with another therapeutic agent alleviate or ameliorate at least one symptom of a disorder being treated as compared to that symptom in the absence of use of a composition comprising PRP cells, theAttorney Docket No.: 132042-5009- WOresult should be considered an effective treatment of the underlying disorder regardless of whether all the symptoms of the disorder are alleviated or not.

[0148] As used herein, "undifferentiated" refers to cells that display characteristic markers and morphological characteristics of undifferentiated cells that clearly distinguish them from terminally differentiated cells of embryo or adult origin.

[0149] For a medium, extracellular matrix, or culture system used with human cells, the term " Xeno-Free (XF)" refers to a condition in which the materials used are not of non-human animal origin.Photoreceptor Precursor Cell (PRP) Compositions

[0150] In an aspect, at least about 80% of the composition comprising the population of PRP cells expresses RCVRN (e.g., about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95% about 96%, about 97%, about 98% about 99%, or about 100% of the composition comprising the population of PRP cells expresses RCVRN). In particular embodiments, the disclosure provides a composition comprising a population of PRP cells. In some embodiments, about 80% to about 100% (e.g., about 80% to about 100%, about 80% to about 90%, about 90% to about 100%, about 90% to about 99%, about 90% to about 98%, about 90% to about 97%, about 90% to about 96%, about 90% to about 95%, about 90% to about 94%, about 90% to about 93%, about 90% to about 92%, about 90% to about 91 %, about 91 % to about 100%, about 91% to about 99%, about 91% to about 98%, about 91% to about 97%, about 91% to about 96%, about 91 % to about 95%, about 91 % to about 94%, about 91 % to about 93%, about 91% to about 92%, about 92% to about 100%, about 92% to about 99%, about 92% to about 98%, about 92% to about 97%, about 92% to about 96%, about 92% to about 95%, about 92% to about 94%, about 92% to about 93%, about 93% to about 100%, about 93% to about 99%, about 93% to about 98%, about 93% to about 97%, about 93% to about 96%, about 93% to about 95%, about 93% to about 94%, about 94% to about 100%, about 94% to about 99%, about 94% to about 98%, about 94% to about 97%, about 94% to about 96%, about 94% to about 95%, about 95% to about 100%, about 95% to about 99%, about 95% to about 98%, about 95% to about 97%, about 95% to about 96%, about 96% to about 100%, about 96% to about 99%, about 96% to about 98%, about 96% to about 97%, about 97% to about 100%, about 97% to about 99%, about 97% to about 98%, about 98% to about 100%, about 98% to about 99%, or about 99% to about 100%) of the composition comprising the population of PRP cells expresses RecoverinAttorney Docket No.: 132042-5009- WO(RCVRN). In some embodiments, the composition comprising the population of PRP cells comprises at least about 90% of RCVRN expressing cells.

[0151] In an aspect, the disclosure provides a composition comprising a population of PRP cells. In particular embodiments, at least about 80% of the composition comprising the population of PRP cells expresses AIPL1 (e.g., about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% of the composition comprising the population of PRP cells expresses AIPL1). In some embodiments, about 90% to about 100% (e.g., about 90% to about 100%, about 90% to about 99%, about 90% to about 98%, about 90% to about 97%, about 90% to about 96%, about 90% to about 95%, about 90% to about 94%, about 90% to about 93%, about 90% to about 92%, about 90% to about 91%, about 91% to about 100%, about 91% to about 99%, about 91% to about 98%, about 91% to about 97%, about 91% to about 96%, about 91% to about 95%, about 91% to about 94%, about 91% to about 93%, about 91% to about 92%, about 92% to about 100%, about 92% to about 99%, about 92% to about 98%, about 92% to about 97%, about 92% to about 96%, about 92% to about 95%, about 92% to about 94%, about 92% to about 93%, about 93% to about 100%, about 93% to about 99%, about 93% to about 98%, about 93% to about 97%, about 93% to about 96%, about 93% to about 95%, about 93% to about 94%, about 94% to about 100%, about 94% to about 99%, about 94% to about 98%, about 94% to about 97%, about 94% to about 96%, about 94% to about 95%, about 95% to about 100%, about 95% to about 99%, about 95% to about 98%, about 95% to about 97%, about 95% to about 96%, about 96% to about 100%, about 96% to about 99%, about 96% to about 98%, about 96% to about 97%, about 97% to about 100%, about 97% to about 99%, about 97% to about 98%, about 98% to about 100%, about 98% to about 99%, or about 99% to about 100%) of the composition comprising the population of PRP cells expresses aryl-hydrocarbon interacting protein-like 1 (AIPL1). In some embodiments, the composition comprising the population of PRP cells comprises at least about 90% of AIPL1-expressing cells.

[0152] In some embodiments, the composition comprising the population of PRP cells comprises at least about 20% PPP4R4-expressing cells (e.g., at least about 20%, about 21%, at least 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%,Attorney Docket No.: 132042-5009- WOabout 54%, about 55%, about 56%, about 57%, about 58%, about 59%, or about 60% PPP4R4-expressing cells). In some embodiments, the composition comprising the population of PRP cells comprises at most about 60% (e.g., about 20%, about 21%, at least 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%, about 59%, or about 60% PPP4R4-expressing cells). In some embodiments, the composition comprising the population of PRP cells comprises between about 20% and about 60% (e.g., about 20% to about 60%, about 20% to about 50%, about 20% to about 40%, about 20% to about 30%, about 30% to about 60%, about 30% to about 50%, about 30% to about 40%, about 40% to about 60%, about 40% to about 50%, or about 50% to about 60%) PPP4R4 expressing cells. In some embodiments, PPP4R4 expressing cells are cone-committed PRPs. In some embodiments, the composition comprising the population of PRP cells comprises at least about 20% PPP4R4-expressing cells. In some embodiments, the composition comprising the population of PRP cells comprises at most about 60% PPP4R4-expressing cells. In some embodiments, the composition comprising the population of PRP cells comprises at least about 20% of PPP4R4-expressing cells and at most about 60% PPP4R4-expressing cells.

[0153] In some embodiments, the composition comprising the population of PRP cells comprises at least about 10% to at most about 100% NR2E3-expressing cells (e.g., at least about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%, about 59%, about 60%, about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% NR2E3-expressing cells). In some embodiments, the composition comprising the population of PRP cells comprises between about 10% and about 100% (e.g., about 10% to about 100%, about 10% to about 90%, about 10% to about 80%, aboutAttorney Docket No.: 132042-5009- WO10% to about 70%, about 10% to about 60%, about 10% to about 50%, about 10% to about 40%, about 10% to about 30%, about 10% to about 20%, about 20% to about 100%, about 20% to about 90%, about 20% to about 80%, about 20% to about 70%, about 20% to about 60%, about 20% to about 50%, about 20% to about 40%, about 20% to about 30%, about 30% to about 100%, about 30% to about 80%, about 30% to about 70%, about 30% to about 60%, about 30% to about 50%, about 30% to about 40%, about 40% to about 100%, about 40% to about 90%, about 40% to about 80%, about 40% to about 70%, about 40% to about 60%, about 40% to about 50%, about 50% to about 100%, about 50% to about 90%, about 50% to about 80%, about 50% to about 70%, about 50% to about 60%, about 60% to about 100%, about 60% to about 90%, about 60% to about 80%, about 60% to about 70%, about 70% to about 100%, about 70% to about 90%, about 70% to about 80%, about 80% to about 100%, about 80% to about 90%, or about 90% to about 100%) NR2E3-expressing cells. In some embodiments, NR2E3 expressing cells are rod-committed PRPs. In some embodiments, the composition comprising the population of PRP cells comprises at least about 25% to at most about 65% NR2E3-expressing cells. In some embodiments, the composition comprising the population of PRP cells comprises at least about 40% to at most about 80% NR2E3-expressing cells.

[0154] In some embodiments, a composition comprising the population of cells comprising 90% PRP cells comprises at least about 90% AIPL1-expressing cells and at least about 90% RCVRN-expressing cells. In further embodiments, of those 90% PRPs expressing AIPL1 and RCVRN, a first portion will express PPP4R4 and a second portion will express NR2E3. In further embodiments, of those 90% PRPs expressing AIPL1 and RCVRN, the first portion will express PPP4R4 but will not express NR2E3. In further embodiments, of those 90% PRPs expressing AIPL1 and RCVRN, the second portion will express NR2E3 but will not express PPP4R4. In further embodiments, of those 90% PRPs expressing AIPL1 and RCVRN, at least about 20% of the cells will express PPP4R4, at least about 80% of the cells will express NR2E3. In further embodiments, of those 90% PRPs expressing AIPL1 and RCVRN, at least about 30% of the cells will express PPP4R4, at least about 70% of the cells will express NR2E3. In further embodiments, of those 90% PRPs expressing AIPL1 and RCVRN, at least about 40% of the cells will express PPP4R4, at least about 60% of the cells will express NR2E3. In further embodiments, of those 90% PRPs expressing AIPL1 and RCVRN, at least about 50% of the cells will express PPP4R4, at least about 50% of the cells will express NR2E3. In further embodiments, of those 90% PRPs expressing AIPL1 and RCVRN, at least about 60% of the cells will express PPP4R4, at least about 40% of the cells will express NR2E3.Attorney Docket No.: 132042-5009- WO

[0155] In some embodiments, the composition comprising the population of PRP cells comprises about 0.0 copies to about 0.5 copies VIM per copy of SDHA as measured by ddPCR, (e.g., about 0.0, about 0.05, about 0.10, about 0.15, about 0.20, about 0.25, about 0.30, about 0.35, about 0.40, about 0.45, or about 0.50 copies VIM per copy SDHA as measured by ddPCR). In some embodiments, the composition comprising the population of PRP cells comprises VIM+ cells. In some embodiments, the composition comprising the population of PRP cells comprises between about 0.0 copies and about 0.50 copies (e.g., about 0.0 copies to about 0.1, about 0.0 copies to about 0.2, about 0.0 copies to about 0.3, about 0.0 copies to about 0.4, about 0.0 copies to about 0.5, about 0.1 copies to about 0.2, about 0.1 copies to about 0.3, about 0.1 copies to about 0.4, about 0.1 copies to about 0.5, about 0.2 copies to about 0.3, about 0.2 copies to about 0.4, about 0.2 copies to about 0.5, about 0.3 copies to about 0.4, about 0.3 copies to about 0.5, or about 0.4 copies to about 0.5) VIM per copy of a reference gene, e.g., SDHA, as measured by ddPCR. In some embodiments, the composition comprising the population of PRP cells comprises at most 0.5 copies VIM per copy SDHA as measured by ddPCR. In some embodiments, ddPCR is performed using Bio-Rad’s QX200™ ddPCR System. In some embodiments, copies of VIM is determined relative to reference gene SDHA.

[0156] In some embodiments, the composition comprising the population of PRP cells comprises at most 7% PAX6-expressing cells (e.g., about 7.0%, about 6.75%, about 6.50%, about 6.25%, about 6.0%, about 5.75%, about 5.50%, about 5.25%, about 5.0%, about 4.75%, about 4.50%, about 4.25%, about 4.0%, about 3.75%, about 3.50%, about 3.25%, about 3.0%, about 2.75%, about 2.50%, about 2.25%, about 2.0%, about 1.75%, about 1.50%, about 1.25%, about 1.0%, about 0.75%, about 0.50%, about 0.25%, or about 0.0% PAX6-expressing cells). In some embodiments, the composition comprising the population of PRP cells comprises between about 0% and about 7% (e.g., about 0% to about 7%, about 0% to about 6%, about 0% to about 5%, about 0% to about 4%, about 0% to about 3%, about 0% to about 2%, about 0% to about 1%, about 1% to about 7%, about 1% to about 6%, about 1% to about 5%, about 1% to about 4%, about 1% to about 3%, about 1% to about 2%, about 2% to about 7%, about 2% to about 6%, about 2% to about 5%, about 2% to about 4%, about 2% to about 3%, about 3% to about 7%, about 3% to about 6%, about 3% to about 5%, about 3% to about 4%, about 4% to about 7%, about 4% to about 6%, about 4% to about 5%, about 5% to about 7%, about 5% to about 6%, or about 6% to about 7%) PAX6--expressing cells. In some embodiments, the composition comprising the population of PRP cells comprises at most about 7% PAX6-expressing cells.Attorney Docket No.: 132042-5009- WO

[0157] In some embodiments, the composition comprising the population of PRP cells comprises at most 5% CHX10-expressing cells (e.g., about 7.0%, about 6.75%, about 6.50%, about 6.25%, about 6.0%, about 5.75%, about 5.50%, about 5.25%, about 5.0%, about 4.75%, about 4.50%, about 4.25%, about 4.0%, about 3.75%, about 3.50%, about 3.25%, about 3.0%, about 2.75%, about 2.50%, about 2.25%, about 2.0%, about 1.75%, about 1.50%, about 1.25%, about 1.0%, about 0.75%, about 0.50%, about 0.25%, or about 0.0% CHX10-expressing cells). In some embodiments, the composition comprising the population of PRP cells comprises between about 0% and about 7% (e.g., about 0% to about 7%, about 0% to about 6%, about 0% to about 5%, about 0% to about 4%, about 0% to about 3%, about 0% to about 2%, about 0% to about 1%, about 1% to about 7%, about 1% to about 6%, about 1% to about 5%, about 1% to about 4%, about 1% to about 3%, about 1% to about 2%, about 2% to about 7%, about 2% to about 6%, about 2% to about 5%, about 2% to about 4%, about 2% to about 3%, about 3% to about 7%, about 3% to about 6%, about 3% to about 5%, about 3% to about 4%, about 4% to about 7%, about 4% to about 6%, about 4% to about 5%, about 5% to about 7%, about 5% to about 6%, or about 6% to about 7%) CHX10-expressing cells. In some embodiments, the composition comprising the population of PRP cells comprises at most about 7% CHX10-expressing cells.

[0158] In some embodiments, the composition comprising the population of PRP cells comprises at most about 0.5% Ki67-expressing cells (e.g., about 0.00%, about 0.05%, about 0.10%, about 0.15%, about 0.20%, about 0.25%, about 0.30%, about 0.35%, about 0.40%, about 0.45%, or about 0.50% Ki67-expressing cells). In some embodiments, the composition comprising the population of PRP cells comprises between about 0% and about 0.5% (e.g., about 0.0% to about 0.1%, about 0.0% to about 0.2%, about 0.0% to about 0.3%, about 0.0% to about 0.4%, about 0.0% to about 0.5%, about 0.1% to about 0.2%, about 0.1% to about 0.3%, about 0.1% to about 0.4%, about 0.1% to about 0.5%, about 0.2% to about 0.3%, about 0.2% to about 0.4%, about 0.2% to about 0.5%, about 0.3% to about 0.4%, about 0.3% to about 0.5%, or about 0.4% to about 0.5%) Ki67-expressing cells. In some embodiments, the composition comprising the population of PRP cells comprises at most 0.5% Ki67-expressing cells.

[0159] In some embodiments, the composition comprising the population of PRP cells comprises at most 0.5% TYRP1 -expressing cells (e.g., about 0.00%, about 0.05%, about 0.10%, about 0.15%, about 0.20%, about 0.25%, about 0.30%, about 0.35%, about 0.40%, about 0.45%, or about 0.50% TYRP1 -expressing cells. In some embodiments, the composition comprising the population of PRP cells comprises between about 0% and about 0.5% (e.g., about 0.0% to aboutAttorney Docket No.: 132042-5009- WO0.1%, about 0.0% to about 0.2%, about 0.0% to about 0.3%, about 0.0% to about 0.4%, about 0.0% to about 0.5%, about 0.1% to about 0.2%, about 0.1% to about 0.3%, about 0.1% to about 0.4%, about 0.1% to about 0.5%, about 0.2% to about 0.3%, about 0.2% to about 0.4%, about 0.2% to about 0.5%, about 0.3% to about 0.4%, about 0.3% to about 0.5%, or about 0.4% to about 0.5%) TYRP1- expressing cells. In some embodiments, the composition comprising the population of PRP cells comprises at most 0.5% TYRP1 -expressing cells.

[0160] In some embodiments, the composition comprising the population of PRP cells comprises NR2E3+ cells (e.g., at an amount or percentage described herein), between at least about 20% and at most about 60% PPP4R4+ cells, at most 0.5 copies VIM per copy SDHA, at least about 90% AIPL1+ cells, at least about 90% RCVRN+ cells, at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, and / or at most about 0.5% Ki67+ cells. In some embodiments, the composition comprising the population of PRP cells comprises between at least about 20% and at most about 60% PPP4R4+ cells and at most 0.5 copies VIM per copy SDHA. In some embodiments, the composition comprising the population of PRP cells comprises NR2E3+ cells and between at least about 20% and at most about 60% PPP4R4+ cells. In some embodiments, the composition comprising the population of PRP cells comprises NR2E3+ cells, between at least about 20% and at most about 60% PPP4R4+ cells, and at most 0.5 copies VIM per copy SDHA. In some embodiments, the composition comprising the population of PRP cells comprises at least about 90% AIPL1+ cells and at least about 90% RCVRN+ cells. In some embodiments, the composition comprising the population of PRP cells comprises NR2E3+ cells, between at least about 20% and at most about 60% PPP4R4+ cells, at most 0.5 copies VIM per copy SDHA, at least about 90% AIPL1+ cells, and at least about 90% RCVRN+ cells. In some embodiments, the composition comprising the population of PRP cells comprises at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, and / or at most about 0.5% Ki67+ cells. In some embodiments, the composition comprising the population of PRP cells comprises NR2E3+ cells and between at least about 20% to about 60% PPP4R4+ cells. In some embodiments, the composition comprising the population of PRP cells comprises between about 40% and about 80% NR2E3+ cells, between at least about 20% and at most about 60% PPP4R4+ cells, at most 0.5 copies VIM per copy SDHA, at least about 90% AIPL1+ cells, at least about 90% RCVRN+ cells, at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, and / or at most about 0.5% Ki67+ cells.Attorney Docket No.: 132042-5009- WO

[0161] In certain aspects, the composition comprising the population of PRP cells does not express or have substantially no expression of CRALBP, BEST1, IGFBP5, COL8A1, ELN, UPK3B, TPM2, PTGDS, SERPINE3, TIMP3, MITF, and / or PMEL17. In some embodiments, the composition comprising the population of PRP cells has low or substantially no expression of PAX6, CHX10 (also referred to as VSX2), Ki67, TYRP1, and / or ONECUT1. In particular embodiments, at most about 15%, (e.g., about 0% to about 15%, about 0% to about 14%, about 0% to about 13%, about 0% to about 12%, about 0% to about 11%, about 0% to about 10%, about 0% to about 9%, about 0% to about 8%, about 0% to about 7%, about 0% to about 6%, about 0% to about 5%, about 0% to about 4%, about 0% to about 3%, about 0% to about 2%, about 0% to about 1%, about 1% to about 15%, about 1% to about 14%, about 1% to about 13%, about 1% to about 12%, about 1% to about 11%, about 1% to about 10%, about 1% to about 9%, about 1% to about 8%, about 1% to about 7%, about 1% to about 6%, about 1% to about 5%, about 1% to about 4%, about 1% to about 3%, about 1% to about 2%, about 2% to about 15%, about 2% to about 14%, about 2% to about 13%, about 2% to about 12%, about 2% to about 11%, about 2% to about 10%, about 2% to about 9%, about 2% to about 8%, about 2% to about 7%, about 2% to about 6%, about 2% to about 5%, about 2% to about 4%, about 2% to about 3%, about 3% to about 15%, about 3% to about 14%, about 3% to about 13%, about 3% to about 12%, about 3% to about 11%, about 3% to about 10%, about 3% to about 9%, about 3% to about 8%, about 3% to about 7%, about 3% to about 6%, about 3% to about 5%, about 3% to about 4%, about 4% to about 15%, about 4% to about 14%, about 4% to about 13%, about 4% to about 12%, about 4% to about 11%, about 4% to about 10%, about 4% to about 9%, about 4% to about 8%, about 4% to about 7%, about 4% to about 6%, about 4% to about 5%, about 5% to about 15%, about 5% to about 14%, about 5% to about 13%, about 5% to about 12%, about 5% to about 11%, about 5% to about 10%, about 5% to about 9%, about 5% to about 8%, about 5% to about 7%, about 5% to about 6%, about 6% to about 15%, about 6% to about 14%, about 6% to about 13%, about 6% to about 12%, about 6% to about 11%, about 6% to about 10%, about 6% to about 9%, about 6% to about 8%, about 6% to about 7%, about 7% to about 15%, about 7% to about 14%, about 7% to about 13%, about 7% to about 12%, about 7% to about 11%, about 7% to about 10%, about 7% to about 9%, about 7% to about 8%, about 8% to about 15%, about 8% to about 14%, about 8% to about 13%, about 8% to about 12%, about 8% to about 11%, about 8% to about 10%, about 8% to about 9%, about 9% to about 15%, about 9% to about 14%, about 9% to about 13%, about 9% to about 12%, about 9% to about 11%, about 9% to about 10%, about 10% to about 15%, about 10% to about 14%, about 10% to about 13%, about 10% to about 12%, about 10% to about 11%, about 11% to about 15%, about 11% to about 14%, about 11% to about 13%, about 11% toAttorney Docket No.: 132042-5009- WOabout 12%, about 12% to about 15%, about 12% to about 14%, about 12% to about 13%, about 13% to about 15%, about 13% to about 14%, or about 14% to about 15%) of the composition comprising the population of PRP cells express PAX6. In some embodiments, the composition comprising the population of PRP cells comprises at most about 10% or about 5% PAX6-positive cells. In certain embodiments, the composition comprising the population of PRP cells comprises at most about 7% PAX6-positive cells, at most about 0.05% Ki67-positive cells, at most about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 45%, about 50%, about 55%, about 60%, about 70%, about 80%, about 90%, about 95%, or about 100% CHX10-positive cells, and / or at most about 2% ONECUTI-positive cells. In some aspects, the composition comprising the population of PRP cells comprises at most about 7% PAX6-positive cells, at most about 0.5% Ki67-positive cells, at most about 7% CHX10-positive cells, and / or at most about 1% ONECUTI-positive cells. In certain aspects, the composition comprising the population of PRP cells comprises at most about 7% PAX6-positive cells, at most about 0.5% Ki67-positive cells, at most about 7% CHX10-positive cells, and at most about 1% ONECUTI-positive cells.

[0162] In some embodiments, at least about 90% of the composition comprising the population of PRPs expresses TUBB3 (e.g., 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% of the composition comprising the population of PRP cells expresses TUBB3). In some embodiments, at least about 90% to about 100% (e.g., about 90% to about 100%, about 90% to about 99%, about 90% to about 98%, about 90% to about 97%, about 90% to about 96%, about 90% to about 95%, about 90% to about 94%, about 90% to about 93%, about 90% to about 92%, about 90% to about 91 %, about 91% to about 100%, about 91% to about 99%, about 91% to about 98%, about 91% to about 97%, about 91% to about 96%, about 91% to about 95%, about 91% to about 94%, about 91% to about 93%, about 91% to about 92%, about 92% to about 100%, about 92% to about 99%, about 92% to about 98%, about 92% to about 97%, about 92% to about 96%, about 92% to about 95%, about 92% to about 94%, about 92% to about 93%, about 93% to about 100%, about 93% to about 99%, about 93% to about 98%, about 93% to about 97%, about 93% to about 96%, about 93% to about 95%, about 93% to about 94%, about 94% to about 100%, about 94% to about 99%, about 94% to about 98%, about 94% to about 97%, about 94% to about 96%, about 94% to about 95%, about 95% to about 100%, about 95% to about 99%, about 95% to about 98%, about 95% to about 97%, about 95% to about 96%, about 96% to about 100%, about 96% to about 99%, about 96% to about 98%, about 96% to about 97%, about 97% to about 100%, about 97% to about 99%, about 97% to about 98%, about 98% to about 100%, about 98% to aboutAttorney Docket No.: 132042-5009- WO99%, or about 99% to about 100%) of the composition comprising the population of PRP cells expresses Class III β-tubulin (TUBB3). In some embodiments, the composition comprising the population of PRP cells expresses one or more markers selected from the group consisting of: AIPL1, NR2E3, PPP4R4, OTX2, CRX, BLIMP 1, NEUROD1, RCVRN, TUBB3 and CD171 / L1CAM.

[0163] In particular embodiments, the composition comprising the population of PRP cells comprises at least about 70% cell aggregate biomass (e.g., about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% cell aggregate biomass). In some embodiments, the composition comprising the population of PRP cells comprises between about 70% and about 100% (e.g., about 70% to about 100%, about 70% to about 90%, about 70% to about 80%, about 80% to about 100%, about 80% to about 90%, or about 90% to about 100%) cell aggregate biomass. In some embodiments, the composition comprising the population of PRP cells comprises at least about 70% cell aggregate biomass.

[0164] In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of, one or more, two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, ten or more, eleven or more, or twelve of the characteristics provided in Table 1.Table 1. Specifications for Drug Products Comprising a Composition of Cells Comprising PRPs as Disclosed HereinSpecification CharacteristicAIPL1+ At least 90%RCVRN+ At least 90%PPP4R4+ At least 20% and at most 60%NR2E3+ DetectablePAX6+ At most 7%CHX10+ At most 7%TYRP1+ At most 0.5%Ki67+ At most 0.5%Copies of VIM per copy of SDHA At most 0.5 copies / copyAttorney Docket No.: 132042-5009- WOAggregate biomass At least 70%Percentage Viability At least 50%LNCPRESS2 and AC009446.1 Not detectable

[0165] In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least 90% AIPL1+ cells, at least 90% RCVRN+ cells, at least 20% and at most 60% PPP4R4+ cells, NR2E3+ cells, at most 7% PAX6+ cells, at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, at most 0.5% Ki67+ cells, at most 0.5 copies of VIM per copy of SDHA, at least 70% aggregate biomass, a percentage viability of at least 50%, no detectable expression of LNCPRESS2 and / or AC009446.1, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least 90% AIPL1+ cells, at least 90% RCVRN+ cells, at least 20% and at most 60% PPP4R4+ cells, NR2E3+ cells, at most 7% PAX6+ cells, at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, at most 0.5% Ki67+ cells, at most 0.5 copies of VIM per copy of SDHA, at least 70% aggregate biomass, a percentage viability of at least 50%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least 90% AIPL1+ cells, at least 90% RCVRN+ cells, at least 20% and at most 60% PPP4R4+ cells, NR2E3+ cells, at most 7% PAX6+ cells, at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, at most 0.5% Ki67+ cells, at most 0.5 copies of VIM per copy of SDHA, at least 70% aggregate biomass, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least 90% AIPL1+ cells, at least 90% RCVRN+ cells, at least 20% and at most 60% PPP4R4+ cells, NR2E3+ cells, at most 7% PAX6+ cells, at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, at most 0.5% Ki67+ cells, at most 0.5 copies of VIM per copy of SDHA, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least 90% AIPL1+ cells, at least 90% RCVRN+ cells, at least 20% and at most 60% PPP4R4+ cells, NR2E3+ cells, at most 7% PAX6+ cells, at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, at most 0.5% Ki67+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, aAttorney Docket No.: 132042-5009- WOcomposition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least 90% AIPL1+ cells, at least 90% RCVRN+ cells, at least 20% and at most 60% PPP4R4+ cells, NR2E3+ cells, at most 7% PAX6+ cells, at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least 90% AIPL1+ cells, at least 90% RCVRN+ cells, at least 20% and at most 60% PPP4R4+ cells, NR2E3+ cells, at most 7% PAX6+ cells, at most 7% CHX10+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least 90% AIPL1+ cells, at least 90% RCVRN+ cells, at least 20% and at most 60% PPP4R4+ cells, NR2E3+ cells, at most 7% PAX6+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least 90% AIPL1+ cells, at least 90% RCVRN+ cells, at least 20% and at most 60% PPP4R4+ cells, NR2E3+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least 90% AIPL1+ cells, at least 90% RCVRN+ cells, at least 20% and at most 60% PPP4R4+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least 90% AIPL1+ cells, at least 90% RCVRN+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least 90% AIPL1+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form.

[0166] In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least 90% RCVRN+ cells, at least 20% and at most 60% PPP4R4+ cells, NR2E3+ cells, at most 7% PAX6+ cells, at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, at most 0.5% Ki67+ cells, at most 0.5 copies of VIM per copy of SDHA, at least 70% aggregate biomass, a percentage viability of at least 50%, no detectable expression of LNCPRESS2 and / or AC009446.1, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of atAttorney Docket No.: 132042-5009- WOleast 90% RCVRN+ cells, at least 20% and at most 60% PPP4R4+ cells, NR2E3+ cells, at most 7% PAX6+ cells, at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, at most 0.5% Ki67+ cells, at most 0.5 copies of VIM per copy of SDHA, at least 70% aggregate biomass, a percentage viability of at least 50%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least 90% RCVRN+ cells, at least 20% and at most 60% PPP4R4+ cells, NR2E3+ cells, at most 7% PAX6+ cells, at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, at most 0.5% Ki67+ cells, at most 0.5 copies of VIM per copy of SDHA, at least 70% aggregate biomass, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least 90% RCVRN+ cells, at least 20% and at most 60% PPP4R4+ cells, NR2E3+ cells, at most 7% PAX6+ cells, at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, at most 0.5% Ki67+ cells, at most 0.5 copies of VIM per copy of SDHA, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least 90% RCVRN+ cells, at least 20% and at most 60% PPP4R4+ cells, NR2E3+ cells, at most 7% PAX6+ cells, at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, at most 0.5% Ki67+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least 90% RCVRN+ cells, at least 20% and at most 60% PPP4R4+ cells, NR2E3+ cells, at most 7% PAX6+ cells, at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least 90% RCVRN+ cells, at least 20% and at most 60% PPP4R4+ cells, NR2E3+ cells, at most 7% PAX6+ cells, at most 7% CHX10+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least 90% RCVRN+ cells, at least 20% and at most 60% PPP4R4+ cells, NR2E3+ cells, at most 7% PAX6+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least 90% RCVRN+ cells, at least 20% and at most 60% PPP4R4+ cells, NR2E3+ cells, and wherein the composition is mostly in aggregate form, whichAttorney Docket No.: 132042-5009- WOis in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least 90% RCVRN+ cells, at least 20% and at most 60% PPP4R4+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least 90% RCVRN+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least 20% and at most 60% PPP4R4+ cells, NR2E3+ cells, at most 7% PAX6+ cells, at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, at most 0.5% Ki67+ cells, at most 0.5 copies of VIM per copy of SDHA, at least 70% aggregate biomass, a percentage viability of at least 50%, no detectable expression of LNCPRESS2 and / or AC009446.1, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least 20% and at most 60% PPP4R4+ cells, NR2E3+ cells, at most 7% PAX6+ cells, at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, at most 0.5% Ki67+ cells, at most 0.5 copies of VIM per copy of SDHA, at least 70% aggregate biomass, a percentage viability of at least 50%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least 20% and at most 60% PPP4R4+ cells, NR2E3+ cells, at most 7% PAX6+ cells, at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, at most 0.5% Ki67+ cells, at most 0.5 copies of VIM per copy of SDHA, at least 70% aggregate biomass, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least 20% and at most 60% PPP4R4+ cells, NR2E3+ cells, at most 7% PAX6+ cells, at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, at most 0.5% Ki67+ cells, at most 0.5 copies of VIM per copy of SDHA, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least 20% and at most 60% PPP4R4+ cells, NR2E3+ cells, at most 7% PAX6+ cells, at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, at most 0.5% Ki67+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least 20% and at most 60% PPP4R4+ cells, NR2E3+ cells, at mostAttorney Docket No.: 132042-5009- WO7% PAX6+ cells, at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least 20% and at most 60% PPP4R4+ cells, NR2E3+ cells, at most 7% PAX6+ cells, at most 7% CHX10+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least 90% AIPL1+ cells, at least 90% RCVRN+ cells, at least 20% and at most 60% PPP4R4+ cells, NR2E3+ cells, at most 7% PAX6+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least 20% and at most 60% PPP4R4+ cells, NR2E3+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least 20% and at most 60% PPP4R4+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form.

[0167] In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of NR2E3+ cells, at most 7% PAX6+ cells, at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, at most 0.5% Ki67+ cells, at most 0.5 copies of VIM per copy of SDHA, at least 70% aggregate biomass, a percentage viability of at least 50%, no detectable expression of LNCPRESS2 and / or AC009446.1, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of NR2E3+ cells, at most 7% PAX6+ cells, at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, at most 0.5% Ki67+ cells, at most 0.5 copies of VIM per copy of SDHA, at least 70% aggregate biomass, a percentage viability of at least 50%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of NR2E3+ cells, at most 7% PAX6+ cells, at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, at most 0.5% Ki67+ cells, at most 0.5 copies of VIM per copy of SDHA, at least 70% aggregate biomass, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of NR2E3+ cells, at most 7% PAX6+ cells, at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, at most 0.5% Ki67+ cells, atAttorney Docket No.: 132042-5009- WOmost 0.5 copies of VIM per copy of SDHA, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of NR2E3+ cells, at most 7% PAX6+ cells, at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, at most 0.5% Ki67+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of NR2E3+ cells, at most 7% PAX6+ cells, at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of NR2E3+ cells, at most 7% PAX6+ cells, at most 7% CHX10+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of NR2E3+ cells, at most 7% PAX6+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of NR2E3+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form.

[0168] In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at most 7% PAX6+ cells, at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, at most 0.5% Ki67+ cells, at most 0.5 copies of VIM per copy of SDHA, at least 70% aggregate biomass, a percentage viability of at least 50%, no detectable expression of LNCPRESS2 and / or AC009446.1, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at most 7% PAX6+ cells, at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, at most 0.5% Ki67+ cells, at most 0.5 copies of VIM per copy of SDHA, at least 70% aggregate biomass, a percentage viability of at least 50%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at most 7% PAX6+ cells, at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, at most 0.5% Ki67+ cells, at most 0.5 copies of VIM per copy of SDHA, at least 70% aggregate biomass, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of atAttorney Docket No.: 132042-5009- WOmost 7% PAX6+ cells, at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, at most 0.5% Ki67+ cells, at most 0.5 copies of VIM per copy of SDHA, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at most 7% PAX6+ cells, at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, at most 0.5% Ki67+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at most 7% PAX6+ cells, at most 7% CHX10+ cells, at most 0.5% TYRP1 + cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at most 7% PAX6+ cells, at most 7% CHX10+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at most 7% PAX6+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form.

[0169] In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, at most 0.5% Ki67+ cells, at most 0.5 copies of VIM per copy of SDHA, at least about 70% aggregate biomass, a percentage viability of at least about 50%, no detectable expression of LNCPRESS2 and / or AC009446.1, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, at most 0.5% Ki67+ cells, at most 0.5 copies of VIM per copy of SDHA, at least about 70% aggregate biomass, a percentage viability of at least about 50%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, at most 0.5% Ki67+ cells, at most 0.5 copies of VIM per copy of SDHA, at least about 70% aggregate biomass, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, at most 0.5% Ki67+ cells, at most 0.5 copies of VIM per copy of SDHA, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein,Attorney Docket No.: 132042-5009- WOcomprises, or consists of, or consists essentially of at most 7% CHX10+ cells, at most 0.5% TYRP1 + cells, at most 0.5% Ki67+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at most 7% CHX10+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form.

[0170] In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at most 0.5% TYRP1+ cells, at most 0.5% Ki67+ cells, at most 0.5 copies of VIM per copy of SDHA, at least 70% aggregate biomass, a percentage viability of at least 50%, no detectable expression of LNCPRESS2 and / or AC009446.1, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at most 0.5% TYRP1+ cells, at most 0.5% Ki67+ cells, at most 0.5 copies of VIM per copy of SDHA, at least 70% aggregate biomass, a percentage viability of at least 50%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at most 0.5% TYRP1+ cells, at most 0.5% Ki67+ cells, at most 0.5 copies of VIM per copy of SDHA, at least 70% aggregate biomass, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at most 0.5% TYRP1+ cells, at most 0.5% Ki67+ cells, at most 0.5 copies of VIM per copy of SDHA, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at most 0.5% TYRP1+ cells, at most 0.5% Ki67+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at most 0.5% TYRP1+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form.Attorney Docket No.: 132042-5009- WO

[0171] In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at most 0.5% Ki67+ cells, at most 0.5 copies of VIM per copy of SDHA, at least 70% aggregate biomass, a percentage viability of at least 50%, no detectable expression of LNCPRESS2 and / or AC009446.1, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at most 0.5% Ki67+ cells, at most 0.5 copies of VIM per copy of SDHA, at least 70% aggregate biomass, a percentage viability of at least 50%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at most 0.5% Ki67+ cells, at most 0.5 copies of VIM per copy of SDHA, at least 70% aggregate biomass, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at most 0.5% Ki67+ cells, at most 0.5 copies of VIM per copy of SDHA, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at most 0.5% Ki67+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form.

[0172] In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at most 0.5 copies of VIM per copy of SDHA, at least 70% aggregate biomass, a percentage viability of at least 50%, no detectable expression of LNCPRESS2 and / or AC009446.1, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at most 0.5 copies of VIM per copy of SDHA, at least 70% aggregate biomass, a percentage viability of at least 50%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at most 0.5 copies of VIM per copy of SDHA, at least 70% aggregate biomass, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at most 0.5 copies of VIM per copy of SDHA, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form.Attorney Docket No.: 132042-5009- WO

[0173] In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least 70% aggregate biomass, a percentage viability of at least 50%, no detectable expression of LNCPRESS2 and / or AC009446.1, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least 70% aggregate biomass, a percentage viability of at least 50%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least 70% aggregate biomass, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form.

[0174] In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of a percentage viability of at least 50%, no detectable expression of LNCPRESS2 and / or AC009446.1, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of a percentage viability of at least 50%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form.

[0175] In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of no detectable expression of LNCPRESS2 and / or AC009446.1, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form.

[0176] In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least about 90% AIPL1+ cells, at least about 90% RCVRN+ cells, at least about 20% and at most about 60% PPP4R4+ cells, NR2E3+ cells, at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, at most about 0.5% TYRP1 + cells, at most about 0.5% Ki67+ cells, at most about 0.5 copies of VIM per copy of SDHA, at least about 70% aggregate biomass, a percentage viability of at least about 50%, no detectable expression of LNCPRESS2 and / or AC009446.1, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least about 90% AIPL1+ cells, at least about 90% RCVRN+ cells, at least about 20% and at most about 60% PPP4R4+ cells, NR2E3+ cells, at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, at most about 0.5% Ki67+ cells, at most aboutAttorney Docket No.: 132042-5009- WO0.5 copies of VIM per copy of SDHA, at least about 70% aggregate biomass, a percentage viability of at least about 50%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least about 90% AIPL1 + cells, at least about 90% RCVRN+ cells, at least about 20% and at most about 60% PPP4R4+ cells, NR2E3+ cells, at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, at most about 0.5% Ki67+ cells, at most about 0.5 copies of VIM per copy of SDHA, at least about 70% aggregate biomass, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least about 90% AIPL1+ cells, at least about 90% RCVRN+ cells, at least about 20% and at most about 60% PPP4R4+ cells, NR2E3+ cells, at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, at most about 0.5% Ki67+ cells, at most about 0.5 copies of VIM per copy of SDHA, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least about 90% AIPL1+ cells, at least about 90% RCVRN+ cells, at least about 20% and at most about 60% PPP4R4+ cells, NR2E3+ cells, at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, at most about 0.5% Ki67+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least about 90% AIPL1+ cells, at least about 90% RCVRN+ cells, at least about 20% and at most about 60% PPP4R4+ cells, NR2E3+ cells, at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least about 90% AIPL1+ cells, at least about 90% RCVRN+ cells, at least about 20% and at most about 60% PPP4R4+ cells, NR2E3+ cells, at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least about 90% AIPL1 + cells, at least about 90% RCVRN+ cells, at least about 20% and at most about 60% PPP4R4+ cells, NR2E3+ cells, at most about 7% PAX6+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition ofAttorney Docket No.: 132042-5009- WOcells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least about 90% AIPL1+ cells, at least about 90% RCVRN+ cells, at least about 20% and at most about 60% PPP4R4+ cells, NR2E3+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least about 90% AIPL1+ cells, at least about 90% RCVRN+ cells, at least about 20% and at most about 60% PPP4R4+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least about 90% AIPL1 + cells, at least about 90% RCVRN+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least about 90% AIPL1+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form.

[0177] In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least about 90% RCVRN+ cells, at least about 20% and at most about 60% PPP4R4+ cells, NR2E3+ cells, at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, at most about 0.5% Ki67+ cells, at most about 0.5 copies of VIM per copy of SDHA, at least about 70% aggregate biomass, a percentage viability of at least about 50%, no detectable expression of LNCPRESS2 and / or AC009446.1, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least about 90% RCVRN+ cells, at least about 20% and at most about 60% PPP4R4+ cells, NR2E3+ cells, at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, at most about 0.5% Ki67+ cells, at most about 0.5 copies of VIM per copy of SDHA, at least about 70% aggregate biomass, a percentage viability of at least about 50%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least about 90% RCVRN+ cells, at least about 20% and at most about 60% PPP4R4+ cells, NR2E3+ cells, at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, at most about 0.5% Ki67+ cells, at most about 0.5 copies of VIM per copy of SDHA, at least about 70% aggregate biomass, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprisingAttorney Docket No.: 132042-5009- WOPRPs as disclosed herein, comprises, or consists of, or consists essentially of at least about 90% RCVRN+ cells, at least about 20% and at most about 60% PPP4R4+ cells, NR2E3+ cells, at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, at most about 0.5% Ki67+ cells, at most about 0.5 copies of VIM per copy of SDHA, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least about 90% RCVRN+ cells, at least about 20% and at most about 60% PPP4R4+ cells, NR2E3+ cells, at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, at most about 0.5% Ki67+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least about 90% RCVRN+ cells, at least about 20% and at most about 60% PPP4R4+ cells, NR2E3+ cells, at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least about 90% RCVRN+ cells, at least about 20% and at most about 60% PPP4R4+ cells, NR2E3+ cells, at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least about 90% RCVRN+ cells, at least about 20% and at most about 60% PPP4R4+ cells, NR2E3+ cells, at most about 7% PAX6+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least about 90% RCVRN+ cells, at least about 20% and at most about 60% PPP4R4+ cells, NR2E3+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least about 90% RCVRN+ cells, at least about 20% and at most about 60% PPP4R4+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least about 90% RCVRN+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form.Attorney Docket No.: 132042-5009- WO

[0178] In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least about 20% and at most about 60% PPP4R4+ cells, NR2E3+ cells, at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, at most about 0.5% Ki67+ cells, at most about 0.5 copies of VIM per copy of SDHA, at least about 70% aggregate biomass, a percentage viability of at least about 50%, no detectable expression of LNCPRESS2 and / or AC009446.1, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least about 20% and at most about 60% PPP4R4+ cells, NR2E3+ cells, at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, at most about 0.5% Ki67+ cells, at most about 0.5 copies of VIM per copy of SDHA, at least about 70% aggregate biomass, a percentage viability of at least about 50%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least about 20% and at most about 60% PPP4R4+ cells, NR2E3+ cells, at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, at most about 0.5% Ki67+ cells, at most about 0.5 copies of VIM per copy of SDHA, at least about 70% aggregate biomass, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least about 20% and at most about 60% PPP4R4+ cells, NR2E3+ cells, at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, at most about 0.5% Ki67+ cells, at most about 0.5 copies of VIM per copy of SDHA, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least about 20% and at most about 60% PPP4R4+ cells, NR2E3+ cells, at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, at most about 0.5% Ki67+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least about 20% and at most about 60% PPP4R4+ cells, NR2E3+ cells, at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least about 20%Attorney Docket No.: 132042-5009- WOand at most about 60% PPP4R4+ cells, NR2E3+ cells, at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least about 90% AIPL1 + cells, at least about 90% RCVRN+ cells, at least about 20% and at most about 60% PPP4R4+ cells, NR2E3+ cells, at most about 7% PAX6+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least about 20% and at most about 60% PPP4R4+ cells, NR2E3+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least about 20% and at most about 60% PPP4R4+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form.

[0179] In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of NR2E3+ cells, at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, at most about 0.5% Ki67+ cells, at most about 0.5 copies of VIM per copy of SDHA, at least about 70% aggregate biomass, a percentage viability of at least about 50%, no detectable expression of LNCPRESS2 and / or AC009446.1, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of NR2E3+ cells, at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, at most about 0.5% Ki67+ cells, at most about 0.5 copies of VIM per copy of SDHA, at least about 70% aggregate biomass, a percentage viability of at least about 50%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of NR2E3+ cells, at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, at most about 0.5% Ki67+ cells, at most about 0.5 copies of VIM per copy of SDHA, at least about 70% aggregate biomass, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of NR2E3+ cells, at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, at most about 0.5% Ki67+ cells, at most about 0.5 copies of VIM per copy of SDHA, and wherein the composition is mostly in aggregate form, which is in suspension or pelletAttorney Docket No.: 132042-5009- WOform. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of NR2E3+ cells, at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, at most about 0.5% Ki67+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of NR2E3+ cells, at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of NR2E3+ cells, at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of NR2E3+ cells, at most about 7% PAX6+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of NR2E3+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form.

[0180] In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, at most about 0.5% Ki67+ cells, at most about 0.5 copies of VIM per copy of SDHA, at least about 70% aggregate biomass, a percentage viability of at least about 50%, no detectable expression of LNCPRESS2 and / or AC009446.1, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, at most about 0.5% TYRP1 + cells, at most about 0.5% Ki67+ cells, at most about 0.5 copies of VIM per copy of SDHA, at least about 70% aggregate biomass, a percentage viability of at least about 50%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, at most about 0.5% Ki67+ cells, at most about 0.5 copies of VIM per copy of SDHA, at least about 70% aggregate biomass, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consistsAttorney Docket No.: 132042-5009- WOof, or consists essentially of at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, at most about 0.5% Ki67+ cells, at most about 0.5 copies of VIM per copy of SDHA, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, at most about 0.5% Ki67+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at most about 7% PAX6+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form.

[0181] In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, at most about 0.5% Ki67+ cells, at most about 0.5 copies of VIM per copy of SDHA, at least about 70% aggregate biomass, a percentage viability of at least about 50%, no detectable expression of LNCPRESS2 and / or AC009446.1, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, at most about 0.5% Ki67+ cells, at most about 0.5 copies of VIM per copy of SDHA, at least about 70% aggregate biomass, a percentage viability of at least about 50%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, at most about 0.5% Ki67+ cells, at most about 0.5 copies of VIM per copy of SDHA, at least about 70% aggregate biomass, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at most about 7% CHX10+Attorney Docket No.: 132042-5009- WOcells, at most about 0.5% TYRP1 + cells, at most about 0.5% Ki67+ cells, at most about 0.5 copies of VIM per copy of SDHA, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, at most about 0.5% Ki67+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at most about 7% CHX10+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at most about 0.5% TYRP1+ cells, at most about 0.5% Ki67+ cells, at most about 0.5 copies of VIM per copy of SDHA, at least about 70% aggregate biomass, a percentage viability of at least about 50%, no detectable expression of LNCPRESS2 and / or AC009446.1, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form.

[0182] In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at most about 0.5% TYRP1+ cells, at most about 0.5% Ki67+ cells, at most about 0.5 copies of VIM per copy of SDHA, at least about 70% aggregate biomass, a percentage viability of at least about 50%, no detectable expression of LNCPRESS2 and / or AC009446.1, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at most about 0.5% TYRP1+ cells, at most about 0.5% Ki67+ cells, at most about 0.5 copies of VIM per copy of SDHA, at least about 70% aggregate biomass, a percentage viability of at least about 50%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at most about 0.5% TYRP1+ cells, at most about 0.5% Ki67+ cells, at most about 0.5 copies of VIM per copy of SDHA, at least about 70% aggregate biomass, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at most about 0.5% TYRP1+ cells, at most about 0.5% Ki67+Attorney Docket No.: 132042-5009- WOcells, at most about 0.5 copies of VIM per copy of SDHA, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at most about 0.5% TYRP1+ cells, at most about 0.5% Ki67+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at most about 0.5% TYRP1+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form.

[0183] In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at most about 0.5% Ki67+ cells, at most about 0.5 copies of VIM per copy of SDHA, at least about 70% aggregate biomass, a percentage viability of at least about 50%, no detectable expression of LNCPRESS2 and / or AC009446.1, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at most about 0.5% Ki67+ cells, at most about 0.5 copies of VIM per copy of SDHA, at least about 70% aggregate biomass, a percentage viability of at least about 50%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at most about 0.5% Ki67+ cells, at most about 0.5 copies of VIM per copy of SDHA, at least about 70% aggregate biomass, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at most about 0.5% Ki67+ cells, at most about 0.5 copies of VIM per copy of SDHA, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at most about 0.5% Ki67+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form.

[0184] In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at most about 0.5 copies of VIM per copy of SDHA, at least about 70% aggregate biomass, a percentage viability of at least about 50%, no detectable expression of LNCPRESS2 and / or AC009446.1, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consistsAttorney Docket No.: 132042-5009- WOessentially of at most about 0.5 copies of VIM per copy of SDHA, at least about 70% aggregate biomass, a percentage viability of at least about 50%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at most about 0.5 copies of VIM per copy of SDHA, at least about 70% aggregate biomass, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at most about 0.5 copies of VIM per copy of SDHA, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form.

[0185] In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least about 70% aggregate biomass, a percentage viability of at least about 50%, no detectable expression of LNCPRESS2 and / or AC009446.1, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least about 70% aggregate biomass, a percentage viability of at least about 50%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least about 70% aggregate biomass, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form.

[0186] In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of a percentage viability of at least about 50%, no detectable expression of LNCPRESS2 and / or AC009446.1, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of a percentage viability of at least about 50%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form.

[0187] In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of, one or more, two or more, or three or more of the characteristics provided in Table 2.Table 2. Specifications for Doses for Administration Comprising a Composition of Cells Comprising PRPs as Disclosed HereinAttorney Docket No.: 132042-5009- WOSpecification Characteristic1 X106dose - Live Cell Concentration At least 2.72x107and at most 4.08x1072X106dose - Live Cell Concentration At least 5.04x107and at most 7.56x1073X106dose - Live Cell Concentration At least 7.12x107and at most 1.07x1084x106dose - Live Cell Concentration At least 9.44x107and at most 1.42x108Endotoxin contamination levels At most 5.0 EU / mLPercentage Viability At least 40%

[0188] In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least 2.72x107cells / mL and at most 4.08x107cells / mL, an endotoxin level that is at most 5.0 EU / mL, a percentage viability of at least 40%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least 2.72x107cells / mL and at most 4.08x107cells / mL, a percentage viability of at least 40%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least 2.72x107cells / mL and at most 4.08x107cells / mL, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form.

[0189] In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least 5.04x107cells / mL and at most 7.56X107cells / mL, an endotoxin level that is at most 5.0 EU / mL, a percentage viability of at least 40%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least 5.04x107cells / mL and at most 7.56x107cells / mL, a percentage viability of at least 40%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least 5.04x107cells / mL and at most 7.56x107cells / mL, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form.

[0190] In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least 7.12x107cells / mL and at mostAttorney Docket No.: 132042-5009- WO1.07x108cells / mL, an endotoxin level that is at most 5.0 EU / mL, a percentage viability of at least 40%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least 7.12x107cells / mL and at most 1.07x108cells / mL, a percentage viability of at least 40%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least 7.12x107cells / mL and at most 1.07x108cells / mL, an endotoxin level that is at most 5.0 EU / mL, wherein the composition is mostly in aggregate form, which is in suspension or pellet form.

[0191] In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least 9.44x107cells / mL and at most 1.42x108cells / mL, an endotoxin level that is at most 5.0 EU / mL, a percentage viability of at least 40%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least 9.44x107cells / mL and at most 1.42X108cells / mL, a percentage viability of at least 40%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least 9.44x107cells / mL and at most 1.42X108cells / mL, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form.

[0192] In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least about 2.72x107cells / mL and at most about 4.08x107cells / mL, an endotoxin level that is at most about 5.0 EU / mL, a percentage viability of at least about 40%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least about 2.72x107cells / mL and at most about 4.08x107cells / mL, a percentage viability of at least about 40%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least about 2.72x107cells / mL and at most about 4.08x107cells / mL, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form.Attorney Docket No.: 132042-5009- WO

[0193] In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least about 5.04x107cells / mL and at most about 7.56x107cells / mL, an endotoxin level that is at most about 5.0 EU / mL, a percentage viability of at least about 40%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least about 5.04x107cells / mL and at most about 7.56x107cells / mL, a percentage viability of at least about 40%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least about 5.04x107cells / mL and at most about 7.56x107cells / mL, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form.

[0194] In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least about 7.12x107cells / mL and at most about 1.07x108cells / mL, an endotoxin level that is at most about 5.0 EU / mL, a percentage viability of at least about 40%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least about 7.12x107cells / mL and at most about 1.07x108cells / mL, a percentage viability of at least about 40%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least about 7.12x107cells / mL and at most about 1.07x108cells / mL, an endotoxin level that is at most about 5.0 EU / mL, wherein the composition is mostly in aggregate form, which is in suspension or pellet form.

[0195] In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least about 9.44x107cells / mL and at most about 1.42x108cells / mL, an endotoxin level that is at most about 5.0 EU / mL, a percentage viability of at least about 40%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, or consists of, or consists essentially of at least about 9.44x107cells / mL and at most about 1.42x108cells / mL, a percentage viability of at least about 40%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, a composition of cells comprising PRPs as disclosed herein, comprises, orAttorney Docket No.: 132042-5009- WOconsists of, or consists essentially of at least about 9.44x107cells / mLand at most about 1.42x108cells / mL, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form.

[0196] In some embodiments, the composition of cells consists of or consists essentially of photoreceptor precursor cells (PRPs) and, optionally, a pharmaceutically acceptable excipient thereof, wherein the composition comprises: NR2E3+ cells and between at least about 20% to about 60% PPP4R4+ cells; wherein the PRPs comprise less than or equal to about 0.5 copies of VIM per copy of SDHA, and wherein the composition of comprises at least about 90% PRP cells. In some embodiments, the composition consists of or consists essentially of at least about 90% AIPL1+ cells; at least about 90% RCVRN+ cells; less than or equal to about 7% PAX6+ cells; less than or equal to about 7% CHX10+ cells; less than or equal to about 0.5% TYRP1+ cells; and less than or equal to about 0.5% Ki67+ cells.

[0197] In some embodiments, the median diameter of a cell aggregate is about 15 pm to about 120 pm, (e.g., about 15 pm, about 16 pm, about 17 pm, about 18 pm, about 19 pm, about 20 pm, about 21 pm, about 22 pm, about 23 pm, about 24 pm, about 25 pm, about 26 pm, about 27 pm, about 28 pm, about 29 pm, about 30 pm, about 31 pm, about 32 pm, about 33 pm, about 34 pm, about 35 pm, about 36 pm, about 37 pm, about 38 pm, about 39 pm, about 40 pm, about 41 pm, about 42 pm, about 43 pm, about 44 pm, about 45 pm, about 46 pm, about 47 pm, about 48 pm, about 49 pm, about 50 pm, about 51 pm, about 52 pm, about 53 pm, about 54 pm, about 55 pm, about 55 pm, about 56 pm, about 57 pm, about 58 pm, about 59 pm, about 60 pm, about 61 pm, about 62 pm, about 63 pm, about 64 pm, about 65 pm, about 66 pm, about 67 pm, about 68 pm, about 69 pm, about 70 pm, about 71 pm, about 72 pm, about 73 pm, about 74 pm, about 75 pm, about 76 pm, about 77 pm, about 78 pm, about 79 pm, about 80 pm, about 81 pm, about 82 pm, about 83 pm, about 84 pm, about 85 pm, about 86 pm, about 87 pm, about 88 pm, about 89 pm, about 90 pm, about 91 pm, about 92 pm, about 93 pm, about 94 pm, about 95 pm, about 96 pm, about 97 pm, about 98 pm, about 99 pm, about 100 pm, about 101 pm, about 102 pm, about 103 pm, about 104 pm, about 105 pm, about 106 pm, about 107 pm, about 108 pm, about 109 pm, about 110 pm, about 111 pm, about 112 pm, about 113 pm, about 114 pm, about 115 pm, about 116 pm, about 117 pm, about 118 pm, about 119 pm, or about 120 pm). In some embodiments, the median diameter (e.g., particle diameter) of a cell aggregate is between about 15 pm and about 120 pm (e.g., about 15 pm to about 120 pm, about 20 pm to about 115 pm, about 35 pm to about 110 pm, about 35 pm to about 105 pm, about 40 pm to about 100 pm, about 45 pm to about 95 pm, about 50 pm to about 90 pm, about 55 pm to about 85 pm, about 60 pm to about 80 pm,Attorney Docket No.: 132042-5009- WOabout 65 pm to about 75 pm, about 30 pm to about 60 pm, about 40 pm to about 50 pm, about 20 pm to about 60 pm, about 20 pm to about 50 pm, or about 30 pm to about 60 pm). In some embodiments, the median diameter of a cell aggregate is between about 30 pm and about 60 pm. In some embodiments, the median diameter of a cell aggregate is about 50 pm. In some embodiments, the median diameter of a cell aggregate is at least about 20 pm.

[0198] In some embodiments, the composition comprising the population of PRP cells does not express LNCPRESS2 and / or AC009446.1 pluripotency markers above the limit of detection (LOD). Methods for detecting, characterizing, and / or quantitating, nucleic acid sequences; and for detecting, characterizing, and / or quantitating, mRNA expression, are known to persons skilled in the art, and include, but are not limited to, for example, PCR procedures, RT-PCR, quantitative PCR or RT-PCR, Northern blot analysis, differential gene expression, RNA protection assay, microarray analysis, hybridization methods, serial analysis of gene expression (SAGE), hybridization based on digital barcode quantification assays, multiplex RT-PCR, ddPCR, qRT-PCR, qPCR, UV spectroscopy, DNA sequencing, RNA sequencing, next-generation sequencing, including RNA-seq, lysate-based hybridization assays utilizing branched DNA signal amplification, such as the QuantiGene 2.0 Single Plex, and branched DNA analysis methods. In some embodiments, the composition comprising the population of PRP cells does not express LNCPRESS2 and / or AC009446.1 pluripotency markers above the limit of detection as measured by droplet digital polymerase chain reaction (ddPCR).

[0199] In some embodiments, ddPCR is performed using Bio-Rad’s QX200™ ddPCR System. In some embodiments, the LOD is determined against a reference gene, e.g., SDHA. In some embodiments, the number of copies of VIM is determined relative to copies of a reference gene, e.g., SDHA.

[0200] In some embodiments, expression of SDHA, VIM, LNCPRESS2, and / or AC009446.1 was assessed by droplet digital PCR (ddPCR) for cDNA derived from a composition comprising the population of PRP cells. In some embodiments, sample cDNA is diluted and prepared in a PCR master mix. In some embodiments, the master mix containing diluted sample cDNA may be transferred to a 96-well plate. In some embodiments, the plate may be sealed with a ddPCR PX1 PCR Plate Sealer (Bio-Rad, Hercules, CA; Cat. No. 1814000). In some embodiments, droplets may be generated using a QX200™ Automated Droplet Generator (Bio-Rad, Hercules, CA; Cat. No. 1864101). In some embodiments, PCR may be performed to produce amplified droplets using a C1000 Touch™ Thermal Cycler (Bio-Rad, Hercules, CA; Cat. No. 1851148). In some embodiments, the amplified droplets may be assessed using a QX200™ Droplet Reader (BioAttorney Docket No.: 132042-5009- WORad, Hercules, CA; Cat. No. 1864003) to assess VIM, LNCPRESS2, and / or AC009446.1 in channel 1 and SDHA (reference gene) in channel 2 with FAM / VIC probes. In some embodiments, copies per pL of VIM, LNCPRESS2, and / or AC009446.1 divided by copies per pL of SDHA may be reported as a ratio (copies / copy).

[0201] In some embodiments, acceptable samples contain at least 10,000 droplets. In some embodiments, acceptable samples contain a percentage coefficient of variation of less than or equal to 25%. In some embodiments, the cDNA derived from a composition comprising the population of PRP cells may contain between 800-4,000 SDHA copies per pL. In some embodiments, a cell product suitable for downstream applications will contain no more 0.50 copies / copy of VIM per SDHA (copies per pL of VIM divided by copies per pL of SDHA). In some embodiments, outliers may be assessed and removed, if appropriate, with a Dixon Q Test.

[0202] In some embodiments, the composition of cells comprising PRPs has an HLA genotype as shown in Table 3.Table 3. HLA GenotypeHLA Class GenotypeClass I HLA-A*02:01:01:01Class I HLA-B*07:02:01:01Class I HLA-C*07:02:01:03; HLA-C*07:02:01:10Class II HLA-DRB1*15:01:01:01Class II HLA-DRB5*01:01:01:01Class II HLA-DQB1*06:02:01:01Class II HLA-DPB1*04:01:01:01; HLA-DPB1*04:01:01:110 Class II HLA-DQA1*01:02:01:01Class II HLA-DPA1 *01:03:01:02

[0203] In some embodiments, the composition of cells comprising PRPs do not express (e.g., do not substantially express or do not express a detectable level of) Class I HLA-A on the surface of the cells. In some embodiments, the composition of cells comprising PRPs do not express (e.g., do not substantially express or do not express a detectable level of) Class I HLA-B on the surface of the cells. In some embodiments, the composition of cells comprising PRPs do not express (e.g., do not substantially express or do not express a detectable level of) Class I HLA-A and / or Class I HLA-B on the surface of the cells. In some embodiments, the composition of cells comprising PRPs do not express (e.g., do not substantially express or do not express a detectableAttorney Docket No.: 132042-5009- WOlevel of) Class II HLA-DPA1 on the surface of the cells. In some embodiments, the composition of cells comprising PRPs do not express (e.g., do not substantially express or do not express a detectable level of) Class II HLA-DRB1 on the surface of the cells. In some embodiments, the composition of cells comprising PRPs do not express (e.g., do not substantially express or do not express a detectable level of) Class II HLA-DQA1 on the surface of the cells. In some embodiments, the composition of cells comprising PRPs do not express (e.g., do not substantially express or do not express a detectable level of) Class II HLA-DQB1 on the surface of the cells. In some embodiments, the composition of cells comprising PRPs do not express (e.g., do not substantially express or do not express a detectable level of) Class II HLA-DRB5 on the surface of the cells. In some embodiments, the composition of cells comprising PRPs do not express (e.g., do not substantially express or do not express a detectable level of) Class II HLA-DPA1, Class II HLA-DRB1, Class II HLA-DQA1, Class II HLA-DQB1, and / or Class II HLA-DRB5 on the surface of the cells. In some embodiments, the composition of cells comprising PRPs do not express (e.g., do not substantially express or do not express a detectable level of) Class I HLA-A, Class I HLA-B, Class II HLA-DPA1, Class II HLA-DRB1, Class II HLA-DQA1, Class II HLA-DQB1, and / or Class II HLA-DRB5 on the surface of the cells.

[0204] In some embodiments, the composition of cells comprising PRPs do not express (e.g., do not substantially express or do not express a detectable level of) Class II H LA in the absence of stimulation with inflammatory cytokines. In some embodiments, composition of cells comprising PRPs express (e.g., substantially express or express a detectable level of) HLA Class I in the absence of stimulation with inflammatory cytokines. In some embodiments, the inflammatory cytokines include one or more of interferon gamma (IFN-y) and / or tumor necrosis factor alpha (TNFa). In some embodiments, Class II HLA-DR accounts for more than half of stimulated Class II HLA expression. In some embodiments, Class II HLA-DR accounts at least about 30%, at least about 35%, at least about 40% at least about 41%, at least about 42%, at least about 43%, at least about 44%, at least about 45%, at least about 46%, at least about 47%, at least about 48%, at least ab out 49%, at least about 50%, at least about 51%, at least about 52%, at least about 53%, at least about 54%, at least about 55%, at least about 56%, at least about 57%, at least about 58%, at least about 59%, at least about 60%, at least about 65%, at least about 70%, or at least about 75% stimulated Class II HLA expression. In some embodiments, Class II HLA-DR accounts at least about 50% stimulated Class II HLA expression.

[0205] In some embodiments, the composition of cells comprising PRPs only express (e.g., substantially express or express a detectable level of) Class I HLA-C on the surface of the cellsAttorney Docket No.: 132042-5009- WOin the absence of stimulation with inflammatory cytokines. In some embodiments, the composition of cells comprising PRPs only express (e.g., substantially express or express a detectable level of) Class I HLA-C on the surface of the cells. In some embodiments, the composition of cells comprising PRPs express (e.g., substantially express or express a detectable level of) Class I HLA-C, Class II HLA-DR, and HLA-DPB1 on the surface of the cells in the presence of stimulation with inflammatory cytokines.

[0206] In some embodiments, the expression of HLA on the surface of cells in the composition of cells comprising PRPs is evaluated by single cell RNA sequence (scRNA-seq). In some embodiments, the expression of HLA on the surface of cells in the composition of cells comprising PRPs is evaluated by flow cytometry.

[0207] In some embodiments, a drug product comprising PRPs comprises a suspension of at least about 70% to about 100% (e.g., about 70% to about 100%, about 70% to about 90%, about 70% to about 80%, about 80% to about 100%, about 80% to about 90%, or about 90% to about 100%) induced PRP cells (iPRP). In some embodiments, a drug product comprising PRPs comprises a suspension of at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% induced PRP cells (iPRP). In some embodiments, the drug product may be suspended in a balanced salt solution (BSS) buffer supplemented with human serum albumin (HSA) (e.g., 0.2% HSA). In some embodiments, the drug product is in a single cell form, an aggregate form, or in a suspended form. In some embodiments, the drug product is in a suspended form. In some embodiments, the drug product is in a single cell form or an aggregate form. In some embodiments, the drug product is in a pellet formed by centrifugation of a suspension of the drug product. In some embodiments, the drug product comprises aggregates in suspension. In some embodiments, the drug product comprises aggregates in pellet form. In some embodiments, the drug product comprises aggregates that have settled to the bottom of a tube or vial. In some embodiments, the drug product comprises aggregates and single cells in suspension. In some embodiments, the drug product comprises aggregates and single cells in pellet form. In some embodiments, the drug product comprises aggregates and single cells that have settled to the bottom of a tube or vial.

[0208] In some embodiments, a percentage cell viability of a drug product comprising PRP cells in a suspended (e.g., single cell suspension) form may be calculated using automated cell counting including, for example, with acridine orange and / or propidium iodide using, for example, a Cellaca™ MX. In some embodiments, the percentage viability of the drug product comprisingAttorney Docket No.: 132042-5009- WOPRP cells in a suspended form may be calculated to be at least about 50% (e.g., about 50%, at least about 51 %, at least about 52%, at least about 53%, at least about 54%, at least about 55%, at least about 56%, at least about 57%, at least about 58%, at least about 59%, at least about 60%, at least about 61%, at least about 62%, at least about 63%, at least about 64%, at least about 65%, at least about 66%, at least about 67%, at least about 68%, at least about 69%, at least about 70%, at least about 71%, at least about 72%, at least about 73%, at least about 74%, at least about 75%, at least about 76%, at least about 77%, at least about 78%, at least about 79%, at least about 80%, at least about 81%, at least about 82%, at least about 83%, at least about 84%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100%). In some embodiments, the percentage viability of the drug product comprising PRP cells in a suspended form may be calculated to be at least about 50% to at least about 100% (e.g., about 50% to about 100%, about 50% to about 90%, about 50% to about 80%, about 50% to about 70%, about 50% to about 60%, about 60% to about 100%, about 60% to about 90%, about 60% to about 80%, about 60% to about 70%, about 70% to about 100%, about 70% to about 90%, about 70% to about 80%, about 80% to about 100%, about 80% to about 90%, or about 90% to about 100%). In some embodiments, the percentage viability of the drug product comprising PRP cells in a suspended form may be calculated to be at least about 50%.

[0209] In some embodiments, a percentage cell viability of a drug product comprising PRP cells in a suspended form may be calculated using automated cell counting including, for example, with an IncuCyte® Live-Cell Analysis System (Sartorius; Gottingen, Germany; Cat. No. SX5). In some embodiments, the percentage viability of the drug product comprising PRP cells in a suspended form may be calculated to be at least about 50% (e.g., about 50%, at least about 51%, at least about 52%, at least about 53%, at least about 54%, at least about 55%, at least about 56%, at least about 57%, at least about 58%, at least about 59%, at least about 60%, at least about 61 %, at least about 62%, at least about 63%, at least about 64%, at least about 65%, at least about 66%, at least about 67%, at least about 68%, at least about 69%, at least about 70%, at least about 71%, at least about 72%, at least about 73%, at least about 74%, at least about 75%, at least about 76%, at least about 77%, at least about 78%, at least about 79%, at least about 80%, at least about 81%, at least about 82%, at least about 83%, at least about 84%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, atAttorney Docket No.: 132042-5009- WOleast about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100%). In some embodiments, the percentage viability of the drug product comprising PRP cells in a suspended form may be calculated to be at least about 50% to at least about 100% (e.g., about 50% to about 100%, about 50% to about 90%, about 50% to about 80%, about 50% to about 70%, about 50% to about 60%, about 60% to about 100%, about 60% to about 90%, about 60% to about 80%, about 60% to about 70%, about 70% to about 100%, about 70% to about 90%, about 70% to about 80%, about 80% to about 100%, about 80% to about 90%, or about 90% to about 100%). In some embodiments, the percentage viability of the drug product comprising PRP cells in a suspended form may be calculated to be at least about 50%.

[0210] In some embodiments, a percentage cell viability of a drug product comprising PRP cells in a single cell form or an aggregate form may be calculated using automated cell counting including, for example, with acridine orange and / or propidium iodide using, for example, a Cellaca™ MX. In some embodiments, the percentage viability of the drug product comprising PRP cells in a single cell form or an aggregate form may be calculated to be at least about 50% (e.g., about 50%, at least about 51%, at least about 52%, at least about 53%, at least about 54%, at least about 55%, at least about 56%, at least about 57%, at least about 58%, at least about 59%, at least about 60%, at least about 61%, at least about 62%, at least about 63%, at least about 64%, at least about 65%, at least about 66%, at least about 67%, at least about 68%, at least about 69%, at least about 70%, at least about 71%, at least about 72%, at least about 73%, at least about 74%, at least about 75%, at least about 76%, at least about 77%, at least about 78%, at least about 79%, at least about 80%, at least about 81%, at least about 82%, at least about 83%, at least about 84%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91 %, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100%). In some embodiments, the percentage viability of the drug product comprising PRP cells in a single cell form or an aggregate form may be calculated to be at least about 50% to at least about 100% (e.g., about 50% to about 100%, about 50% to about 90%, about 50% to about 80%, about 50% to about 70%, about 50% to about 60%, about 60% to about 100%, about 60% to about 90%, about 60% to about 80%, about 60% to about 70%, about 70% to about 100%, about 70% to about 90%, about 70% to about 80%, about 80% to about 100%, about 80% to about 90%, or about 90% to about 100%). In some embodiments, the percentage viability of the drug product comprising PRP cells in a single cell form or an aggregate form may be calculated to be at least about 50%.Attorney Docket No.: 132042-5009- WO

[0211] In some embodiments, a percentage cell viability of a drug product comprising PRP cells in a single cell form or an aggregate form may be calculated using automated cell counting including, for example, with an IncuCyte® Live-Cell Analysis System (Sartorius; Gottingen, Germany; Cat. No. SX5). In some embodiments, the percentage viability of the drug product comprising PRP cells may be calculated to be at least about 50% (e.g., about 50%, at least about 51%, at least about 52%, at least about 53%, at least about 54%, at least about 55%, at least about 56%, at least about 57%, at least about 58%, at least about 59%, at least about 60%, at least about 61 %, at least about 62%, at least about 63%, at least about 64%, at least about 65%, at least about 66%, at least about 67%, at least about 68%, at least about 69%, at least about 70%, at least about 71%, at least about 72%, at least about 73%, at least about 74%, at least about 75%, at least about 76%, at least about 77%, at least about 78%, at least about 79%, at least about 80%, at least about 81%, at least about 82%, at least about 83%, at least about 84%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100%). In some embodiments, the percentage viability of the drug product comprising PRP cells in a single cell form or an aggregate form may be calculated to be at least about 50% to at least about 100% e.g., about 50% to about 100%, about 50% to about 90%, about 50% to about 80%, about 50% to about 70%, about 50% to about 60%, about 60% to about 100%, about 60% to about 90%, about 60% to about 80%, about 60% to about 70%, about 70% to about 100%, about 70% to about 90%, about 70% to about 80%, about 80% to about 100%, about 80% to about 90%, or about 90% to about 100%). In some embodiments, the percentage viability of the drug product comprising PRP cells in a single cell form or an aggregate form may be calculated to be at least about 50%.

[0212] In some embodiments, a percentage cell viability of a dose for administration comprising PRP cells in a suspended form may be calculated using automated cell counting including, for example, with acridine orange and / or propidium iodide using, for example, a Cellaca™ MX. In some embodiments, the percentage viability of the dose for administration comprising PRP cells in a suspended form may be calculated to be at least about 40% (e.g., about 40%, at least about 41%, at least about 42%, at least about 43%, at least about 44%, at least about 45%, at least about 46%, at least about 47%, at least about 48%, at least about 49%, at least about 50%, at least about 51 %, at least about 52%, at least about 53%, at least about 54%, at least about 55%, at least about 56%, at least about 57%, at least about 58%, at least about 59%, at least about 60%, at least about 61%, at least about 62%, at least about 63%, at least about 64%, at leastAttorney Docket No.: 132042-5009- WOabout 65%, at least about 66%, at least about 67%, at least about 68%, at least about 69%, at least about 70%, at least about 71%, at least about 72%, at least about 73%, at least about 74%, at least about 75%, at least about 76%, at least about 77%, at least about 78%, at least about 79%, at least about 80%, at least about 81%, at least about 82%, at least about 83%, at least about 84%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100%). In some embodiments, the percentage viability of the dose for administration comprising PRP cells in a suspended form may be calculated to be at least about 40% to at least about 100% (e.g., about 40% to about 100%, about 40% to about 90%, about 40% to about 80%, about 40% to about 70%, about 40% to about 60%, about 40% to about 50%, about 50% to about 100%, about 50% to about 90%, about 50% to about 80%, about 50% to about 70%, about 50% to about 60%, about 60% to about 100%, about 60% to about 90%, about 60% to about 80%, about 60% to about 70%, about 70% to about 100%, about 70% to about 90%, about 70% to about 80%, about 80% to about 100%, about 80% to about 90%, or about 90% to about 100%). In some embodiments, the percentage viability of the dose for administration comprising PRP cells in a suspended form may be calculated to be at least about 40%.

[0213] In some embodiments, a percentage cell viability of a dose for administration comprising PRP cells in a suspended form may be calculated using automated cell counting including, for example, with an IncuCyte® Live-Cell Analysis System (Sartorius; Gottingen, Germany; Cat. No. SX5). In some embodiments, the percentage viability of the dose for administration comprising PRP cells in a suspended form may be calculated to be at least about 40% (e.g., about 40%, at least about 41 %, at least about 42%, at least about 43%, at least about 44%, at least about 45%, at least about 46%, at least about 47%, at least about 48%, at least about 49%, at least about 50%, at least about 51%, at least about 52%, at least about 53%, at least about 54%, at least about 55%, at least about 56%, at least about 57%, at least about 58%, at least about 59%, at least about 60%, at least about 61 %, at least about 62%, at least about 63%, at least about 64%, at least about 65%, at least about 66%, at least about 67%, at least about 68%, at least about 69%, at least about 70%, at least about 71%, at least about 72%, at least about 73%, at least about 74%, at least about 75%, at least about 76%, at least about 77%, at least about 78%, at least about 79%, at least about 80%, at least about 81%, at least about 82%, at least about 83%, at least about 84%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at leastAttorney Docket No.: 132042-5009- WOabout 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100%). In some embodiments, the percentage viability of the dose for administration comprising PRP cells in a suspended form may be calculated to be at least about 40% to at least about 100% (e.g., about 40% to about 100%, about 40% to about 90%, about 40% to about 80%, about 40% to about 70%, about 40% to about 60%, about 40% to about 50%, about 50% to about 100%, about 50% to about 90%, about 50% to about 80%, about 50% to about 70%, about 50% to about 60%, about 60% to about 100%, about 60% to about 90%, about 60% to about 80%, about 60% to about 70%, about 70% to about 100%, about 70% to about 90%, about 70% to about 80%, about 80% to about 100%, about 80% to about 90%, or about 90% to about 100%). In some embodiments, the percentage viability of the dose for administration comprising PRP cells in a suspended form may be calculated to be at least about 40%.

[0214] In some embodiments, the percentage viability of the dose for administration comprising PRP cells in a single cell form or an aggregate form may be calculated to be at least about 40% (e.g., about 40%, at least about 41%, at least about 42%, at least about 43%, at least about 44%, at least about 45%, at least about 46%, at least about 47%, at least about 48%, at least about 49%, at least about 50%, at least about 51%, at least about 52%, at least about 53%, at least about 54%, at least about 55%, at least about 56%, at least about 57%, at least about 58%, at least about 59%, at least about 60%, at least about 61 %, at least about 62%, at least about 63%, at least about 64%, at least about 65%, at least about 66%, at least about 67%, at least about 68%, at least about 69%, at least about 70%, at least about 71%, at least about 72%, at least about 73%, at least about 74%, at least about 75%, at least about 76%, at least about 77%, at least about 78%, at least about 79%, at least about 80%, at least about 81 %, at least about 82%, at least about 83%, at least about 84%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100%). In some embodiments, a percentage cell viability of a dose for administration comprising PRP cells in a single cell form or an aggregate form may be calculated using automated cell counting including, for example, with an IncuCyte® Live-Cell Analysis System (Sartorius; Gottingen, Germany; Cat. No. SX5). In some embodiments, the percentage viability of the dose for administration comprising PRP cells in a single cell form or an aggregate form may be calculated to be at least about 40% to at least about 100% (e.g., about 40% to about 100%, about 40% to about 90%, about 40% to about 80%, about 40% to about 70%, about 40% to about 60%, about 40% to aboutAttorney Docket No.: 132042-5009- WO50%, about 50% to about 100%, about 50% to about 90%, about 50% to about 80%, about 50% to about 70%, about 50% to about 60%, about 60% to about 100%, about 60% to about 90%, about 60% to about 80%, about 60% to about 70%, about 70% to about 100%, about 70% to about 90%, about 70% to about 80%, about 80% to about 100%, about 80% to about 90%, or about 90% to about 100%). In some embodiments, the percentage viability of the dose for administration comprising PRP cells in a single cell form or an aggregate form may be calculated to be at least about 40%.

[0215] In some embodiments, the dose for administration comprises aggregates in suspension. In some embodiments, the dose for administration comprises aggregates in pellet form. In some embodiments, the dose for administration comprises aggregates that have settled to the bottom of a tube or vial. In some embodiments, the dose for administration comprises aggregates and single cells in suspension. In some embodiments, the dose for administration comprises aggregates and single cells in pellet form. In some embodiments, the dose for administration comprises aggregates and single cells that have settled to the bottom of a tube or vial. In some embodiments, the dose for administration is made by the methods disclosed in WO 2024 / 073759 A1, which is incorporated herein by reference in its entirety.Methods of Qualifying a Composition of Cells for Treatment of an Eye Disease

[0216] A composition of cells disclosed herein may be assessed for suitability (e.g., qualified for use as a therapeutic) for an eye (e.g., ocular) disease or disorder, such as a retinal disease or disorder. In some embodiments, the eye disease or disorder and / or the retinal disease or disorder may be characterized by loss of photoreceptor cells (e.g., loss of rod cells and / or cone cells) and / or a loss of photoceptor cell function. In some embodiments, the eye disease or disorder and / or the retinal disease may include, for example, a primary photoreceptor disease. In some embodiments, the primary photoreceptor disease may include, for example, retinitis pigmentosa, cone-rod disease, rod-cone disease, cone dystrophy, and cone-rod dystrophy. In some embodiments, the primary photoreceptor disease is an inherited retinal disorder. In some embodiments the inherited retinal disorder may be, for example, Usher Syndrome. As used herein, the term “suitable” may mean that a cell population is suitable for administration, and / or contains the correct proportions of cells, and / or the cells are functional, and / or the cell population is subsequently therapeutically effective after administration.

[0217] In an aspect, provided herein is a method of identifying a suitable cell population for treatment of an eye disease, the method comprising obtaining a population of PRPs, measuring a percentage of PPP4R4+ cells in a cell population, and measuring a copy number of VIM perAttorney Docket No.: 132042-5009- WOcopy SDHA, wherein the cell population is identified as a suitable cell population for treatment of an eye disease when the percentage of PPP4R4+ cells in the cell population is between about 20% and about 60%, and the copy number of VIM per copy of SDHA is less than or equal to about 0.5. In some embodiments, the method further comprises measuring a percentage of NR2E3+, AIPL1+, RCVRN+, PAX6+, CHX10+, TYRP1+; and / or Ki67+ cells in the cell population, wherein the cell population is identified as a suitable cell population for treatment of an eye disease when a substantial portion of the cells are NR2E3+, the percentage of AIPL1+ cells is least about 90%, the percentage of RCVRN+ cells is least about 90%, the percentage of PAX6+ cells is no more than about 7%, the percentage of CHX10+ cells is no more than about 7%, the percentage of TYRP1+ cells is no more than about 0.5%, and the percentage of Ki67+ cells is no more than about 0.5%. In some embodiments, when the cell population comprises between at least about 20% to about 60% PPP4R4+ cells, and wherein and the cells comprise less than or equal to 0.5 copies of VIM per copy of SDHA, then the cells are identified as suitable for the treatment.

[0218] In some embodiments, the method further comprises measuring a percentage biomass of cell aggregates in the cell composition, wherein the cell population is identified as a suitable cell population for treatment of an eye disease or disorder when the cell composition comprises at least 70% biomass of cell aggregates. In some embodiments, the method further comprises measuring a median diameter (e.g., particle diameter) of cell aggregates in the cell composition, wherein the cell population is identified as a suitable cell population for treatment of an eye disease or disorder when the cell aggregates are observed to have a median diameter of at least about 30 pm to at least about 60 pm.

[0219] In some embodiments, the method further comprises measuring a percentage viability of the cell composition, wherein the cell population is identified as a suitable cell population for treatment of an eye disease or disorder when the cell composition is observed to have a percentage viability of at least about 50%. In some embodiments, the method further comprises measuring a percentage viability of the cell composition, wherein the cell population is identified as a suitable cell population for treatment of an eye disease or disorder when the cell composition is observed to have a percentage viability of at least about 40%.

[0220] In some embodiments, a percentage of PPP4R4+, AIPL1+, RCVRN+, PAX6+, CHX10+, TYRP1+, or Ki67+ cells is determined by flow cytometry. In some embodiments, copies of VIM per copy of SDHA is determined by ddPCR. In some embodiments, ddPCR is performed using Bio-Rad’s QX200™ ddPCR System. In some embodiments, the copies of VIM are determined relative to reference gene SDHA. In some embodiments, the percentage biomass of aggregatesAttorney Docket No.: 132042-5009- WOand / or medium diameter of cell aggregates in the cell composition is quantified using a particle size analyzer. In some embodiments, the percentage viability of a cell population is determined by an automated cell counter using cell stains, including, for example, acridine orange and / or propidium iodine.

[0221] In some embodiments, the cell population is derived from PSCs or PSC-derived cells, optionally iPSCs. In some embodiments, the cell population is of human origin. In some embodiments, the cell population is suitable for grafting to a subretinal space of a subject’s eye.

[0222] In particular embodiments, the cell population is identified as a suitable cell population for treatment of an eye disease when the percentage of RCVRN+ cells in the cell population is at least about 80% (e.g., about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100%). In some embodiments, the cell population is identified as a suitable cell population (e.g., qualified for use as a therapeutic) for treatment of an eye disease when the percentage of RCVRN+ cells in the cell population is about 80% to about 100% (e.g., about 80% to about 100%, about 80% to about 90%, about 90% to about 100%, about 90% to about 99%, about 90% to about 98%, about 90% to about 97%, about 90% to about 96%, about 90% to about 95%, about 90% to about 94%, about 90% to about 93%, about 90% to about 92%, about 90% to about 91 %, about 91 % to about 100%, about 91 % to about 99%, about 91 % to about 98%, about 91 % to about 97%, about 91 % to about 96%, about 91% to about 95%, about 91% to about 94%, about 91% to about 93%, about 91% to about 92%, about 92% to about 100%, about 92% to about 99%, about 92% to about 98%, about 92% to about 97%, about 92% to about 96%, about 92% to about 95%, about 92% to about 94%, about 92% to about 93%, about 93% to about 100%, about 93% to about 99%, about 93% to about 98%, about 93% to about 97%, about 93% to about 96%, about 93% to about 95%, about 93% to about 94%, about 94% to about 100%, about 94% to about 99%, about 94% to about 98%, about 94% to about 97%, about 94% to about 96%, about 94% to about 95%, about 95% to about 100%, about 95% to about 99%, about 95% to about 98%, about 95% to about 97%, about 95% to about 96%, about 96% to about 100%, about 96% to about 99%, about 96% to about 98%, about 96% to about 97%, about 97% to about 100%, about 97% to about 99%, about 97% to about 98%, about 98% to about 100%, about 98% to about 99%, or about 99% to about 100%). In some embodiments, the cell population is identified as a suitable cell population for treatment of an eye disease when the percentage of RCVRN+ cells in the cell population is at least about 90% of RCVRN expressing cells.Attorney Docket No.: 132042-5009- WO

[0223] In particular embodiments, the cell population is identified as a suitable cell population for treatment of an eye disease (e.g., qualified for use as a therapeutic) when the percentage of AIPL1+ cells in the cell population is at least about 80% (e.g., about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89% about 90%, about 91%, about 92%, about 93%, about 94%, about 95% about 96%, about 97%, about 98%, about 99%, or about 100%). In some embodiments, the cell population is identified as a suitable cell population e.g., qualified for use as a therapeutic) for treatment of an eye disease when the percentage of AIPL1+ cells in the cell population is about 80% to about 100% (e.g., about 80% to about 100%, about 80% to about 90%, about 90% to about 100%, about 90% to about 99%, about 90% to about 98%, about 90% to about 97%, about 90% to about 96%, about 90% to about 95%, about 90% to about 94%, about 90% to about 93%, about 90% to about 92%, about 90% to about 91%, about 91% to about 100%, about 91% to about 99%, about 91% to about 98%, about 91% to about 97%, about 91 % to about 96%, about 91 % to about 95%, about 91 % to about 94%, about 91% to about 93%, about 91% to about 92%, about 92% to about 100%, about 92% to about 99%, about 92% to about 98%, about 92% to about 97%, about 92% to about 96%, about 92% to about 95%, about 92% to about 94%, about 92% to about 93%, about 93% to about 100%, about 93% to about 99%, about 93% to about 98%, about 93% to about 97%, about 93% to about 96%, about 93% to about 95%, about 93% to about 94%, about 94% to about 100%, about 94% to about 99%, about 94% to about 98%, about 94% to about 97%, about 94% to about 96%, about 94% to about 95%, about 95% to about 100%, about 95% to about 99%, about 95% to about 98%, about 95% to about 97%, about 95% to about 96%, about 96% to about 100%, about 96% to about 99%, about 96% to about 98%, about 96% to about 97%, about 97% to about 100%, about 97% to about 99%, about 97% to about 98%, about 98% to about 100%, about 98% to about 99%, or about 99% to about 100%). In some embodiments, the cell population is identified as a suitable cell population for treatment of an eye disease when the percentage of RCVRN+ cells in the cell population is at least about 90% of AIPL1-expressing cells.

[0224] In some In some embodiments, the cell population is identified as a suitable cell population for treatment of an eye disease (e.g., qualified for use as a therapeutic) when the percentage of PPP4R4+ cells in the cell population is at least about 20% (e.g., about 20%, about 21%, at least 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%, about 59%, or about 60%). InAttorney Docket No.: 132042-5009- WOsome embodiments, the cell population is identified as a suitable cell population for treatment of an eye disease when the percentage of PPP4R4+ cells in the cell population is at most 60% (e.g., about 20%, about 21%, at least 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%, about 59%, or about 60%. embodiments, the cell population is identified as a suitable cell population (e.g., qualified for use as a therapeutic) for treatment of an eye disease when the percentage of PPP4R4+ cells in the cell population is between about 20% and about 60% (e.g., about 20% to about 60%, about 20% to about 50%, about 20% to about 40%, about 20% to about 30%, about 30% to about 60%, about 30% to about 50%, about 30% to about 40%, about 40% to about 60%, about 40% to about 50%, or about 50% to about 60%). In some embodiments, the cell population is identified as a suitable cell population for treatment of an eye disease when the percentage of PPP4R4+ cells in the cell population is at least about 20%. In some embodiments, the cell population is identified as a suitable cell population for treatment of an eye disease when the percentage of PPP4R4+ cells in the cell population is at most about 60%. In some embodiments, the cell population is identified as a suitable cell population for treatment of an eye disease when the percentage of PPP4R4+ cells in the cell population is at least about 20% and at most about 60%.

[0225] In some embodiments, the cell population is identified as a suitable cell population for treatment of an eye disease (e.g., qualified for use as a therapeutic) when the percentage of NR2E3+ cells in the cell population is at least about 10% to at most about 100% (e.g., about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%, about 59%, about 60%, about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%,Attorney Docket No.: 132042-5009- WOabout 99%, or about 100%). In some embodiments, the cell population is identified as a suitable cell population (e.g., qualified for use as a therapeutic) for treatment of an eye disease when the percentage of NR2E3+ cells in the cell population is between about 10% and about 100% (e.g., about 10% to about 100%, about 10% to about 90%, about 10% to about 80%, about 10% to about 70%, about 10% to about 60%, about 10% to about 50%, about 10% to about 40%, about 10% to about 30%, about 10% to about 20%, about 20% to about 100%, about 20% to about 90%, about 20% to about 80%, about 20% to about 70%, about 20% to about 60%, about 20% to about 50%, about 20% to about 40%, about 20% to about 30%, about 30% to about 100%, about 30% to about 80%, about 30% to about 70%, about 30% to about 60%, about 30% to about 50%, about 30% to about 40%, about 40% to about 100%, about 40% to about 90%, about 40% to about 80%, about 40% to about 70%, about 40% to about 60%, about 40% to about 50%, about 50% to about 100%, about 50% to about 90%, about 50% to about 80%, about 50% to about 70%, about 50% to about 60%, about 60% to about 100%, about 60% to about 90%, about 60% to about 80%, about 60% to about 70%, about 70% to about 100%, about 70% to about 90%, about 70% to about 80%, about 80% to about 100%, about 80% to about 90%, or about 90% to about 100%). In some embodiments, the cell population is identified as a suitable cell population for treatment of an eye disease when the percentage of NR2E3+ cells in the cell population is at least about 25% to at most about 65% NR2E3-expressing cells. In some embodiments, the cell population is identified as a suitable cell population for treatment of an eye disease when the percentage of NR2E3+ cells in the cell population is at least about 40% to at most about 80% NR2E3-expressing cells.

[0226] In some embodiments, the cell population is identified as a suitable cell population for treatment of an eye disease when a composition comprising the population of cells comprising 90% PRP cells comprises at least about 90% AIPL1-expressing cells and at least about 90% RCVRN-expressing cells. In further embodiments, the cell population is identified as a suitable cell population for treatment of an eye disease when, of those 90% PRPs expressing AIPL1 and RCVRN, a first portion will express PPP4R4 and a second portion will express NR2E3. In further embodiments, In further embodiments, the cell population is identified as a suitable cell population for treatment of an eye disease when, of those 90% PRPs expressing AIPL1 and RCVRN, the first portion will express PPP4R4 but will not express NR2E3. In further embodiments, the cell population is identified as a suitable cell population for treatment of an eye disease when, of those 90% PRPs expressing AIPL1 and RCVRN, the second portion will express NR2E3 but will not express PPP4R4. In further embodiments,, the cell population is identified as a suitable cell population for treatment of an eye disease when, of those 90% PRPs expressing AIPL1 andAttorney Docket No.: 132042-5009- WORCVRN, at least about 20% of the cells will express PPP4R4, at least about 80% of the cells will express NR2E3. In further embodiments, the cell population is identified as a suitable cell population for treatment of an eye disease when, of those 90% PRPs expressing AIPL1 and RCVRN, at least about 30% of the cells will express PPP4R4, at least about 70% of the cells will express NR2E3. In further embodiments, the cell population is identified as a suitable cell population for treatment of an eye disease when, of those 90% PRPs expressing AIPL1 and RCVRN, at least about 40% of the cells will express PPP4R4, at least about 60% of the cells will express NR2E3. In further embodiments, the cell population is identified as a suitable cell population for treatment of an eye disease when, of those 90% PRPs expressing AIPL1 and RCVRN, at least about 50% of the cells will express PPP4R4, at least about 50% of the cells will express NR2E3. In further embodiments, the cell population is identified as a suitable cell population for treatment of an eye disease when, of those 90% PRPs expressing AIPL1 and RCVRN, at least about 60% of the cells will express PPP4R4, at least about 40% of the cells will express NR2E3.

[0227] In some embodiments, the cell population is identified as a suitable cell population for treatment of an eye disease when the copies of VIM per copy of SDHA of cells in the cell population is about 0.0 to at most 0.5 copies as measured by ddPCR (e.g., about 0.0, about 0.05, about 0.10, about 0.15, about 0.20, about 0.25, about 0.30, about 0.35, about 0.40, about 0.45, or about 0.50 copies as measured by ddPCR). In some embodiments, the cell population is identified as a suitable cell population (e.g., qualified for use as a therapeutic) for treatment of an eye disease when the copies of VIM per copy of SDHA of cells in the cell population is between about 0.0 copies and about 0.50 copies (e.g., about 0.0 copies to about 0.1, about 0.0 copies to about 0.2, about 0.0 copies to about 0.3, about 0.0 copies to about 0.4, about 0.0 copies to about 0.5, about 0.1 copies to about 0.2, about 0.1 copies to about 0.3, about 0.1 copies to about 0.4, about 0.1 copies to about 0.5, about 0.2 copies to about 0.3, about 0.2 copies to about 0.4, about 0.2 copies to about 0.5, about 0.3 copies to about 0.4, about 0.3 copies to about 0.5, or about 0.4 copies to about 0.5), as measured by ddPCR In some embodiments, the cell population is identified as a suitable cell population for treatment of an eye disease when the copies of VIM per copy of SDHA of cells in the cell population is at most 0.5 as measured by ddPCR.

[0228] In some embodiments, the cell population is identified as a suitable cell population for treatment of an eye disease (e.g., qualified for use as a therapeutic) when the percentage of PAX6+ cells in the cell population is at most about 7.0% (e.g., about 7.0%, about 6.75%, about 6.50%, about 6.25%, about 6.0%, about 5.75%, about 5.50%, about 5.25%, about 5.0%, aboutAttorney Docket No.: 132042-5009- WO4.75%, about 4.50%, about 4.25%, about 4.0%, about 3.75%, about 3.50%, about 3.25%, about 3.0%, about 2.75%, about 2.50%, about 2.25%, about 2.0%, about 1.75%, about 1.50%, about 1.25%, about 1.0%, about 0.75%, about 0.50%, about 0.25%, or about 0.0%). In some embodiments, the cell population is identified as a suitable cell population (e.g., qualified for use as a therapeutic) for treatment of an eye disease when the percentage of PAX6+ cells in the cell population is between about 0% and about 7% (e.g., about 0% to about 7%, about 0% to about 6%, about 0% to about 5%, about 0% to about 4%, about 0% to about 3%, about 0% to about 2%, about 0% to about 1%, about 1% to about 7%, about 1% to about 6%, about 1% to about 5%, about 1% to about 4%, about 1% to about 3%, about 1% to about 2%, about 2% to about 7%, about 2% to about 6%, about 2% to about 5%, about 2% to about 4%, about 2% to about 3%, about 3% to about 7%, about 3% to about 6%, about 3% to about 5%, about 3% to about 4%, about 4% to about 7%, about 4% to about 6%, about 4% to about 5%, about 5% to about 7%, about 5% to about 6%, or about 6% to about 7%). In some embodiments, the cell population is identified as a suitable cell population for treatment of an eye disease when the percentage of PAX6+ cells in the cell population is at most about 7%.

[0229] In some embodiments, the cell population is identified as a suitable cell population (e.g., qualified for use as a therapeutic) for treatment of an eye disease when the percentage of CHX10+ cells in the cell population is at most about 7.0% (e.g., about 7.0%, about 6.75%, about 6.50%, about 6.25%, about 6.0%, about 5.75%, about 5.50%, about 5.25%, about 5.0%, about 4.75%, about 4.50%, about 4.25%, about 4.0%, about 3.75%, about 3.50%, about 3.25%, about 3.0%, about 2.75%, about 2.50%, about 2.25%, about 2.0%, about 1.75%, about 1.50%, about 1.25%, about 1.0%, about 0.75%, about 0.50%, about 0.25%, or about 0.0%). In some embodiments, the cell population is identified as a suitable cell population (e.g., qualified for use as a therapeutic) for treatment of an eye disease when the percentage of CHX10+ cells in the cell population is between about 0% and about 7% (e.g., about 0% to about 7%, about 0% to about 6%, about 0% to about 5%, about 0% to about 4%, about 0% to about 3%, about 0% to about 2%, about 0% to about 1%, about 1% to about 7%, about 1% to about 6%, about 1% to about 5%, about 1% to about 4%, about 1% to about 3%, about 1% to about 2%, about 2% to about 7%, about 2% to about 6%, about 2% to about 5%, about 2% to about 4%, about 2% to about 3%, about 3% to about 7%, about 3% to about 6%, about 3% to about 5%, about 3% to about 4%, about 4% to about 7%, about 4% to about 6%, about 4% to about 5%, about 5% to about 7%, about 5% to about 6%, or about 6% to about 7%). In some embodiments, the cell population is identified as a suitable cell population for treatment of an eye disease when the percentage of CHX10+ cells in the cell population is at most about 7%.Attorney Docket No.: 132042-5009- WO

[0230] In some embodiments, the cell population is identified as a suitable cell population (e.g., qualified for use as a therapeutic) for treatment of an eye disease when the percentage of TYRP1 + cells in the cell population is at most about 0.5% (e.g., about 0.00%, about 0.05%, about 0.10%, about 0.15%, about 0.20%, about 0.25%, about 0.30%, about 0.35%, about 0.40%, about 0.45%, or about 0.50%). In some embodiments, the cell population is identified as a suitable cell population (e.g., qualified for use as a therapeutic) for treatment of an eye disease when the percentage of TYRP1 + cells in the cell population is between about 0% and about 0.5% (e.g., about 0.0% to about 0.1%, about 0.0% to about 0.2%, about 0.0% to about 0.3%, about 0.0% to about 0.4%, about 0.0% to about 0.5%, about 0.1% to about 0.2%, about 0.1% to about 0.3%, about 0.1% to about 0.4%, about 0.1% to about 0.5%, about 0.2% to about 0.3%, about 0.2% to about 0.4%, about 0.2% to about 0.5%, about 0.3% to about 0.4%, about 0.3% to about 0.5%, or about 0.4% to about 0.5%). In some embodiments, the cell population is identified as a suitable cell population for treatment of an eye disease when the percentage of TYRP1+ cells in the cell population is at most 0.5%. In some embodiments, the cell population is identified as a suitable cell population for treatment of an eye disease when expression of TYRP1+ cells is not detectable.

[0231] In some embodiments, the cell population is identified as a suitable cell population (e.g., qualified for use as a therapeutic) for treatment of an eye disease when the percentage of Ki67+ cells in the cell population is at most about 0.5% (e.g., about 0.00%, about 0.05%, about 0.10%, about 0.15%, about 0.20%, about 0.25%, about 0.30%, about 0.35%, about 0.40%, about 0.45%, or about 0.50%. In some embodiments, the cell population is identified as a suitable cell population (e.g., qualified for use as a therapeutic) for treatment of an eye disease when the percentage of Ki67+ cells in the cell population is between about 0% and about 0.5% (e.g., about 0.0% to about 0.1%, about 0.0% to about 0.2%, about 0.0% to about 0.3%, about 0.0% to about 0.4%, about 0.0% to about 0.5%, about 0.1% to about 0.2%, about 0.1% to about 0.3%, about 0.1% to about 0.4%, about 0.1% to about 0.5%, about 0.2% to about 0.3%, about 0.2% to about 0.4%, about 0.2% to about 0.5%, about 0.3% to about 0.4%, about 0.3% to about 0.5%, or about 0.4% to about 0.5%). In some embodiments, the cell population is identified as a suitable cell population for treatment of an eye disease when the percentage of Ki67+ cells in the cell population is at most 0.5%. In some embodiments, the cell population is identified as a suitable cell population for treatment of an eye disease when expression of Ki67+ cells is not detectable.

[0232] In some embodiments, the cell population is identified as a suitable cell population (e.g., qualified for use as a therapeutic) for treatment of an eye disease when the composition consists of or consists essentially of: NR2E3+ cells and between at least about 20% to about 60%Attorney Docket No.: 132042-5009- WOPPP4R4+ cells; wherein the PRPs comprise less than or equal to about 0.5 copies of VIM per copy of SDHA, and wherein the composition comprises at least about 90% PRP cells. In some embodiments the cell population is identified as a suitable cell population (e.g., qualified for use as a therapeutic) for treatment of an eye disease when the composition consists of or consists essentially of at least about 90% AIPL1+ cells; at least about 90% RCVRN+ cells; less than or equal to about 7% PAX6+ cells; less than or equal to about 7% CHX10+ cells; less than or equal to about 0.5% TYRP1+ cells; and less than or equal to about 0.5% Ki67+ cells.

[0233] In some embodiments, the cell population is identified as a suitable cell population (e.g., qualified for use as a therapeutic) for treatment of an eye disease when the cell population comprises substantially NR2E3+ cells, between at least about 20% and at most about 60% PPP4R4+ cells, at most 0.5 copies VIM per copy SDHA, at least about 90% AIPL1+ cells, at least about 90% RCVRN+ cells, at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, and / or at most about 0.5% Ki67+ cells. In some embodiments, the cell population is identified as a suitable cell population for treatment of an eye disease when the cell population comprises between at least about 20% and at most about 60% PPP4R4+ cells and at most 0.5 copies VIM per copy SDHA. In some embodiments, the cell population is identified as a suitable cell population for treatment of an eye disease when the cell population comprises NR2E3+ cells and between at least about 20% and at most about 60% PPP4R4+ cells. In some embodiments, the cell population is identified as a suitable cell population for treatment of an eye disease when the cell population comprises NR2E3+ cells, between at least about 20% and at most about 60% PPP4R4+ cells, and at most 0.5 copies VIM per copy SDHA. In some embodiments, the cell population is identified as a suitable cell population for treatment of an eye disease when the cell population comprises at least about 90% AIPL1+ cells and at least about 90% RCVRN+ cells. In some embodiments, the cell population is identified as a suitable cell population for treatment of an eye disease when the cell population comprises NR2E3+ cells, between at least about 20% and at most about 60% PPP4R4+ cells, at most 0.5 copies VIM per copy SDHA, at least about 90% AIPL1+ cells, and at least about 90% RCVRN+ cells. In some embodiments, the cell population is identified as a suitable cell population for treatment of an eye disease when the cell population comprises at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, and / or at most about 0.5% Ki67+ cells.

[0234] In some embodiments, the cell population is identified as a suitable cell population for treatment of an eye disease (e.g., a disease in which there has been or is a risk of loss of photoreceptors) when the cell population comprises, or consists of, or consists essentially of, oneAttorney Docket No.: 132042-5009- WOor more, two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, ten or more, eleven or more, or twelve of the characteristics provided in Table 4.Table 4. Specifications for Drug Products Comprising a Composition of Cells Comprising PRPs as Disclosed HereinSpecification CharacteristicAIPL1+ At least 90%RCVRN+ At least 90%PPP4R4+ At least 20% and at most 60%NR2E3+ DetectablePAX6+ At most 7%CHX10+ At most 7%TYRP1+ At most 0.5%Ki67+ At most 0.5%Copies of VIM per copy of SDHA At most 0.5 copies / copyAggregate biomass At least 70%Percentage Viability At least 50%LNCPRESS2 and AC009446.1 Not detectable

[0235] In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least 90%AIPL1+ cells, at least 90% RCVRN+ cells, at least 20% and at most 60% PPP4R4+ cells, NR2E3+ cells, at most 7% PAX6+ cells, at most 7% CHX10+ cells, at most 0.5% TYRP1 + cells, at most 0.5% Ki67+ cells, at most 0.5 copies of VIM per copy of SDHA, at least 70% aggregate biomass, a percentage viability of at least 50%, no detectable expression of LNCPRESS2 and / or AC009446.1, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least 90% AIPL1+ cells, at least 90% RCVRN+ cells, at least 20% and at most 60% PPP4R4+ cells, NR2E3+ cells, at most 7% PAX6+ cells, at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, at most 0.5% Ki67+ cells, at most 0.5 copies of VIM per copy of SDHA, at least 70% aggregate biomass, a percentage viability of at least 50%, and whereinAttorney Docket No.: 132042-5009- WOthe composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least 90% AIPL1+ cells, at least 90% RCVRN+ cells, at least20% and at most 60% PPP4R4+ cells, NR2E3+ cells, at most 7% PAX6+ cells, at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, at most 0.5% Ki67+ cells, at most 0.5 copies of VIM per copy of SDHA, at least 70% aggregate biomass, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least 90% AIPL1+ cells, at least 90% RCVRN+ cells, at least 20% and at most 60% PPP4R4+ cells, NR2E3+ cells, at most 7% PAX6+ cells, at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, at most 0.5% Ki67+ cells, at most 0.5 copies of VIM per copy of SDHA, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least 90% AIPL1+ cells, at least 90% RCVRN+ cells, at least20% and at most 60% PPP4R4+ cells, NR2E3+ cells, at most 7% PAX6+ cells, at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, at most 0.5% Ki67+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least 90% AIPL1+ cells, at least 90% RCVRN+ cells, at least 20% and at most 60% PPP4R4+ cells, NR2E3+ cells, at most 7% PAX6+ cells, at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least 90% AIPL1+ cells, at least 90% RCVRN+ cells, at least 20% and at most 60% PPP4R4+ cells, NR2E3+ cells, at most 7% PAX6+ cells, at most 7% CHX10+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least 90% AIPL1+ cells, at least 90% RCVRN+ cells, at least 20% and at most 60% PPP4R4+ cells, NR2E3+ cells, at most 7% PAX6+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consistsAttorney Docket No.: 132042-5009- WOof, or consists essentially of at least 90% AIPL1+ cells, at least 90% RCVRN+ cells, at least 20% and at most 60% PPP4R4+ cells, NR2E3+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least 90% AIPL1+ cells, at least 90% RCVRN+ cells, at least 20% and at most 60% PPP4R4+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least 90% AIPL1+ cells, at least 90% RCVRN+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least 90% AIPL1+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form.

[0236] In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least 90% RCVRN+ cells, at least 20% and at most 60% PPP4R4+ cells, NR2E3+ cells, at most 7% PAX6+ cells, at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, at most 0.5% Ki67+ cells, at most 0.5 copies of VIM per copy of SDHA, at least 70% aggregate biomass, a percentage viability of at least 50%, no detectable expression of LNCPRESS2 and / or AC009446.1, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least 90% RCVRN+ cells, at least 20% and at most 60% PPP4R4+ cells, NR2E3+ cells, at most 7% PAX6+ cells, at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, at most 0.5% Ki67+ cells, at most 0.5 copies of VIM per copy of SDHA, at least 70% aggregate biomass, a percentage viability of at least 50%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least 90% RCVRN+ cells, at least 20% and at most 60% PPP4R4+ cells, NR2E3+ cells, at most 7% PAX6+ cells, at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, at most 0.5% Ki67+ cells, at most 0.5 copies of VIM per copy of SDHA, at least 70% aggregate biomass, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatmentAttorney Docket No.: 132042-5009- WOof an eye disease when the population comprises, or consists of, or consists essentially of at least 90% RCVRN+ cells, at least 20% and at most 60% PPP4R4+ cells, NR2E3+ cells, at most 7% PAX6+ cells, at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, at most 0.5% Ki67+ cells, at most 0.5 copies of VIM per copy of SDHA, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least 90% RCVRN+ cells, at least 20% and at most 60% PPP4R4+ cells, NR2E3+ cells, at most 7% PAX6+ cells, at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, at most 0.5% Ki67+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least 90% RCVRN+ cells, at least 20% and at most 60% PPP4R4+ cells, NR2E3+ cells, at most 7% PAX6+ cells, at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least 90% RCVRN+ cells, at least 20% and at most 60% PPP4R4+ cells, NR2E3+ cells, at most 7% PAX6+ cells, at most 7% CHX10+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least 90% RCVRN+ cells, at least 20% and at most 60% PPP4R4+ cells, NR2E3+ cells, at most 7% PAX6+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least 90% RCVRN+ cells, at least 20% and at most 60% PPP4R4+ cells, NR2E3+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least 90% RCVRN+ cells, at least 20% and at most 60% PPP4R4+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least 90% RCVRN+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form.Attorney Docket No.: 132042-5009- WO

[0237] In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least 20% and at most 60% PPP4R4+ cells, NR2E3+ cells, at most 7% PAX6+ cells, at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, at most 0.5% Ki67+ cells, at most 0.5 copies of VIM per copy of SDHA, at least 70% aggregate biomass, a percentage viability of at least 50%, no detectable expression of LNCPRESS2 and / or AC009446.1, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least 20% and at most 60% PPP4R4+ cells, NR2E3+ cells, at most 7% PAX6+ cells, at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, at most 0.5% Ki67+ cells, at most 0.5 copies of VIM per copy of SDHA, at least 70% aggregate biomass, a percentage viability of at least 50%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least 20% and at most 60% PPP4R4+ cells, NR2E3+ cells, at most 7% PAX6+ cells, at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, at most 0.5% Ki67+ cells, at most 0.5 copies of VIM per copy of SDHA, at least 70% aggregate biomass, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least 20% and at most 60% PPP4R4+ cells, NR2E3+ cells, at most 7% PAX6+ cells, at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, at most 0.5% Ki67+ cells, at most 0.5 copies of VIM per copy of SDHA, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least 20% and at most 60% PPP4R4+ cells, NR2E3+ cells, at most 7% PAX6+ cells, at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, at most 0.5% Ki67+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least 20% and at most 60% PPP4R4+ cells, NR2E3+ cells, at most 7% PAX6+ cells, at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when theAttorney Docket No.: 132042-5009- WOpopulation comprises, or consists of, or consists essentially of at least 20% and at most 60% PPP4R4+ cells, NR2E3+ cells, at most 7% PAX6+ cells, at most 7% CHX10+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least 90% AIPL1+ cells, at least 90% RCVRN+ cells, at least20% and at most 60% PPP4R4+ cells, NR2E3+ cells, at most 7% PAX6+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least 20% and at most 60% PPP4R4+ cells, NR2E3+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least 20% and at most 60% PPP4R4+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form.

[0238] In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of NR2E3+ cells, at most 7% PAX6+ cells, at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, at most 0.5% Ki67+ cells, at most 0.5 copies of VIM per copy of SDHA, at least 70% aggregate biomass, a percentage viability of at least 50%, no detectable expression of LNCPRESS2 and / or AC009446.1, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of NR2E3+ cells, at most 7% PAX6+ cells, at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, at most 0.5% Ki67+ cells, at most 0.5 copies of VIM per copy of SDHA, at least 70% aggregate biomass, a percentage viability of at least 50%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of NR2E3+ cells, at most 7% PAX6+ cells, at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, at most 0.5% Ki67+ cells, at most 0.5 copies of VIM per copy of SDHA, at least 70% aggregate biomass, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of NR2E3+Attorney Docket No.: 132042-5009- WOcells, at most 7% PAX6+ cells, at most 7% CHX10+ cells, at most 0.5% TYRP1 + cells, at most 0.5% Ki67+ cells, at most 0.5 copies of VIM per copy of SDHA, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of NR2E3+ cells, at most 7% PAX6+ cells, at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, at most 0.5% Ki67+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of NR2E3+ cells, at most 7% PAX6+ cells, at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of NR2E3+ cells, at most 7% PAX6+ cells, at most 7% CHX10+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of NR2E3+ cells, at most 7% PAX6+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of NR2E3+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form.

[0239] In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at most 7% PAX6+ cells, at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, at most 0.5% Ki67+ cells, at most 0.5 copies of VIM per copy of SDHA, at least 70% aggregate biomass, a percentage viability of at least 50%, no detectable expression of LNCPRESS2 and / or AC009446.1, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at most 7% PAX6+ cells, at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, at most 0.5% Ki67+ cells, at most 0.5 copies of VIM per copy of SDHA, at least 70% aggregate biomass, a percentage viability of at least 50%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell populationAttorney Docket No.: 132042-5009- WOas defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at most 7% PAX6+ cells, at most 7% CHX10+ cells, at most 0.5% TYRP1 + cells, at most 0.5% Ki67+ cells, at most 0.5 copies of VIM per copy of SDHA, at least 70% aggregate biomass, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at most 7% PAX6+ cells, at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, at most 0.5% Ki67+ cells, at most 0.5 copies of VIM per copy of SDHA, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at most 7% PAX6+ cells, at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, at most 0.5% Ki67+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at most 7% PAX6+ cells, at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at most 7% PAX6+ cells, at most 7% CHX10+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at most 7% PAX6+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form.

[0240] In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, at most 0.5% Ki67+ cells, at most 0.5 copies of VIM per copy of SDHA, at least 70% aggregate biomass, a percentage viability of at least 50%, no detectable expression of LNCPRESS2 and / or AC009446.1, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, at most 0.5% Ki67+ cells, at most 0.5 copies of VIM per copy of SDHA, at least 70% aggregate biomass, a percentage viability of at least 50%, andAttorney Docket No.: 132042-5009- WOwherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, at most 0.5% Ki67+ cells, at most 0.5 copies of VIM per copy of SDHA, at least 70% aggregate biomass, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, at most 0.5% Ki67+ cells, at most 0.5 copies of VIM per copy of SDHA, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, at most 0.5% Ki67+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at most 7% CHX10+ cells, at most 0.5% TYRP1+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at most 7% CHX10+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form.

[0241] In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at most 0.5% TYRP1+ cells, at most 0.5% Ki67+ cells, at most 0.5 copies of VIM per copy of SDHA, at least 70% aggregate biomass, a percentage viability of at least 50%, no detectable expression of LNCPRESS2 and / or AC009446.1, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at most 0.5% TYRP1+ cells, at most 0.5% Ki67+ cells, at most 0.5 copies of VIM per copy of SDHA, at least 70% aggregate biomass, a percentage viability of at least 50%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at most 0.5% TYRP1+ cells, at most 0.5% Ki67+ cells, at most 0.5Attorney Docket No.: 132042-5009- WOcopies of VIM per copy of SDHA, at least 70% aggregate biomass, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at most 0.5% TYRP1+ cells, at most 0.5% Ki67+ cells, at most 0.5 copies of VIM per copy of SDHA, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at most 0.5% TYRP1 + cells, at most 0.5% Ki67+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at most 0.5% TYRP1+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form.

[0242] In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at most 0.5% Ki67+ cells, at most 0.5 copies of VIM per copy of SDHA, at least 70% aggregate biomass, a percentage viability of at least 50%, no detectable expression of LNCPRESS2 and / or AC009446.1, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at most 0.5% Ki67+ cells, at most 0.5 copies of VIM per copy of SDHA, at least 70% aggregate biomass, a percentage viability of at least 50%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at most 0.5% Ki67+ cells, at most 0.5 copies of VIM per copy of SDHA, at least 70% aggregate biomass, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at most 0.5% Ki67+ cells, at most 0.5 copies of VIM per copy of SDHA, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at most 0.5% Ki67+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form.Attorney Docket No.: 132042-5009- WO

[0243] In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at most 0.5 copies of VIM per copy of SDHA, at least 70% aggregate biomass, a percentage viability of at least 50%, no detectable expression of LNCPRESS2 and / or AC009446.1, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at most 0.5 copies of VIM per copy of SDHA, at least 70% aggregate biomass, a percentage viability of at least 50%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at most 0.5 copies of VIM per copy of SDHA, at least 70% aggregate biomass, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at most 0.5 copies of VIM per copy of SDHA, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form.

[0244] In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least 70% aggregate biomass, a percentage viability of at least 50%, no detectable expression of LNCPRESS2 and / or AC009446.1, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least 70% aggregate biomass, a percentage viability of at least 50%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least 70% aggregate biomass, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form.

[0245] In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of a percentage viability of at least 50%, no detectable expression of LNCPRESS2 and / or AC009446.1, and wherein the composition is mostly in aggregate form, which is in suspension orAttorney Docket No.: 132042-5009- WOpellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of a percentage viability of at least 50%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form.

[0246] In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of no detectable expression of LNCPRESS2 and / or AC009446.1, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form.

[0247] In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least about 90% AIPL1+ cells, at least about 90% RCVRN+ cells, at least about 20% and at most about 60% PPP4R4+ cells, NR2E3+ cells, at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, at most about 0.5% Ki67+ cells, at most about 0.5 copies of VIM per copy of SDHA, at least about 70% aggregate biomass, a percentage viability of at least about 50%, no detectable expression of LNCPRESS2 and / or AC009446.1, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least about 90% AIPL1+ cells, at least about 90% RCVRN+ cells, at least about 20% and at most about 60% PPP4R4+ cells, NR2E3+ cells, at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, at most about 0.5% TYRP1 + cells, at most about 0.5% Ki67+ cells, at most about 0.5 copies of VIM per copy of SDHA, at least about 70% aggregate biomass, a percentage viability of at least about 50%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least about 90% AIPL1+ cells, at least about 90% RCVRN+ cells, at least about 20% and at most about 60% PPP4R4+ cells, NR2E3+ cells, at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, at most about 0.5% Ki67+ cells, at most about 0.5 copies of VIM per copy of SDHA, at least about 70% aggregate biomass, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least about 90% AIPL1+ cells, at least about 90% RCVRN+ cells, at least about 20% and at most aboutAttorney Docket No.: 132042-5009- WO60% PPP4R4+ cells, NR2E3+ cells, at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, at most about 0.5% TYRP1 + cells, at most about 0.5% Ki67+ cells, at most about 0.5 copies of VIM per copy of SDHA, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least about 90% AIPL1+ cells, at least about 90% RCVRN+ cells, at least about 20% and at most about 60% PPP4R4+ cells, NR2E3+ cells, at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, at most about 0.5% Ki67+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least about 90% AIPL1+ cells, at least about 90% RCVRN+ cells, at least about 20% and at most about 60% PPP4R4+ cells, NR2E3+ cells, at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least about 90% AIPL1 + cells, at least about 90% RCVRN+ cells, at least about 20% and at most about 60% PPP4R4+ cells, NR2E3+ cells, at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least about 90% AIPL1+ cells, at least about 90% RCVRN+ cells, at least about 20% and at most about 60% PPP4R4+ cells, NR2E3+ cells, at most about 7% PAX6+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least about 90% AIPL1+ cells, at least about 90% RCVRN+ cells, at least about 20% and at most about 60% PPP4R4+ cells, NR2E3+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least about 90% AIPL1+ cells, at least about 90% RCVRN+ cells, at least about 20% and at most about 60% PPP4R4+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identifiedAttorney Docket No.: 132042-5009- WOas suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least about 90% AIPL1+ cells, at least about 90% RCVRN+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least about 90% AIPL1+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form.

[0248] In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least about 90% RCVRN+ cells, at least about 20% and at most about 60% PPP4R4+ cells, NR2E3+ cells, at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, at most about 0.5% Ki67+ cells, at most about 0.5 copies of VIM per copy of SDHA, at least about 70% aggregate biomass, a percentage viability of at least about 50%, no detectable expression of LNCPRESS2 and / or AC009446.1, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least about 90% RCVRN+ cells, at least about 20% and at most about 60% PPP4R4+ cells, NR2E3+ cells, at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, at most about 0.5% Ki67+ cells, at most about 0.5 copies of VIM per copy of SDHA, at least about 70% aggregate biomass, a percentage viability of at least about 50%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least about 90% RCVRN+ cells, at least about 20% and at most about 60% PPP4R4+ cells, NR2E3+ cells, at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, at most about 0.5% Ki67+ cells, at most about 0.5 copies of VIM per copy of SDHA, at least about 70% aggregate biomass, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least about 90% RCVRN+ cells, at least about 20% and at most about 60% PPP4R4+ cells, NR2E3+ cells, at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, at most about 0.5% TYRP1 + cells, at most about 0.5% Ki67+ cells, at most about 0.5 copies of VIM per copy of SDHA, and wherein the composition is mostly in aggregate form, which is inAttorney Docket No.: 132042-5009- WOsuspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least about 90% RCVRN+ cells, at least about 20% and at most about 60% PPP4R4+ cells, NR2E3+ cells, at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, at most about 0.5% Ki67+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least about 90% RCVRN+ cells, at least about 20% and at most about 60% PPP4R4+ cells, NR2E3+ cells, at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least about 90% RCVRN+ cells, at least about 20% and at most about 60% PPP4R4+ cells, NR2E3+ cells, at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least about 90% RCVRN+ cells, at least about 20% and at most about 60% PPP4R4+ cells, NR2E3+ cells, at most about 7% PAX6+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least about 90% RCVRN+ cells, at least about 20% and at most about 60% PPP4R4+ cells, NR2E3+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least about 90% RCVRN+ cells, at least about 20% and at most about 60% PPP4R4+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least about 90% RCVRN+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form.

[0249] In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentiallyAttorney Docket No.: 132042-5009- WOof at least about 20% and at most about 60% PPP4R4+ cells, NR2E3+ cells, at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, at most about 0.5% Ki67+ cells, at most about 0.5 copies of VIM per copy of SDHA, at least about 70% aggregate biomass, a percentage viability of at least about 50%, no detectable expression of LNCPRESS2 and / or AC009446.1, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least about 20% and at most about 60% PPP4R4+ cells, NR2E3+ cells, at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, at most about 0.5% Ki67+ cells, at most about 0.5 copies of VIM per copy of SDHA, at least about 70% aggregate biomass, a percentage viability of at least about 50%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least about 20% and at most about 60% PPP4R4+ cells, NR2E3+ cells, at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, at most about 0.5% Ki67+ cells, at most about 0.5 copies of VIM per copy of SDHA, at least about 70% aggregate biomass, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least about 20% and at most about 60% PPP4R4+ cells, NR2E3+ cells, at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, at most about 0.5% Ki67+ cells, at most about 0.5 copies of VIM per copy of SDHA, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least about 20% and at most about 60% PPP4R4+ cells, NR2E3+ cells, at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, at most about 0.5% Ki67+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least about 20% and at most about 60% PPP4R4+ cells, NR2E3+ cells, at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell populationAttorney Docket No.: 132042-5009- WOas defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least about 20% and at most about 60% PPP4R4+ cells, NR2E3+ cells, at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least about 90% AIPL1+ cells, at least about 90% RCVRN+ cells, at least about 20% and at most about 60% PPP4R4+ cells, NR2E3+ cells, at most about 7% PAX6+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least about 20% and at most about 60% PPP4R4+ cells, NR2E3+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least about 20% and at most about 60% PPP4R4+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form.

[0250] In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of NR2E3+ cells, at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, at most about 0.5% Ki67+ cells, at most about 0.5 copies of VIM per copy of SDHA, at least about 70% aggregate biomass, a percentage viability of at least about 50%, no detectable expression of LNCPRESS2 and / or AC009446.1, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of NR2E3+ cells, at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, at most about 0.5% Ki67+ cells, at most about 0.5 copies of VIM per copy of SDHA, at least about 70% aggregate biomass, a percentage viability of at least about 50%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of NR2E3+ cells, at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, at most about 0.5% Ki67+ cells, at most about 0.5 copies of VIM per copy of SDHA, at least about 70% aggregate biomass, and wherein the composition is mostly in aggregate form, which is inAttorney Docket No.: 132042-5009- WOsuspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of NR2E3+ cells, at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, at most about 0.5% TYRP1 + cells, at most about 0.5% Ki67+ cells, at most about 0.5 copies of VIM per copy of SDHA, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of NR2E3+ cells, at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, at most about 0.5% Ki67+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of NR2E3+ cells, at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of NR2E3+ cells, at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of NR2E3+ cells, at most about 7% PAX6+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of NR2E3+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form.

[0251] In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, at most about 0.5% TYRP1 + cells, at most about 0.5% Ki67+ cells, at most about 0.5 copies of VIM per copy of SDHA, at least about 70% aggregate biomass, a percentage viability of at least about 50%, no detectable expression of LNCPRESS2 and / or AC009446.1, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at most about 7% PAX6+ cells, at most aboutAttorney Docket No.: 132042-5009- WO7% CHX10+ cells, at most about 0.5% TYRP1+ cells, at most about 0.5% Ki67+ cells, at most about 0.5 copies of VIM per copy of SDHA, at least about 70% aggregate biomass, a percentage viability of at least about 50%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, at most about 0.5% Ki67+ cells, at most about 0.5 copies of VIM per copy of SDHA, at least about 70% aggregate biomass, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, at most about 0.5% Ki67+ cells, at most about 0.5 copies of VIM per copy of SDHA, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, at most about 0.5% Ki67+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at most about 7% PAX6+ cells, at most about 7% CHX10+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at most about 7% PAX6+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form.

[0252] In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, at most about 0.5% Ki67+ cells, at most about 0.5 copies of VIM per copy of SDHA, at least about 70% aggregate biomass, a percentage viability of at least about 50%, no detectable expression of LNCPRESS2 and / orAttorney Docket No.: 132042-5009- WOAC009446.1, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, at most about 0.5% Ki67+ cells, at most about 0.5 copies of VIM per copy of SDHA, at least about 70% aggregate biomass, a percentage viability of at least about 50%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, at most about 0.5% Ki67+ cells, at most about 0.5 copies of VIM per copy of SDHA, at least about 70% aggregate biomass, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, at most about 0.5% Ki67+ cells, at most about 0.5 copies of VIM per copy of SDHA, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, at most about 0.5% Ki67+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at most about 7% CHX10+ cells, at most about 0.5% TYRP1+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at most about 7% CHX10+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form.

[0253] In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at most about 0.5% TYRP1+ cells, at most about 0.5% Ki67+ cells, at most about 0.5 copies of VIM per copy of SDHA, at least about 70% aggregate biomass, a percentage viability of at least about 50%, no detectable expression of LNCPRESS2 and / or AC009446.1, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In someAttorney Docket No.: 132042-5009- WOembodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at most about 0.5% TYRP1 + cells, at most about 0.5% Ki67+ cells, at most about 0.5 copies of VIM per copy of SDHA, at least about 70% aggregate biomass, a percentage viability of at least about 50%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at most about 0.5% TYRP1 + cells, at most about 0.5% Ki67+ cells, at most about 0.5 copies of VIM per copy of SDHA, at least about 70% aggregate biomass, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at most about 0.5% TYRP1+ cells, at most about 0.5% Ki67+ cells, at most about 0.5 copies of VIM per copy of SDHA, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at most about 0.5% TYRP1 + cells, at most about 0.5% Ki67+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at most about 0.5% TYRP1+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form.

[0254] In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at most about 0.5% Ki67+ cells, at most about 0.5 copies of VIM per copy of SDHA, at least about 70% aggregate biomass, a percentage viability of at least about 50%, no detectable expression of LNCPRESS2 and / or AC009446.1, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at most about 0.5% Ki67+ cells, at most about 0.5 copies of VIM per copy of SDHA, at least about 70% aggregate biomass, a percentage viability of at least about 50%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at most about 0.5% Ki67+ cells, at most about 0.5 copies of VIM per copyAttorney Docket No.: 132042-5009- WOof SDHA, at least about 70% aggregate biomass, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at most about 0.5% Ki67+ cells, at most about 0.5 copies of VIM per copy of SDHA, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at most about 0.5% Ki67+ cells, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form.

[0255] In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at most about 0.5 copies of VIM per copy of SDHA, at least about 70% aggregate biomass, a percentage viability of at least about 50%, no detectable expression of LNCPRESS2 and / or AC009446.1, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at most about 0.5 copies of VIM per copy of SDHA, at least about 70% aggregate biomass, a percentage viability of at least about 50%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at most about 0.5 copies of VIM per copy of SDHA, at least about 70% aggregate biomass, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at most about 0.5 copies of VIM per copy of SDHA, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form.

[0256] In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least about 70% aggregate biomass, a percentage viability of at least about 50%, no detectable expression of LNCPRESS2 and / or AC009446.1, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when theAttorney Docket No.: 132042-5009- WOpopulation comprises, or consists of, or consists essentially of at least about 70% aggregate biomass, a percentage viability of at least about 50%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least about 70% aggregate biomass, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form.

[0257] In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of a percentage viability of at least about 50%, no detectable expression of LNCPRESS2 and / or AC009446.1, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of a percentage viability of at least about 50%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form.

[0258] In some embodiments, the cell population is identified as a suitable cell population for treatment of an eye disease when the cell population comprises, or consists of, or consists essentially of, one or more, two or more, or three or more of the characteristics provided in Table 5.Table 5. Specifications for Doses for Administration Comprising a Composition of Cells Comprising PRPs as Disclosed HereinSpecification Characteristic1 X106dose - Live Cell Concentration At least 2.72x107and at most 4.08x1072X106dose - Live Cell Concentration At least 5.04x107and at most 7.56x1073x106dose - Live Cell Concentration At least 7.12x107and at most 1.07x1084x106dose - Live Cell Concentration At least 9.44x107and at most 1.42x108Endotoxin contamination levels At most 5.0 EU / mLPercentage Viability At least 40%

[0259] In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least 2.72x107cells / mL and at most 4.08x107cells / mL, an endotoxin level that is at most 5.0 EU / mL, a percentage viability of at least 40%, and wherein the composition is mostly in aggregateAttorney Docket No.: 132042-5009- WOform, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least 2.72x107cells / mL and at most 4.08x107cells / mL, a percentage viability of at least 40%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least 2.72x107cells / mL and at most 4.08x107cells / mL, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form.

[0260] In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least 5.04x107cells / mL and at most 7.56x107cells / mL, an endotoxin level that is at most 5.0 EU / mL, a percentage viability of at least 40%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least 5.04x107cells / mL and at most 7.56x107cells / mL, a percentage viability of at least 40%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least 5.04x107cells / mL and at most 7.56x107cells / mL, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form.

[0261] In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least 7.12x107cells / mL and at most 1.07x108cells / mL, an endotoxin level that is at most 5.0 EU / mL, a percentage viability of at least 40%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least 7.12x107cells / mL and at most 1.07X108cells / mL, a percentage viability of at least 40%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least 7.12x107cells / mL and at most 1.07x108cells / mL, an endotoxin level that is at most 5.0 EU / mL, wherein the composition is mostly in aggregate form, which is in suspension or pellet form.Attorney Docket No.: 132042-5009- WO

[0262] In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least 9.44x107cells / mL and at most 1.42x108cells / mL, an endotoxin level that is at most 5.0 EU / mL, a percentage viability of at least 40%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least 9.44x107cells / mL and at most 1.42x108cells / mL, a percentage viability of at least 40%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least 9.44x107cells / mL and at most 1.42x108cells / mL, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form.

[0263] In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least about 2.72x107cells / mL and at most about 4.08x107cells / mL, an endotoxin level that is at most about 5.0 EU / mL, a percentage viability of at least about 40%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least about 2.72x107cells / mL and at most about 4.08x107cells / mL, a percentage viability of at least about 40%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least about 2.72x107cells / mL and at most about 4.08x107cells / mL, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form.

[0264] In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least about 5.04x107cells / mL and at most about 7.56x107cells / mL, an endotoxin level that is at most about 5.0 EU / mL, a percentage viability of at least about 40%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least about 5.04x107cells / mL and at most about 7.56x107cells / mL, a percentage viability of at leastAttorney Docket No.: 132042-5009- WOabout 40%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least about 5.04x107cells / mL and at most about 7.56x107cells / mL, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form.

[0265] In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least about 7.12x107cells / mL and at most about 1.07x108cells / mL, an endotoxin level that is at most about 5.0 EU / mL, a percentage viability of at least about 40%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least about 7.12x107cells / mL and at most about 1.07x108cells / mL, a percentage viability of at least about 40%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least about 7.12x107cells / mL and at most about 1.07x108cells / mL, an endotoxin level that is at most about 5.0 EU / mL, wherein the composition is mostly in aggregate form, which is in suspension or pellet form.

[0266] In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least about 9.44x107cells / mL and at most about 1.42X108cells / mL, an endotoxin level that is at most about 5.0 EU / mL, a percentage viability of at least about 40%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least about 9.44x107cells / mL and at most about 1.42x108cells / mL, a percentage viability of at least about 40%, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form. In some embodiments, the cell population as defined herein is identified as suitable for treatment of an eye disease when the population comprises, or consists of, or consists essentially of at least about 9.44x107cells / mL and at most about 1.42x108cells / mL, and wherein the composition is mostly in aggregate form, which is in suspension or pellet form.Attorney Docket No.: 132042-5009- WO

[0267] In certain aspects, the cell population is identified as a suitable cell population (e.g., qualified for use as a therapeutic) for treatment of an eye disease when the cell population wherein the cell population does not express or has substantially no expression of CRALBP, BEST1, IGFBP5, COL8A1, ELN, UPK3B, TPM2, PTGDS, SERPINE3, TIMP3, MITF, and / or PMEL17. In some embodiments, the cell population is identified as a suitable cell population for treatment of an eye disease when the cell population has low or substantially no expression of PAX6, CHX10, Ki67, TYRP1, and / or ONECUT1. In particular embodiments, the cell population is identified as a suitable cell population for treatment of an eye disease when the cell population comprises at most about 15% (e.g., about 0% to about 15%, about 0% to about 14%, about 0% to about 13%, about 0% to about 12%, about 0% to about 11%, about 0% to about 10%, about 0% to about 9%, about 0% to about 8%, about 0% to about 7%, about 0% to about 6%, about 0% to about 5%, about 0% to about 4%, about 0% to about 3%, about 0% to about 2%, about 0% to about 1%, about 1% to about 15%, about 1% to about 14%, about 1% to about 13%, about 1% to about 12%, about 1% to about 11%, about 1% to about 10%, about 1% to about 9%, about 1% to about 8%, about 1% to about 7%, about 1% to about 6%, about 1% to about 5%, about 1% to about 4%, about 1% to about 3%, about 1% to about 2%, about 2% to about 15%, about 2% to about 14%, about 2% to about 13%, about 2% to about 12%, about 2% to about 11%, about 2% to about 10%, about 2% to about 9%, about 2% to about 8%, about 2% to about 7%, about 2% to about 6%, about 2% to about 5%, about 2% to about 4%, about 2% to about 3%, about 3% to about 15%, about 3% to about 14%, about 3% to about 13%, about 3% to about 12%, about 3% to about 11%, about 3% to about 10%, about 3% to about 9%, about 3% to about 8%, about 3% to about 7%, about 3% to about 6%, about 3% to about 5%, about 3% to about 4%, about 4% to about 15%, about 4% to about 14%, about 4% to about 13%, about 4% to about 12%, about 4% to about 11%, about 4% to about 10%, about 4% to about 9%, about 4% to about 8%, about 4% to about 7%, about 4% to about 6%, about 4% to about 5%, about 5% to about 15%, about 5% to about 14%, about 5% to about 13%, about 5% to about 12%, about 5% to about 11%, about 5% to about 10%, about 5% to about 9%, about 5% to about 8%, about 5% to about 7%, about 5% to about 6%, about 6% to about 15%, about 6% to about 14%, about 6% to about 13%, about 6% to about 12%, about 6% to about 11%, about 6% to about 10%, about 6% to about 9%, about 6% to about 8%, about 6% to about 7%, about 7% to about 15%, about 7% to about 14%, about 7% to about 13%, about 7% to about 12%, about 7% to about 11%, about 7% to about 10%, about 7% to about 9%, about 7% to about 8%, about 8% to about 15%, about 8% to about 14%, about 8% to about 13%, about 8% to about 12%, about 8% to about 11%, about 8% to about 10%, about 8% to about 9%, about 9% to about 15%, about 9% to about 14%, about 9% to about 13%, aboutAttorney Docket No.: 132042-5009- WO9% to about 12%, about 9% to about 11%, about 9% to about 10%, about 10% to about 15%, about 10% to about 14%, about 10% to about 13%, about 10% to about 12%, about 10% to about 11%, about 11% to about 15%, about 11% to about 14%, about 11% to about 13%, about 11% to about 12%, about 12% to about 15%, about 12% to about 14%, about 12% to about 13%, about 13% to about 15%, about 13% to about 14%, or about 14% to about 15%)of PAX6+ cells.

[0268] In some embodiments, the cell population is identified as a suitable cell population for treatment of an eye disease when the cell population comprises at most about 10% or about 5% PAX6-positive cells. In certain embodiments, the cell population is identified as a suitable cell population for treatment of an eye disease when the cell population comprises at most about 10% PAX6-positive cells, at most about 0.05% Ki67-positive cells, at most about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 45%, about 50%, about 55%, about 60%, about 70%, about 80%, about 90%, about 95%, or about 100% CHX10-positive cells, and / or at most about 2% ONECUTI-positive cells. In some aspects, the cell population is identified as a suitable cell population for treatment of an eye disease when the cell population comprises at most about 5% PAX6-positive cells, at most about 0.04% Ki67-positive cells, at most about 15% CHX10-positive cells, and / or at most about 1 % ONECUTI-positive cells. In certain aspects, the cell population is identified as a suitable cell population for treatment of an eye disease when the cell population comprises at most about 5% PAX6-positive cells, at most about 0.04% Ki67-positive cells, at most about 15% CHX10-positive cells, and at most about 1% ONECUTI-positive cells.

[0269] In some embodiments, the cell population is identified as a suitable cell population (e.g., qualified for use as a therapeutic) for treatment of an eye disease when the cell population comprises at least about 90% of TUBB3 (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% of TUBB3). In some embodiments, the cell population is identified as a suitable cell population (e.g., qualified for use as a therapeutic) for treatment of an eye disease when the cell population comprises at least about 90% to about 100% (e.g., about 90% to about 100%, about 90% to about 99%, about 90% to about 98%, about 90% to about 97%, about 90% to about 96%, about 90% to about 95%, about 90% to about 94%, about 90% to about 93%, about 90% to about 92%, about 90% to about 91%, about 91% to about 100%, about 91% to about 99%, about 91% to about 98%, about 91% to about 97%, about 91% to about 96%, about 91% to about 95%, about 91% to about 94%, about 91% to about 93%, about 91% to about 92%, about 92% to about 100%, about 92% to about 99%, about 92% to about 98%, about 92% to about 97%, about 92% to aboutAttorney Docket No.: 132042-5009- WO96%, about 92% to about 95%, about 92% to about 94%, about 92% to about 93%, about 93% to about 100%, about 93% to about 99%, about 93% to about 98%, about 93% to about 97%, about 93% to about 96%, about 93% to about 95%, about 93% to about 94%, about 94% to about 100%, about 94% to about 99%, about 94% to about 98%, about 94% to about 97%, about 94% to about 96%, about 94% to about 95%, about 95% to about 100%, about 95% to about 99%, about 95% to about 98%, about 95% to about 97%, about 95% to about 96%, about 96% to about 100%, about 96% to about 99%, about 96% to about 98%, about 96% to about 97%, about 97% to about 100%, about 97% to about 99%, about 97% to about 98%, about 98% to about 100%, about 98% to about 99%, or about 99% to about 100%) of Class III β-tubulin (TUBB3). In some embodiments, the cell population is identified as a suitable cell population for treatment of an eye disease when the cell population expresses one or more markers selected from the group consisting of: AIPL1, NR2E3, PPP4R4, OTX2, CRX, BLIMP 1, NEUROD1, RCVRN, TUBB3 and CD171 / L1CAM.

[0270] In particular embodiments, the cell population is identified as a suitable cell population (e.g., qualified for use as a therapeutic) for treatment of an eye disease when the cell population comprises at least about 70% cell aggregate biomass (e.g., about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% cell aggregate biomass). In some embodiments, the cell population is identified as a suitable cell population (e.g., qualified for use as a therapeutic) for treatment of an eye disease when the cell population comprises between about 70% and about 100% (e.g., about 70% to about 100%, about 70% to about 90%, about 70% to about 80%, about 80% to about 100%, about 80% to about 90%, or about 90% to about 100%) cell aggregate biomass. In some embodiments, the cell population is identified as a suitable cell population for treatment of an eye disease when the cell population comprises at least about 70% cell aggregate biomass.

[0271] In some embodiments, the cell population is identified as a suitable cell population (e.g., qualified for use as a therapeutic) for treatment of an eye disease wherein the median diameter of a cell aggregate is about 15 pm to about 120 pm (e.g., about 15 pm, about 16 pm, about 17 pm, about 18 pm, about 19 pm, about 20 pm, about 21 pm, about 22 pm, about 23 pm, about 24 pm, about 25 pm, about 26 pm, about 27 pm, about 28 pm, about 29 pm, about 30 pm, about 31 pm, about 32 pm, about 33 pm, about 34 pm, about 35 pm, about 36 pm, about 37 pm, about 38Attorney Docket No.: 132042-5009- WOpm, about 39 pm, about 40 pm, about 41 pm, about 42 pm, about 43 pm, about 44 pm, about 45 pm, about 46 pm, about 47 pm, about 48 pm, about 49 pm, about 50 pm, about 51 pm, about 52 pm, about 53 pm, about 54 pm, about 55 pm, about 55 pm, about 56 pm, about 57 pm, about 58 pm, about 59 pm, about 60 pm, about 61 pm, about 62 pm, about 63 pm, about 64 pm, about 65 pm, about 66 pm, about 67 pm, about 68 pm, about 69 pm, about 70 pm, about 71 pm, about 72 pm, about 73 pm, about 74 pm, about 75 pm, about 76 pm, about 77 pm, about 78 pm, about 79 pm, about 80 pm, about 81 pm, about 82 pm, about 83 pm, about 84 pm, about 85 pm, about 86 pm, about 87 pm, about 88 pm, about 89 pm, about 90 pm, about 91 pm, about 92 pm, about 93 pm, about 94 pm, about 95 pm, about 96 pm, about 97 pm, about 98 pm, about 99 pm, about 100 pm, about 101 pm, about 102 pm, about 103 pm, about 104 pm, about 105 pm, about 106 pm, about 107 pm, about 108 pm, about 109 pm, about 110 pm, about 111 pm, about 112 pm, about 113 pm, about 114 pm, about 115 pm, about 116 pm, about 117 pm, about 118 pm, about 119 pm, or about 120 pm). In some embodiments, the cell population is identified as a suitable cell population (e.g., qualified for use as a therapeutic) for treatment of an eye disease wherein the median diameter (e.g., particle diameter) of a cell aggregate is between about 15 pm and about 120 pm (e.g., about 15 pm to about 120 pm, about 20 pm to about 115 pm, about 35 pm to about 110 pm, about 35 pm to about 105 pm, about 40 pm to about 100 pm, about 45 pm to about 95 pm, about 50 pm to about 90 pm, about 55 pm to about 85 pm, about 60 pm to about 80 pm, about 65 pm to about 75 pm, about 30 pm to about 60 pm, about 40 pm to about 50 pm, about 20 pm to about 60 pm, about 20 pm to about 50 pm, or about 30 pm to about 60 pm). In some embodiments, the cell population is identified as a suitable cell population for treatment of an eye disease wherein the median diameter of a cell aggregate is between about 30 pm and about 60 pm. In some embodiments, the cell population is identified as a suitable cell population for treatment of an eye disease wherein the median diameter of a cell aggregate is about 50 pm. In some embodiments, the cell population is identified as a suitable cell population for treatment of an eye disease wherein the median diameter of a cell aggregate is at least about 20 pm.

[0272] In an aspect, provided herein is a method of identifying a suitable cell population for treatment of an eye disease, the method comprising: a) obtaining a population of cells comprising PRPs; b) measuring a percentage of PPP4R4+ cells in a cell population; and c) measuring a copy number of VIM per copy SDHA wherein the cell population is identified as a suitable cell population for treatment of an eye disease when the percentage of PPP4R4+ cells in the cell population is between about 20% and about 60%, and the copy number of VIM per copy of SDHA is less than or equal to about 0.5 copies. In some embodiments, the method further comprises: d) measuring a percentage of AIPL1+ RCVRN+, PAX6+, CHX10+, TYRP1+; and / or Ki67+ cellsAttorney Docket No.: 132042-5009- WOin the cell population, wherein the cell population is identified as a suitable cell population for treatment of an eye disease when the percentage of AIPL1+ cells is least about 90%, the percentage of RCVRN+ cells is least about 90%, the percentage of PAX6+ cells is no more than about 7%, the percentage of CHX10+ cells is no more than about 7%, the percentage of TYRP1 + cells is no more than about 0.5%, and the percentage of Ki67+ cells is no more than about 0.5%.

[0273] In some embodiments, the cell population is identified as a suitable cell population (e.g., qualified for use as a therapeutic) for treatment of an eye disease where the cell population does not express LNCPRESS2 and / or AC009446.1 pluripotency markers above the limit of detection (LOD). Methods for detecting, characterizing, and / or quantitating, nucleic acid sequences; and for detecting, characterizing, and / or quantitating, mRNA expression, are known to persons skilled in the art, and include, but are not limited to, for example, PCR procedures, RT-PCR, quantitative PCR or RT-PCR, Northern blot analysis, differential gene expression, RNA protection assay, microarray analysis, hybridization methods, serial analysis of gene expression (SAGE), hybridization based on digital barcode quantification assays, multiplex RT-PCR, ddPCR, qRT-PCR, qPCR, UV spectroscopy, DNA sequencing, RNA sequencing, next-generation sequencing, including RNA-seq, lysate-based hybridization assays utilizing branched DNA signal amplification, such as the QuantiGene 2.0 Single Plex, and branched DNA analysis methods. In some embodiments, the cell population is identified as a suitable cell population for treatment of an eye disease where the cell population does not express LNCPRESS2 and / or AC009446.1 pluripotency markers above the limit of detection as measured by droplet digital polymerase chain reaction (ddPCR).Methods of Treating an Inherited Retinal Disease

[0274] The disclosure also provides a method of treating an inherited retinal disease (e.g., a primary photoreceptor disease such as retinitis pigmentosa, Usher Syndrome, cone-rod disease, rod-cone disease, cone dystrophy, and cone-rod dystrophy) in an individual in need thereof. Such methods may comprise administering a composition (e.g., a pharmaceutical composition as described herein) comprising photoreceptor precursor cells to said individual. Also provided is a composition (e.g., a pharmaceutical composition) as described herein for use as a medicament, or for use in a method of treating a retinal disease (e.g., a primary photoreceptor disease such as retinitis pigmentosa, Usher Syndrome, cone-rod disease, rod-cone disease, cone dystrophy, and cone-rod dystrophy). The composition may be administered surgically or as a surgical injection to the eye, and / or subretinal space of the eye. Said composition may be administered to the eye, subretinal space, or intravenously. Certain aspects provide a method to produce a compositionAttorney Docket No.: 132042-5009- WOcomprising PRP cells or a PRP-enriched cell population which can be used for a number of important research, development, and commercial purposes.

[0275] The composition comprising the human PRP cells described herein, or a pharmaceutical composition including these cells, can be used for the manufacture of a medicament to treat a condition in a patient in need thereof. The composition comprising the PRP cells can be previously cryopreserved. In certain aspects, the disclosed composition comprising the PRP cells are derived from iPSCs, and thus can be used to provide "personalized medicine" for patients with eye diseases. In some embodiments, somatic cells obtained from patients can be genetically engineered to correct the disease-causing mutation, differentiated into PRP, and engineered to form a PRP tissue. This PRP tissue can be used to replace the endogenous degenerated PRP of the same patient.

[0276] Various eye conditions may be treated or prevented by the introduction of the composition comprising the PRP cells obtained using the methods disclosed herein. The conditions include retinal diseases or disorders generally associated with retinal dysfunction or degradation, retinal injury, and / or loss of retinal pigment epithelium. Conditions that can be treated include, without limitation, retinitis pigmentosa, Usher Syndrome, cone-rod disease, rod-cone disease, cone dystrophy, and cone-rod dystrophy.

[0277] In certain embodiments, methods are provided for treating or preventing a condition characterized by retinal degeneration, comprising administering to a subject in need thereof an effective amount of a composition comprising PRP cells (e.g., as described herein). The composition comprising the PRP cells may be transplanted in various formats. For example, the composition comprising the PRP cells may be introduced into the target site in the form of cell suspension, or adhered onto a matrix, extracellular matrix, or substrate such as a biodegradable polymer, as a monolayer, or a combination. In some embodiments, the composition comprising the PRP cells are produced from iPSCs from the subject to be treated, and thus are autologous. In other embodiments, the composition comprising the PRP cells are produced from a donor.

[0278] In certain embodiments, methods are provided for treating a disease or disorder characterized by retinal degeneration, comprising administering to a subject in need thereof an effective amount of a composition comprising PRP cells. These methods may include selecting a subject with such a disease or disorder and administering a therapeutically effective amount of the composition comprising PRP cells sufficient to treat the condition and / or ameliorate symptoms of the condition. The photoreceptor precursor cells may comprise at least about 50%, at leastAttorney Docket No.: 132042-5009- WOabout 75%, at least about 85%, at least about 95%, at least about 99% or about 100% of the cells in the culture.

[0279] In one aspect, the cells can treat or alleviate the symptoms of retinitis pigmentosa in a patient in need of the treatment. The cells can be autologous or allogeneic to the patient. In a further aspect, the cells of the present disclosure can be administered in combination with other treatments.

[0280] In some embodiments, the composition comprising the PRP cells can be used for autologous PRP grafts to those subjects suitable for receiving regenerative medicine. The composition comprising the PRP cells may be transplanted in combination with other retinal cells, such as with photoreceptors. Transplantation of the composition comprising the PRP cells produced by the disclosed methods can be performed by various techniques known in the art. In accordance with one embodiment, the transplantation is performed via pars plana vitrectomy surgery followed by delivery of the cells through a small retinal opening into the sub-retinal space or by direct injection. The composition comprising the PRP cells can be introduced into the target site in the form of cell suspension, cell aggregates, adhered onto a matrix, ...

Claims

1. Attorney Docket No.: 132042-5009- WO2.WHAT IS CLAIMED IS:

1. A composition of cells comprising photoreceptor precursor cells (PRPs), wherein the composition comprises: NR2E3+ cells and between at least about 20% to about 60% PPP4R4+ cells;4.wherein the PRPs optionally comprise less than or equal to about 0.5 copies of VIM per copy of SDHA.

2. The composition according to claim 1, wherein at least about 20% to about 60% of the cells are PPP4R4+, wherein the cells are substantially NR2E3+, and wherein the cells comprise less than or equal to about 0.5 copies of VIM per copy of SDHA.

3. The composition according to claim 1 or 2, wherein the cells comprise:7.at least about 90% AIPL1+ cells;8.at least about 90% RCVRN+ cells;9.less than or equal to about 7% PAX6+ cells;10.less than or equal to about 7% CHX10+ cells;11.less than or equal to about 0.5% TYRP1+ cells; and12.less than or equal to about 0.5% Ki67+ cells.

4. The composition according to claim 3, wherein percentage NR2E3+, PPP4R4+, AIPL1+, RCVRN+, PAX6+, CHX10+, TYRP1+, and / or Ki67+ cells is determined by flow cytometry.

5. The composition according to any one of claims 1-4, wherein copies of VIM per copy of SDHA is determined by droplet digital polymerase chain reaction (ddPCR).

6. The composition according to any one of claims 1-5, wherein the cells have a percentage viability of at least about 50%.

7. The composition according to claim 6, wherein the percentage viability is determined by automated cell counting using acridine orange and propidium iodide.

8. The composition according to any one of claims 1-7, wherein the cells are of human origin.Attorney Docket No.: 132042-5009- WO9. The composition according to any one of claims 1-8, wherein the cells are derived from pluripotent stem cells (PSCs) or PSC-derived cells, optionally induced PSCs (iPSCs).

10. The composition according to any one of claims 1-9, wherein the cells express H LA Class II during physiological inflammatory cytokine stimulation, and wherein approximately 50% of the HLA Class II is HLA-DR.

11. A composition of cells consisting of photoreceptor precursor cells (PRPs) and, optionally, a pharmaceutically acceptable excipient thereof, wherein the cells consist of: NR2E3+ cells and between at least about 20% to about 60% PPP4R4+ cells; and21.wherein the PRPs comprise less than or equal to about 0.5 copies of VIM per copy of SDHA.

12. The composition according to claim 11, wherein the cells consist of:23.at least about 90% AIPL1+ cells;24.at least about 90% RCVRN+ cells;25.less than or equal to about 7% PAX6+ cells;26.less than or equal to about 7% CHX10+ cells;27.less than or equal to about 0.5% TYRP1+ cells; and28.less than or equal to about 0.5% Ki67+ cells.

13. The composition according to claim 12, wherein percentage NR2E3+, PPP4R4+, AIPL1+, RCVRN+, PAX6+, CHX10+, TYRP1+, and / or Ki67+ cells is determined by flow cytometry.

14. The composition according to any one of claims 11-13, wherein copies of VIM per copy of SDHA is determined by droplet digital polymerase chain reaction (ddPCR).

15. The composition according to any one of claims 11-14, wherein the cells have a percentage viability of at least about 40%.

16. The composition according to claim 15, wherein the percentage viability is determined by automated cell counting using acridine orange and propidium iodide.Attorney Docket No.: 132042-5009- WO17. The composition according to any one of claims 11-16, wherein the cells are of human origin.

18. The composition according to any one of claims 11-16, wherein the cells are derived from pluripotent stem cells (PSCs) or PSC-derived cells, optionally induced PSCs (iPSCs).

19. The composition according to any one of claims 11-18, wherein the cells express HLA Class II during physiological inflammatory cytokine stimulation, and wherein approximately 50% of the HLA Class II is HLA-DR.

20. A composition of cells comprising PRPs, wherein the composition comprises cell aggregates, wherein the cell aggregates have a median diameter of about 30 pm to about 60 pm.

21. The composition of cells comprising PRPs according to claim 20, wherein the median diameter of the cell aggregates is determined by a particle size analyzer.

22. The composition of cells comprising PRPs according to claim 20 or 21, wherein each cell is NR2E3+ or PPP4R4+.

23. The composition of cells comprising PRPs according to claim 20, wherein the cells comprise between at least about 20% to about 60% PPP4R4+ cells and wherein the cells comprise less than or equal to about 0.5 copies of VIM per copy of SDHA.

24. The composition of cells comprising PRPs according to claim 22 or 23, wherein a percentage of NR2E3+ and / or PPP4R4+ cells is determined by flow cytometry.

25. The composition of cells comprising PRPs according to claim 23, wherein copies of VIM per copy of SDHA is determined by ddPCR.

26. The composition of cells comprising PRPs according to any one of claims 20-25, wherein the cells express HLA Class II during physiological inflammatory cytokine stimulation, and wherein approximately 50% of the HLA Class II is HLA-DR.Attorney Docket No.: 132042-5009- WO27. The composition of cells comprising PRPs according to any one of claims 1-26, wherein the cells are in a single cell form, an aggregate form, or a suspended form.

28. The composition of cells comprising PRPs according to any one of claims 1-26, wherein the cells are in a single cell form or an aggregate form.

29. The composition of cells comprising PRPs according to any one of claims 1-26, wherein the cells are in a suspended form.

30. A composition of cells comprising PRPs according to any one of claims 1-19 and a pharmaceutically acceptable carrier.

31. The composition according to any one of claims 1-30, wherein the cells are suitable for grafting to a subretinal space of a subject’s eye.

32. A method of identifying a cell population for treatment of an eye disease or disorder, the method comprising: assaying for PPP4R4+ cells in a cell population, wherein the cell population comprises between at least about 20% to about 60% PPP4R4+ cells, and wherein and the cells comprise less than or equal to 0.5 copies of VIM per copy of SDHA.

33. The method according to claim 32, wherein the method further comprises:50.assaying forAIPL1+ and / or RCVRN+ cells in the cell population, wherein the cells are substantially NR2E3+, at least about 90% of the cells in the cell population are AIPL1+; at least about 90% of the cells in the cell population are RCVRN+; no more than about 7% of the cells are PAX6+; no more than about 7% of the cells are CHX10+; no more than about 0.5% of the cells are TYRP1+; or no more than about 0.5% of the cells are Ki67+.

34. The method according to claim 33, wherein a percentage of NR2E3+, PPP4R4+, AIPL1+, RCVRN+, PAX6+, CHX10+, TYRP1+, and / or Ki67+ cells is determined by flow cytometry.

35. The method according to any one of claims 32-34, wherein copies of VIM per copy of SDHA is determined by ddPCR.Attorney Docket No.: 132042-5009- WO36. The method according to of any one of claims 32-35, wherein the cell population has a percentage viability of at least about 40%.

37. The method according to claim 36, wherein the percentage viability is determined by an automated cell counting using acridine orange and propidium iodide.

38. The method according to any one of claims 32-37, wherein the cell population is of human origin.

39. The method according to any one of claims 32-38, wherein the cell population is derived from PSCs or PSC-derived cells, optionally iPSCs.

40. The method according to any one of claims 32-39, wherein the cell population is in a single cell form, an aggregate form, or a suspended form.

41. The method according to any one of claims 32-39, wherein the cell population is in a single cell form or an aggregate form.

42. The method according to any one of claims 32-39, wherein the cell population is in a suspended form.

43. The method according to any one of claims 32-42, wherein the cell population is suitable for grafting to a subretinal space of a subject’s eye.

44. The method of claim 32-43, wherein the eye disease or disorder is a retinal disorder.

45. The method of claim 44, wherein the retinal disorder is characterized by a loss of photoreceptors and / or a loss of photoreceptor cell function.

46. The method of claim 44 or 45, wherein the eye disease is a primary photoreceptor disease, including retinitis pigmentosa, cone-rod disease, rod-cone disease, cone dystrophy, and / or cone-rod dystrophy.Attorney Docket No.: 132042-5009- WO47. The method of any of claims 44-46, wherein the eye disease of disorder is an inherited retinal disease.

48. The method of any of claims 44-47, wherein the eye disease or disorder is Usher Syndrome.

49. A method of identifying a suitable cell population for treatment of an eye disease, the method comprising:67.a) obtaining a population of cells comprising PRPs;68.b) measuring a percentage of PPP4R4+ cells in a cell population; and c) measuring a copy number of VIM per copy SDHA,69.wherein the cell population is identified as a suitable cell population for treatment of an eye disease when the percentage of PPP4R4+ cells in the cell population is between about 20% and about 60%, and the copy number of VIM per copy of SDHA is less than or equal to about 0.5 copies.

50. The method according to claim 49, wherein the method further comprises:71.d) measuring a percentage of AIPL1+ RCVRN+, PAX6+, CHX10+, TYRP1+; and / or Ki67+ cells in the cell population,72.wherein the cell population is identified as a suitable cell population for treatment of an eye disease when the percentage of AIPL1+ cells is least about 90%, the percentage of RCVRN+ cells is least about 90%, the percentage of PAX6+ cells is no more than about 7%, the percentage of CHX10+ cells is no more than about 7%, the percentage of TYRP1 + cells is no more than about 0.5%, and the percentage of Ki67+ cells is no more than about 0.5%.

51. The method according to claim 50, wherein a percentage of PPP4R4+, AIPL1+, RCVRN+, PAX6+, CHX10+, TYRP1+, or Ki67+ cells is determined by flow cytometry.

52. The method according to any one of claims 49-51, wherein copies of VIM per copy of SDHA is determined by ddPCR.

53. The method according to any one of claims 59-52, wherein the cell population is of human origin.Attorney Docket No.: 132042-5009- WO54. The method according to any one of claims 49-53, wherein the cell population is derived from PSCs or PSC-derived cells, optionally iPSCs.

55. The method according to any one of claims 59-54, wherein the cell population is in a single cell form or an aggregate form or a suspended form.

56. The method according to any one of claims 59-54, wherein the cell population is in a suspended form.

57. The method according to any one of claims 49-56, wherein the cell population is suitable for grafting to a subretinal space of a subject’s eye.

58. A composition comprising human PRPs for treatment of an eye disease or disorder, wherein the composition is in suspension form, and at least a portion of the composition is aggregated.

59. The composition comprising human PRPs of claim 58, wherein the composition comprises an administered dose of about 1x106, about 2x106, about 3X106, or about 4x106human PRPs.

60. The composition comprising human PRPs according to claim 59, wherein a dose for administration comprises:83.a) about 2.72x107total cells / mL to about 4.08x107total cells / mLare present in the composition;84.b) about 5.04x107total cells / mL to about 7.56x107total cells / mL are present in the composition;85.c) about 7.12X107total cells / mLto about 1.07x108total cells / mL are present in the composition; or86.d) about 9.44x1 o7total cells / mLto about 1.42x108total cells / mLare present in the composition. Attorney Docket No.: 132042-5009- WO61. The composition according to claim 60, wherein the dose for administration further comprises balanced salt solution buffer supplemented with 0.2% human serum albumin (HSA).

62. The composition comprising human PRPs according to claim 61, wherein cells / mL is determined by automated cell counting using acridine orange and / or propidium iodide.

63. A drug product comprising human PRPs, wherein the drug product comprising the human PRPs comprises between at least about 20% to about 60% PPP4R4+ cells, wherein the drug product comprising the PRPs is NR2E3+; and90.wherein the drug product comprising the PRPs comprises less than or equal to about 0.5 copies of VIM per copy of SDHA.

64. The drug product comprising human PRPs according to claim 63, wherein the drug product further comprises human PRPs comprising:92.at least about 90% AIPL1+ cells;93.at least about 90% RCVRN+ cells;94.less than or equal to about 7% PAX6+ cells;95.less than or equal to about 7% CHX10+ cells;96.less than or equal to about 0.5% TYRP1+ cells; and / or97.less than or equal to about 0.5% Ki67+ cells.

65. The drug product comprising the human PRPs according to claim 64, wherein a percentage of NR2E3+, PPP4R4+, AIPL1+, RCVRN+, PAX6+, CHX10+, TYRP1+, and / or Ki67+ cells is determined by flow cytometry.

66. The drug product comprising the human PRPs according to claim 64, wherein copies of VIM per copy of SDHA is determined by ddPCR.

67. The drug product comprising the human PRPs according to any one of claims 63-66, wherein the drug product comprising human PRPs has a percentage viability of at least about 50%.Attorney Docket No.: 132042-5009- WO68. The drug product comprising the human PRPs according to claim 37, wherein the percentage viability is determined by automated cell counting using acridine orange and propidium iodide.

69. The drug product comprising the human PRPs according to any one of claims 63-68, wherein the drug product comprising the human PRPs comprises cell aggregates wherein a median diameter of a cell aggregate is about 30 pm to about 60 pm.

70. The drug product comprising the human PRPs according to claim 69, wherein the median diameter of a cell aggregate is determined by a particle size analyzer.

71. The drug product comprising the human PRPs according to any of claims 63-70, wherein the drug product is resuspended in media.

72. The drug product comprising the human PRPs according to any of claims 63-70, wherein the drug product is resuspended in CryoSTOR® CS10 solution.

73. The drug product comprising the human PRPs according to any of claims 63-70, wherein the drug product is reformulated after thaw.

74. The drug product comprising the human PRPs according to any of claims 63-73, wherein the drug product comprises about 25 x 106cells.

75. The drug product according to any one of claims 63-74, wherein the human PRPs express HLA Class II during physiological inflammatory cytokine stimulation, and wherein approximately 50% of the HLA Class II is HLA-DR.

76. A composition comprising human PRPs for treatment of an eye disease or disorder, comprising a therapeutically effective amount of the composition, wherein the composition is in an aggregated form.

77. The composition comprising human PRPs according to claim 76, wherein the composition comprises an administered dose of about 1 x 106, about 2x 106, about 3x 106, or about 4x 106human PRPs.Attorney Docket No.: 132042-5009- WO78. The composition comprising human PRPs according to claim 77, wherein a dose for administration comprises:112.a) about 2.72x107total cells / mLto about 4.08x107total cells / mLare present in the composition;113.b) about 5.04x107total cells / mL to about 7.56x107total cells / mLare present in the composition;114.c) about 7.12X107total cells / mLto about 1.07x108total cells / mL are present in the composition; or115.d) about 9.44x107total cells / mLto about 1.42X108total cells / mLare present in the composition.

79. The composition according to claim 78, wherein the dose for administration is administered within 28 hours after reformulation from a drug product.

80. The composition comprising human PRPs according to claim 79, wherein cells / mL is determined by automated cell counting using acridine orange and / or propidium iodide.

81. The composition comprising human PRPs according to any one of claims 76-80, wherein a drug product comprising the human PRPs comprises between at least about 20% to about 60% PPP4R4+ cells,119.wherein the PRPs are NR2E3+; and120.wherein the PRPs comprise less than or equal to about 0.5 copies of VIM per copy of SDHA.

82. The composition comprising the drug product comprising the human PRPs according to claim 81, wherein the composition comprises:122.at least about 90% AIPL1+ cells;123.at least about 90% RCVRN+ cells;124.less than or equal to about 7% PAX6+ cells;125.less than or equal to about 7% CHX10+ cells;126.less than or equal to about 0.5% TYRP1+ cells; and / or127.less than or equal to about 0.5% Ki67+ cells. Attorney Docket No.: 132042-5009- WO83. The composition comprising the drug product comprising the human PRPs according to claim 81 or 82, wherein a percentage of NR2E3+, PPP4R4+, AIPL1+, RCVRN+, PAX6+, CHX10+, TYRP1+, and / or Ki67+ cells is determined by flow cytometry.

84. The composition comprising the drug product comprising the human PRPs according to claim 81, wherein copies of VIM per copy of SDHA is determined by ddPCR.

85. The composition comprising the drug product comprising the human PRPs of any one of claims 76-84, wherein the composition has a percentage viability of at least about 50%.

86. The composition comprising the drug product comprising the human PRPs according to claim 85, wherein the percentage viability is determined by automated cell counting using acridine orange and propidium iodide.

87. The composition comprising the drug product comprising the human PRPs according to any one of claims 76-86, wherein the composition further comprises cell aggregates, wherein a median diameter of a cell aggregate is about 30 pm to about 60 pm.

88. The composition comprising the drug product comprising the human PRPs according to claim 87, wherein the median diameter of a cell aggregate is determined by a particle size analyzer.

89. The composition comprising the drug product comprising human PRPs according to any one of claims 76-88, wherein the composition expresses HLA Class II during physiological inflammatory cytokine stimulation, and wherein approximately 50% of the HLA Class II is HLA-DR.

90. A composition comprising human PRPs and balanced salt solution buffer supplemented with 0.2% human serum albumin (HSA).

91. The composition of claim 90, wherein the human PRPs are stable at 1-8 °C for 4-31 hours.

92. The composition of claim 90, wherein the human PRPs are stable at 1-8 °C for 4-7 hours.Attorney Docket No.: 132042-5009- WO93. The composition of claim 90, wherein the human PRPs are stable at 1-8 °C for 24-27 hours.

94. The composition of claim 90, wherein the human PRPs are stable at 1-8 °C for 28-31 hours.

95. The composition of any one of claims 90 to 94, wherein stability is assessed by one or more of percentage viability, viable cell concentration, and / or percentage aggregate biomass.

96. The composition of any one of claims 90 to 95, wherein the balanced salt solution buffer comprises 0.3 mg / mL of magnesium chloride, 0.48 mg / mL of calcium chloride, 0.75 mg / mL of potassium chloride, 1.7 mg / mL of sodium citrate, 3.9 mg / mL of sodium acetate, and / or 6.4 mg / mL of sodium chloride.

97. A method for assessing whether a dose for administration comprising PRPs is compatible with a system for administration, the method comprising:143.a) exposing the PRPs to 1-8 °C;144.b) agitating the PRPs;145.c) aspirating the PRPs into a cannula and syringe;146.d) holding the PRPs in the syringe in a vertical orientation;147.e) injecting the PRPs from the cannula and syringe into a tube and / or cell culture plate; and148.f) measuring percentage aggregate biomass, percentage cell viability, and / or viable cell concentration of the PRPs in the tube and / or cell culture plate,149.wherein the dose for administration comprising PRPs is compatible with a system for administration if there is no substantial change in percentage aggregate biomass, percentage cell viability, and / or viable cell concentration of the dose for administration comprising PRPs compared to a composition comprising control PRPs.

98. A kit comprising the composition comprising human PRPs of any one of claims 1-31, 58-62, or 76-98, or the drug product according to any one of claims 63-75.

Images